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ABSTRACT 
B lymphopoiesis declines with age in humans, mice, and rabbits. Impaired 
B lymphopoiesis correlates with increased fat in the bone marrow (BM), 
suggesting that adipocytes negatively regulate this process. In fact, adipocyte 
factors were found to inhibit B cell development in BM cultures. 
Our goal was to understand the mechanism by which adipocytes inhibit B 
cell development. Through culturing mouse BM cells on OP9 stromal cells in the 
presence of adipocyte-conditioned medium (ACM), we found that adipocytes 
promote the accumulation of CD11b+Gr1+ myeloid-derived suppressor cells 
(MDSCs). These cells were not simply bystanders, as we report for the first time 
that MDSCs potently inhibit B cell development.  
ACM-generated MDSCs express high levels of arginase and iNos, which 
are important for suppressing T cells. However, these effector molecules did not 
mediate the loss of B lymphopoiesis. By cytokine array analysis of MDSC-CM, 
we found that ACM-generated MDSCs produce IL-1. Further, neutralization of IL-
1 in BM cultures containing MDSCs restored B lymphopoiesis, suggesting that 
MDSCs inhibit via IL-1. Inhibition by IL-1 did not directly block B lineage 
development, but instead acted at the MPP stage of hematopoietic development 
to drive myelopoiesis at the expense of B lymphopoiesis.  
 xxii 
In contrast to humans and mice, where B lymphopoiesis declines in mid-
to-late life, B lymphopoiesis arrests at two-to-four months of age in rabbits. 
Characterization of rabbit BM showed an increased number of adipocytes, an 
expanded myeloid compartment, and increased expression of inflammatory 
factors when B lymphopoiesis is arrested. This reduction in B lymphopoiesis and 
increase in myeloid cells was recapitulated in BM cultures treated with BM fat-
CM. These data coupled with the identification of an inhibitory myeloid 
population, suggest that the BM microenvironment is responsible for the arrest of 
B lymphopoiesis in rabbits.  
Our study has uncovered potential targets for therapies aimed at boosting 
B lymphopoiesis in scenarios with fatty BM, such as aging and obesity. For 
example, blocking the NLRP3 inflammasome in ACM-treated BM cultures 
prevented MDSC accumulation and enhanced B lymphopoiesis. We envision this 
observation; along with our other findings will provide insight into mechanisms 
that negatively regulate B cell development in fatty BM. 
 
 
 
 
 
1 
CHAPTER I 
LITERATURE REVIEW 
SECTION 1: B CELL DEVELOPMENT 
Introduction 
Production of B cells and antibodies are essential for effective immune 
responses against infectious agents, and for robust immune responses to 
vaccines. Genetic mutations impairing the generation of B cells (eg. X-linked 
agammaglobulinemia (XLA)) or antibodies (eg. XLA and common variable 
immune deficiency (CVID)) result in a severe immunocompromised state (Bonilla 
and Geha, 2009, Bruton, 1952, Durandy et al., 2013). Patients with XLA and 
CVID routinely receive intravenous IgG (IVIG) therapy to protect against 
infections, highlighting the importance of antibodies in immune protection. 
In otherwise healthy individuals, aging imposes changes to hematopoietic 
progenitors and the BM microenvironment that result in reduced production of 
new B cells (Crane et al., 1996, Jasper et al., 2003, McKenna et al., 2001, Miller 
and Allman, 2005, Scholz et al., 2013). Decreased B lymphopoiesis contributes 
to higher susceptibility to infection and poor immune responses to vaccines in 
aged individuals. Therefore, an understanding of mechanisms that 
negatively regulate B cell development will be valuable in developing 
therapeutics to boost naïve B cell production in the elderly. 
2 
B cell development 
B cell development takes place in the bone marrow (BM) of many 
mammals, including humans, mice, and rabbits. The BM consists of 
hematopoietic lineage cells that will differentiate into immune effector cells, as 
well as stromal cells which support the development of immune cells. The normal 
progression of B cell development begins with the hematopoietic stem cell 
(HSC). The HSC has the potential to differentiate into all cell types of the immune 
system, while cues from the microenvironment influence this differentiation 
potential promoting one lineage over the other.  
To generate B cells, the HSC differentiates through a series of multi-
potent progenitors, which can then differentiate into the common lymphoid 
progenitor (CLP), pre-proB cell, proB cell, preB cell, and finally the immature B 
cell that will exit the BM. With each subsequent differentiation step, the genetic 
and epigenetic landscape changes while these cells gradually lose the potential 
to differentiate into other lineages (eg. myeloid and T lineage) resulting in total 
commitment to the B lineage (Hu et al., 1997, Maes et al., 2008, Ramirez et al., 
2010, Weishaupt et al., 2010). 
Mouse B cell development. B lymphopoiesis is best characterized in 
mice, due to an abundance of genetic models and reagents generated to study 
this species. This process begins with the HSC, which differentiates through the 
successive developmental  stages of MPP, CLP (Lin-Sca1+c-kit+IL-7R+), pre-proB 
cell (B220+c-kit-CD19-Flt3+CD24low/-CD43+IgM-), proB cell (B220+c-kit+CD19+Flt3-
CD24+CD43+IgM-), large preB cell (B220+c-kit-CD19+Flt3-CD24+CD43-IgM-), and 
3 
small preB cell (B220+c-kit-CD19+Flt3-CD24+CD43-IgM-FSClow)  before becoming 
the immature B cell (B220+c-kit-CD19+Flt3-CD24+CD43-IgM+) that leaves the BM 
and enters the periphery (Nagasawa, 2006) (Figure1). The timing of specific 
differentiation or proliferative events at each of these developmental stages is 
critical for successful B cell development. Alterations to these developmental 
processes results in immune deficiencies such as XLA (Bruton, 1952, 
Cunningham-Rundles and Ponda, 2005) or B cell cancers (Hamel et al., 2014).  
VDJ gene recombination . Generation of a B cell pool with a diverse 
antibody repertoire is necessary to protect a host from an array of pathogens. 
The way many vertebrates generate this antibody diversity is through 
combinatorial joining of various variable (V), diversity (D), and joining (J) 
segments of the antibody loci. Because surface antibody or the B cell receptor 
(BCR) is critical to B cell identity and function, successful rearrangement of the 
heavy chain (Igµ) and light chain (Igκ  or Igλ) loci are mandatory for successful 
maturation to the immature B cell stage. Rearrangement of the Igµ locus begins 
at the pre-proB cell stage with recombination of the diversity (D) and joining (J) 
regions of this locus (Gellert, 2002, Jung et al., 2006). Upon successful DJ 
rearrangement, this process continues in late proB cells with the joining of 
variable (V) gene regions to the already formed DJ segment through 
recombination. Successful heavy chain VDJ gene recombination allows for 
expression of the Igµ locus which then complexes with surrogate light chain 
(consisting of VpreB and λ5) to form the pre-BCR (Nishimoto et al., 1991). The 
pre-BCR mediates expansion of large preB cells in conjunction with IL-7 
4 
signaling. Attenuation of IL-7 signaling and active pre-BCR signaling transitions 
development to the small preB cell stage, where proliferation is halted and the 
Igκ (light chain) locus becomes accessible for VJ recombination (Mandal et al., 
2015). Successful recombination and expression of the Igκ or Igλ loci allows for 
functional BCRs present on the surface of immature B cells (Clark et al., 2014) 
(Figure 1.1). 
 
 
 
 
 
 
 
 
Figure 1.1 B cell developmental stages in mice. B cell development begins 
with the HSC which progresses through various developmental stages before 
reaching the immature B cell stage (B cell). VDJ gene recombination begins in 
pre-proB cells with Igµ DJ rearrangement, followed by V-DJ recombination in 
proB cells. The Igµ and surrogate light chain are expressed on the surface of 
preB cells as the pre-BCR, followed by rearrangement of Igκ light chain. 
Successful Igκ rearrangement and surface expression of the BCR complete 
differentiation at the immature B cell stage. These cells then leave the BM and 
enter the periphery to participate in immune responses. Each developmental 
5 
stage can be identified with the presence or absence of the indicated cell 
markers. 
 
Human B cell development. The B cell developmental process in 
humans is similar to that found in mice, although a different set of surface 
markers is used to define each progenitor stage (Figure 1.2). Human B lineage 
progenitors are defined as CLP (CD34+CD10+CD19-), Early B lineage progenitor 
(EB) (CD34hiCD10+CD19-), ProB (CD34+CD10+CD19+), large preB (CD34-
CD19+), small preB (CD34-CD19+FSClo), and immature B cell (CD34-
CD19+sIgM+) (Blom and Spits, 2006, Galy et al., 1995, LeBien, 2000). VDJ gene 
recombination occurs in successive developmental stages as occurs in mice 
(LeBien, 2000), where recombination of the heavy chain locus occurs at the EB 
cell stage (Jung et al., 2006). Upon successful IgH recombination, the heavy 
chain pairs with surrogate light chain (consisting of VpreB and λ14.1) to form the 
pre-BCR found on preB cells. Pre-BCR signaling is needed to induce Igκ light 
chain VJ recombination in preB cells. Successful in-frame VJ rearrangements 
and expression of Igκ then allow for formation of the mature BCR and localization 
to the cell surface in immature B cells (Hystad et al., 2007, Schiff et al., 1990). 
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Figure 1.2 Human B cell developmental stages. Human B cell development 
begins with the HSC and MPP as defined above (Pieper et al., 2013, van Galen 
et al., 2014). Early progenitors are followed by the CLP and Early B progenitors. 
VDJ gene recombination begins in the Early B stage and is completed as 
indicated in the subsequent developmental stages. Successful rearrangement of 
the Igµ and Igκ loci result in sIgM expression on the surface of B cells that leave 
the BM and enter the periphery. Each developmental stage is defined as 
indicated above.   
 
Rabbit B cell development. Many fundamental discoveries in the area of 
B cell biology were performed using rabbits. These studies contributed to our 
current understanding of allotypes and allelic exclusion, the antibody genetic 
locus, antibody structure, and the localization of antibody on the cell surface 
(Cebra et al., 1966, Feinstein, 1963, Fleischman et al., 1963, Gilman-Sachs et 
al., 1969, Oudin, 1956, Pernis et al., 1965, Pernis et al., 1970, Sell and Gell, 
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1965, Todd, 1963). Despite many early studies of B cells in rabbits, the number 
of studies has declined over the years. While the B cell developmental process 
appears to resemble that seen in humans and mice, not all of the developmental 
stages have been resolved phenotypically. It is believed that this process starts 
with the HSC (undefined) which can differentiate into the earliest described rabbit 
B lineage progenitor, the rabbit lymphoid progenitor (rLP) (Kalis et al., 2007). 
This population is thought to contain the equivalent of a CLP population seen in 
human and mouse, and is defined as MHCII- IL7R+. Further analysis showed that 
rLPs express Tdt, EBF, and Pax5, genes commonly expressed by B lineage 
cells. Development continues with proB cells defined as CD79a+ cytoplasmic µ- 
surface µ- (CD79a+Cµ- Sµ- ) (Jasper et al., 2003), preB cells (CD79a+Cµ+ Sµ- ) 
(Hayward et al., 1978, Jasper et al., 2003, McElroy et al., 1981), followed by B 
cells (CD79a+Cµ+ Sµ+) (Jasper et al., 2003, Pernis et al., 1965, Sell and Gell, 
1965) (Figure 1.3). 
Rabbit B lineage progenitors also undergo VDJ gene recombination while 
developing in the BM (Figure 1.3). Heavy chain DJ rearrangements are found in 
proB cells, and successful VDJ gene rearrangements are found in preB cells, 
showing a similar stage-specific process of recombination as seen in humans 
and mice (Jasper et al., 2003). Unique to rabbits is the extent to which VDJ gene 
recombination contributes to the diversity of the rabbit antibody repertoire. 
Compared to humans and mice, which rely heavily on VDJ gene recombination 
for antibody diversity, rabbits chiefly rearrange only one VH, VH1, the 3’-most VH 
gene segment of the IgH locus, limiting the amount of diversity generated 
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through this process (Becker et al., 1990, Friedman et al., 1994, Knight and 
Becker, 1990, Raman et al., 1994, Tunyaplin and Knight, 1995). Alternatively, 
rabbits do utilize many V and J regions during κ light chain rearrangement 
(Sehgal et al., 1999). Future studies will be needed understand how light chain 
diversity affects the overall diversity of the rabbit antibody repertoire. 
 
 
 
 
 
 
 
Figure 1.3 Schematic of rabbit B lineage development stages. Rabbit B cell 
development is thought to begin with a yet-to-be defined HSC population. The 
earliest progenitor population defined is the rLP, followed by the proB cell, preB 
cell, and B cell. VDJ gene recombination occurs in rabbit BM beginning in the 
proB cell. Each stage is identified by the combination of markers indicated above. 
 
Generation of antibody diversity in rabbit GALT 
Limited usage of V regions during VDJ gene recombination does not result 
in a restricted rabbit antibody repertoire. This is because rabbits use somatic 
diversification in gut associated lymphoid tissues (GALT) to further diversity their 
BCRs. In fact, naïve B cells, resulting from successful B lymphopoiesis in the 
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BM, leave the BM and home primarily to the appendix where they diversify the 
BCRs through gene conversion and somatic hypermutation (Lanning et al., 2000, 
Mage et al., 2006). This method of diversification is similar to that in chickens and 
sheep, which also utilize GALT for B cell development and maturation (Alitheen 
et al., 2010, Ratcliffe, 2006, Reynaud et al., 1987, Reynaud et al., 1995). 
Therefore, rabbit B lymphopoiesis occurs in two phases; 1. early B cell 
development that mirrors human and mouse generation of naïve B cells; 2. 
Further maturation and diversification in GALT. The focus of this dissertation is 
on B cell development in the BM, but the utilization of GALT for further 
maturation of naïve B cells is important to note in generating additional antibody 
diversity in rabbits. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Rabbit B cell development and maturation in the BM and 
appendix. B lineage cells develop from hematopoietic stem and progenitors cells 
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in the BM. VDJ gene recombination occurs in the BM, but to a limited extent (as 
described in the text). Development in the BM serves as a source of naïve B cells 
which travel to the appendix (and other GALT). In the appendix, naïve B cells 
undergo expansion and somatic diversification. The primary mechanisms by 
which rabbit B cells generate a diverse primary antibody repertoire is through 
gene conversion and somatic hypermutation, occurring in GALT. (Adapted from 
Kennedy et al., 2016). 
 
The bone marrow microenvironment 
As described above for mice, humans, and rabbits, B cell development is 
an orchestrated process where any given differentiation (eg. Igµ VDJ gene 
recombination, Igκ VJ gene recombination) or proliferation (expansion of large 
preB cell) event must occur at the appropriate time. While these events appear to 
occur intrinsically within B lineage progenitors, the timing of each step is 
mediated by signals provided by supporting cells in the BM microenvironment 
(Nagasawa, 2006). For example, mouse large preB cells expand before 
transiting to the small preB cell stage to undergo κ light chain recombination. 
Proliferation cannot occur simultaneously with DNA recombination, as this may 
lead to DNA translocations that result in cell death or transformation (Hamel et 
al., 2014). To separate expansion and recombination preB cells integrate signals 
from the BM microenvironment. Large preB cells require IL-7 from the BM 
microenvironment to proliferate, but must lose the IL-7 signal and gain pre-BCR 
signaling to rearrange the Igκ locus (Johnson et al., 2008, Mandal et al., 2009, 
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Ochiai et al., 2012). Therefore different stromal cell types form niches that 
support successive stages of B lymphopoiesis. 
The use of primary BM stromal cells and BM stromal cells lines (such as 
OP9 cells) to support B lymphopoiesis in vitro (Collins and Dorshkind, 1987, 
Holmes and Zuniga-Pflucker, 2009, Hunt et al., 1987, Whitlock and Witte, 1982, 
Whitlock et al., 1987) further suggests that BM stromal cells produce molecules 
important for this process. Additional studies identified several BM stromal cell 
types that support B cell development including osteoblasts, reticular cells, and 
endothelial cells (Calvi et al., 2003, Jacobsen and Osmond, 1990, Kiel et al., 
2005, Lichtman, 1981, Taichman et al., 1996, Tokoyoda et al., 2004, Weiss, 
1976, Zhu et al., 2007).  
Osteoblasts. Osteoblasts are derived from mesenchymal stem cells 
(MSC) and can be identified by markers that include alkaline phosphatase, type I 
collagen, and osterix (Fakhry et al., 2013, Murshed et al., 2005, Nakashima et 
al., 2002). Aside from their function in bone building, they also serve an important 
role during hematopoiesis. Mature osteoblasts are typically found along the 
endosteal wall of cortical bone and have been visualized in close proximity with 
hematopoietic stem and progenitor cells HSPCs) (Calvi et al., 2003, Zhang et al., 
2003). In vitro cultures suggest osteoblasts support B lymphopoiesis, and in vivo 
ablation of these cells results in impaired B lineage development (Visnjic et al., 
2004). Osteoblasts support general hematopoiesis by providing a niche for 
HSCs, and support B lymphopoiesis by producing factors such as CXCL12 and 
IL-7. 
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One example of osteoblast-mediated support came from a study of mice 
with a genetic deletion that blocked signaling downstream of the PTH/PTH 
peptide receptor (PRR) specifically in osteoblasts. Signaling through PRR on 
osteoblasts is known to enhance support for B lineage development (Zhu et al., 
2007); therefore you would expect blockade of this pathway will result in altered 
B cell development. In fact these mice displayed a decreased amount of 
trabecular bone and impaired development from the proB to preB stage (Wu et 
al., 2008). Interestingly, osteoblasts in these mice exhibited decreased 
expression of IL-7, a critical factor for proB cell development.  
Reticular Cells. Reticular cells are abundant in the BM microenvironment 
and have been implicated in providing niches for B cell development (Tokoyoda 
et al., 2004). CXCL12hi reticular cells support HSCs and early hematopoietic 
progenitors. These cells often surround endothelial cells and are an important 
component of the vascular HSC niche (described below). CXCL12hi reticular cells 
were found to be distinct from IL-7 expressing stromal cells suggesting CXCL12 
and IL-7 expressing stromal cells make up distinctive niches. Overall, these 
reticular stromal cells and osteoblasts provide critical molecules for developing B 
lineage progenitors. 
Adipocytes. Adipocytes are a major contributor to the state of the BM 
microenvironment. These cells, and how they contribute to hematopoiesis, will be 
covered in Section 3, and are a key focus of this dissertation. 
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Stromal cell-derived supportive factors 
CXCL12. CXCL12 is a 10kDa chemokine that interacts with its receptor 
CXCR4. CXCR4 is a seven transmembrane spanning G-protein coupled receptor 
(GPCR). CXCL12 has the alternative names stromal derived factor 1 (SDF-1) 
and preB cell growth stimulating factor (PBSF) alluding to its production by 
stromal cells and its ability to stimulate B lineage progenitors. CXCL12-/- and 
CXCR4-/- mice are embryonic lethal due to improper development of the heart, 
nervous system, and vasculature. Additionally these mice have impaired B 
lymphopoiesis and myelopoiesis resulting in the inability to recruit hematopoietic 
progenitors to their niche (Nagasawa et al., 1994, Nagasawa et al., 1996, Peled 
et al., 1999, Tachibana et al., 1998, Zou et al., 1998). To assess the requirement 
of CXCL12-CXCR4 signaling during adult B cell development, fetal liver CXCR4-/- 
hematopoietic progenitors were adoptively transferred into lethally irradiated WT 
mice. Mice reconstituted with CXCR4-/- hematopoietic progenitors had defects in 
B lineage development (Kawabata et al., 1999, Ma et al., 1999).  A similar result 
was seen in adult mice genetically engineered to remove the CXCR4 gene upon 
poly(I)-poly(C) administration(Sugiyama et al., 2006), suggesting CXCL12-
CXCR4 signaling is required for normal B lymphopoiesis. 
IL-7.This BM stromal cell-derived factor is required for B cell development. 
In fact, von-Freeden-Jeffry reported in 1995 that IL-7-/- mice were the first 
identified single cytokine knockout mouse with severe defects in lymphocyte 
development (von Freeden-Jeffry et al., 1995). Together, studies of IL-7-/- and IL-
7R-/- mice identified IL-7 as a critical factor early in development as these mice 
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exhibit a loss of B lymphopoiesis at the proB cell to preB cell stage (Peschon et 
al., 1994, von Freeden-Jeffry et al., 1995). IL-7 promotes the expansion of proB 
cells and large preB cells (Clark et al., 2005, Clark et al., 2014, Hardy et al., 
1991, Herzog et al., 2009), while later stages do not rely on this cytokine. IL-7R 
signaling is lost in downstream B lineage progenitors, which is a requirement for 
successful transition into the small preB cell stage and Igκ light chain 
rearrangement (Clark et al., 2014, Johnson et al., 2008, Mandal et al., 2009, 
Ochiai et al., 2012). 
SCF, Flt3L, and IGF-1. Additional supportive molecules produced by the 
BM microenvironment include stem cell factor (SCF), Flt3-Ligand (Flt3L), and 
insulin-like growth factor (IGF-1). SCF binds hematopoietic cells through its 
receptor c-kit. Evidence that the SCF-c-kit interaction supports B cell 
development came from the study of mice with mutant c-kit, which exhibited 
impaired B lymphopoiesis (Waskow et al., 2002). Additionally, Driessen et al. 
found membrane bound SCF to be important for HSC attachment to the 
endosteal HSC niche (Driessen et al., 2003). Similar to c-kit mutant mice, Flt3L-/- 
mice (McKenna et al., 2000) and IL-7R-/-Flt3L-/- (Jensen et al., 2008, Sitnicka et 
al., 2003) also have defects in B lineage development. For IGF-1, studies 
suggest that stromal cell-derived IGF-1 is important for enhancing the 
proliferative signal provided to proB cells by IL-7 (Gibson et al., 1993, Landreth et 
al., 1992). These and other microenvironment-derived factors are important to 
support B cell development, but successful development is only achieved when 
these signals are provided at the correct time. Therefore different niches exist in 
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the BM to support the development of each progenitor stage ranging from the 
HSC to immature B cells which leave the BM. 
Development in the context of different niches 
B lineage progenitors require different signals from the BM 
microenvironment to progress through successive stages of development. This 
notion is supported by studies that visualized various B lineage progenitors in 
close contact with stromal cells expressing cytokines required to support B cell 
development in a stage dependent manner (Tokoyoda et al., 2004). Together, 
these observations give rise to a model where micro-niches, made up of a subset 
of BM stromal cells, usher B lineage progenitors through a series of 
differentiation steps. 
HSCs in the endosteal versus vascular niches. There are two primary 
sites that serve as niches for HSCs in the BM; the endosteal niche and the 
vascular niche (Figure 1.5). Calvi et al. and Zhang et al. (2003) described the 
endosteal niche where HSCs are supported by osteoblasts lining the endosteal 
bone surface (Calvi et al., 2003, Zhang et al., 2003). These osteoblasts are the 
source of secreted, as well as membrane bound factors that promote HSC 
maintenance. For example, osteoblasts produce the molecules Ang1, 
osteopontin, and SCF. Ang1 and osteopontin help maintain HSC quiescence 
(Arai et al., 2004, Guerrouahen et al., 2011, Nilsson et al., 2005), while SCF 
through interactions with c-kit on HSCs promotes adherence of HSCs to this 
niche (Driessen et al., 2003). Further, a specialized form of osteoblast  in the 
endosteal niche called the N-Cadherin+CD45- osteoblastic cell (SNO) was found 
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to be in close contact with HSCs through an N-cadherin mediated mechanism 
(Guerrouahen et al., 2011). 
The visualization of HSCs located away from the bone surface, in close 
contact with endothelial cells forming sinuses, provided evidence of what is now 
known as the vascular niche (Kiel et al., 2005). Similar to the endosteal niche, 
Sugiyama et al. found that the HSC vascular niche is dependent on CXCL12-
CXCR4 signaling (Sugiyama et al., 2006). In contrast, the source of CXCL12 was 
believed to come from CXCL12hi reticular cells (CAR) (Tokoyoda et al., 2004) 
that surround endothelial cells and are critical for support.  
Studies of the endosteal and vascular HSC niches suggest these locations 
have different roles in the maintenance of HSC quiescence. As described above, 
the endosteal niche provides molecules, such as Ang-1, osteopontin, and SCF 
that promote quiescence. Low oxygen levels (hypoxia) characterized in the 
endosteal niche is thought to further promote quiescence. In contrast, the less 
hypoxic vascular niche provides more oxygen for proliferation/differentiation and 
therefore contains HSCs in a less quiescent state (Hermitte et al., 2006, Shima et 
al., 2010, Suda et al., 2011, Wilson et al., 2008). In line with this idea, studies of 
the vascular niche suggest it provides signals promoting 
proliferation/differentiation. One such signal was found by Winkler et al., who 
identified E-selectin as a critical factor expressed by endothelial cells in the 
vascular niche. E-selectin promoted proliferation in HSCs, and when blocked 
resulted in HSC quiescence (Winkler et al., 2012). Therefore, the endosteal and 
vascular niches may exist to provide a balance between maintaining a long term 
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HSC pool and repopulating the peripheral compartments in response to various 
stimuli. 
Progression through the BM microenvironment during B cell 
development. Tokayoda et al. visualized various stages of B lineage progenitors 
in the BM of mice, to understand their relationship with BM stromal cells 
(Tokoyoda et al., 2004). Hematopoietic multipotent progenitors (MPP) and pre-
proB cells were visualized in close contact with CXCL12hi reticular cells (CAR) 
dispersed throughout the BM. While MPPs were localized with the processes of 
CAR cells, pre-proB cells were found near the cell body. The next B lineage 
progenitor, the proB cell was not associated with CXCL12hi CAR cells, but 
instead localized with IL-7+ stromal cells. Furthermore, preB cells were visualized 
away from both CXCX12 and IL-7 expressing cells. Instead, preB cells are 
localized with galectin-1+ stromal cells. Galectin-1 is a stromal cell-derived ligand 
for the pre-BCR, expressed on preB cells (Espeli et al., 2009, Gauthier et al., 
2002, Mourcin et al., 2011). Upon successful differentiation to the immature B 
cell stage, these cells leave the BM and enter the periphery. In the periphery, the 
B cells participate in immune responses, and some eventually mature to 
plasmablasts. Plasmablasts express CXCR4 and home to the BM, where 
terminally differentiated plasma cells are found localized to CXCL12hi reticular 
cells (Tokoyoda et al., 2004) (Figure 1.5). 
The BM is a complex space where many processes take place. In addition 
to the cell types described above, the BM is also home to additional stromal cells 
in different stages of maturity (eg. immature stages of osteoblasts and 
18 
adipocytes). Alternatively, hematopoietic lineage cells, such as osteoclasts and 
progenitors differentiating into lineages other than the B lineage also contribute to 
the overall BM microenvironment. The identification of niches for each stage of 
development clarifies how so many processes can occur. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 BM niches for B cell development. HSCs can be found at the 
endosteal and vascular niches. The endosteal niche is formed by osteoblasts 
which line the bone surface, and provide important molecules to HSCs (indicated 
in blue). The vascular niche is made up of endothelial cells and CXCL12hi 
reticular cells which provide support for HSCs through molecules like E-selectin. 
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MPPs are known to localize to the ends of CXCL12hi reticular cells, while pre-
proB cells are found at the cell body. ProB cells are found in a distinct niche in 
contact with IL-7+ stromal cells. PreB cells migrate away from IL-7 producing 
stromal cells and undergo pre-BCR activation from galectin-1 producing stromal 
cells. Once reaching the immature B cell stage, these cells then leave the BM to 
further mature and partake in antibody responses. Upon successful completion of 
germinal center reactions in the periphery, plasmablasts traffic back to the BM 
where terminally differentiated plasma cells are found in contact with CXCL12hi 
reticular cells. (Adapted from Nagasawa, 2006). 
 
SECTION 2: DECLINE OF B LYMPHOPOIESIS IN MAMMALS 
B lymphopoiesis is first found in the fetal liver before moving to the BM in 
humans, mice, and rabbits. The BM serves as the primary site of B cell 
development post birth, producing naïve B cells which can then enter the 
periphery. As these mammals age, changes to hematopoietic progenitors and 
the BM microenvironment results in reduced production of new B cells. While this 
process wanes on a different timeline in each species, many studies in humans, 
mice, and rabbits have contributed to our current understanding of how this may 
occur. Age-related defects to B cells and their development result in increased 
susceptibility to infection and decreased immune responses to vaccination, as 
seen in the elderly (Frasca et al., 2011, McElhaney and Effros, 2009). Therefore 
understanding the mechanisms underlying these changes will identify targets for 
therapeutics aimed at rejuvenating B cell development in aged individuals. 
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Decline of B lymphopoiesis in mice 
The B cell developmental process and age-related decline is best 
characterized in mice. Multiple studies using different mouse strains have 
characterized this decline and have started to uncover various intrinsic and 
extrinsic mechanisms contributing to reduced B lymphopoiesis in aged mice. 
Decreased frequency and production of B lineage precursors with 
age. Several studies have characterized a reduction in frequency or absolute 
number of specific B lineage precursors in aged mice. For example Stephan et 
al. (1996) asked if the number of B lineage precursors in the BM of BALB/c mice 
varied at 1,4,12, and 24 months of age (Stephan et al., 1996). Looking for pre-
proB and proB cell numbers, no difference was found. Alternatively, the number 
of preB cells was reduced as a consequence of aging. The decline in preB cell 
number occurred in two steps; an initial reduction was found between 1 and 4 
months of age, and further decreased between 12 and 24 months. This study is 
further supported by others who reported reduced preB cell pools with age 
(Kirman et al., 1998, Riley et al., 1991, Sherwood et al., 1998). 
Consistent with observations of decreased preB cell number and 
percentage in the BM with age, Johnson et al (2002) found the production rate of 
preB cells was also reduced in aged mice (Johnson et al., 2002). While the rate 
of new immature B cells downstream of the preB cells was not found to be 
different between young and old mice, the authors suggest aged immature B 
cells have impairments in refilling more mature B cell pools in the periphery. 
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In addition to reduced preB cell pools in the BM of aged mice, several 
other studies found reductions in additional B lineage precursor stages with age. 
These observed differences in characterizing the decline of B lymphopoiesis can 
be explained by mouse strain differences or by the use of additional markers to 
define precursors. The studies discussed above characterized B cell 
development in BALB/c mice, while the following studies performed experiments 
using C57BL/6 mice and used AA4.1 as an additional B lineage marker. In 
C57BL/6 mice, Miller and Allman assessed the absolute number and frequency 
of EBP/CLPs (Lin− IL-7Rα+ AA4+ Sca-1low), pre-proB cells 
(Ly6C− CD24/HSA−B220+ AA4+), and proB cells (B220+ CD43+ CD19+ AA4+) in 
mice 2, 7, 10, 14, 20, and 24 months of age (Miller and Allman, 2003). In female 
and male mice, each of these populations declined as a function of aging. In 
females, EBP/CLPs made up 0.058% of BM at 2 months and 0.001% at 24 
months, pre-proB cells 0.191% (2 month) vs. 0.047% (24 months), and proB cells 
0.673% (2 months) vs. 0.084% (24 months). Assessing male mice, EBP/CLPs 
made up 0.042% of BM at 2 months and 0.007% at 18 months, pre-proB cells 
0.189% (2 month) vs. 0.051% (18 months), and proB cells 0.564% (2 months) vs. 
0.078% (18 months). Overall these early B lineage precursors were found at 
lower frequency and absolute number in aged mouse BM, leading the authors to 
conclude that the decreased preB cell pool, often seen in aged mice by other 
studies, could be in part due to diminished populations of earlier B lineage 
precursors that occur with aging. 
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A study by Min et al. also assessed the effect of senescence on B lineage 
development (Min et al., 2006). The authors expected that exposing the 
hematopoietic system to stress could uncover subtle impairments that normally 
occur during aging. To this end, young and old mice were characterized for age-
related changes affecting early B lineage progenitors during homeostasis or after 
5-fluorouracil (5-FU) treatment. In addition to confirming the observations by 
Miller and Allman during normal aging (Miller and Allman, 2003), 5-FU treatment 
uncovered proliferative defects in CLPs and pre-proB cells, as well as an 
impaired differentiation capacity in CLPs from aged mice. The cumulative data 
produced through all the aforementioned studies define the outcome of age-
related changes and how they affect B cell development. Upon establishing this 
phenomenon, additional studies continue to expand our mechanistic 
understanding of this decline. 
Mechanisms that contribute to declining B lymphopoiesis. Successful 
development from the HSC to immature B cell stage requires healthy 
hematopoietic progenitors, as well as the appropriate BM stromal cell support. 
Intrinsic changes in hematopoietic progenitors and extrinsic changes to the BM 
microenvironment are both known to contribute to the decline of B lymphopoiesis 
in aged mice. This becomes evident when comparing several studies that 
performed adoptive transfers of aged HSCs/BM cells into young irradiated 
recipients, and obtained conflicting results. The expectation is if intrinsic defects 
in BM progenitors drive impaired B lymphopoiesis, then transfer of old BM 
progenitors into a young BM microenvironment will not restore B lineage 
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development. If the microenvironment is responsible for the decline, then transfer 
of aged BM progenitors into a young BM microenvironment will restore B lineage 
development from aged BM donors. In fact, several studies found normal B cell 
development of aged BM progenitors when transferred into young recipients 
(Chen et al., 1999, Miller and Allman, 2005, Morrison et al., 1996). Alternatively, 
transfer experiments into young hosts by Sudo et al. did not yield B lineage cells, 
while myeloid cells did develop (Sudo et al., 2000); suggesting age-related 
intrinsic changes affect hematopoietic progenitor potential. Because both intrinsic 
and extrinsic mechanisms result in declining B cell development, it is important to 
understand how these changes affect different stages of development. 
Aging affects even the earliest hematopoietic progenitors. HSC numbers 
are increased in old mice compared to young mice, but their quality is reduced 
(Geiger et al., 2013). A major characteristic of aging hematopoiesis is 
unbalanced production of fewer lymphocytes and increased myeloid cells. This 
may be due to intrinsic changes in HSCs, as gene expression profiling found 
aged HSCs to have upregulated myeloid lineage and decreased expression of 
lymphoid lineage genes (Rossi et al., 2005). This may also be due to intrinsic 
differences in lymphoid and myeloid biased HSCs resulting in more myeloid 
biased HSCs and fewer lymphoid biased HSCs maintained through aging 
(Muller-Sieburg and Sieburg, 2008). 
The reduced preB cell pool during aging observed by Stephan et al. 
(1996) can be explained by changes in B lineage precursors, as well as the 
environment. The authors found that preB cells from aged mice had a decreased 
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ability to proliferate when cultured on BM stromal cells, compared to preB cells 
from young mice (Stephan et al., 1996). Impaired responsiveness to IL-7 was 
also found in earlier B lineage progenitors, such as proB cells in both BALB/c and 
C57BL/6 mice (Miller and Allman, 2003, Stephan et al., 1998). Another difference 
found is that preB cells from aged mice exhibit decreased expression of the SLC 
components VpreB and λ5, which are necessary for pre-BCR surface expression 
in preB cells (Sherwood et al., 1998, Sherwood et al., 2000). Whether due to a 
lack of pre-BCR signaling or not, aged preB cells were found to be more 
apoptotic upon isolation from BM and after in vitro culture (Kirman et al., 1998). 
Multiple B lineage precursors have impaired responsiveness to IL-7 with 
age, but BM stromal cells were also found to change with age. In fact, primary 
BM stromal cells isolated from aged mice could not stimulate IL-7 dependent B 
lineage cell lines as efficiently as BM stromal cells isolated from young mice 
(Stephan et al., 1998). This suggests BM stromal cells from aged mice have a 
lower supportive capacity for B cell development. BM stromal cells isolated from 
young and old mice were actually found to have similar IL-7 protein levels, but 
the defect in aged BM stromal cells appeared to be in IL-7 release.  
One of the most powerful examples linking the aged microenvironment to 
declining B lymphopoiesis came from Labrie et al (Labrie et al., 2004) In this 
study, it was established that aged proB cells exhibit decreased V(D)J 
recombinase activity. To demonstrate this impairment was due to the aged BM 
microenvironment, the authors performed a series of transfer experiments. Aged 
BM hematopoietic progenitors were transferred into young recipients, which 
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resulted in restored V(D)J recombinase activity in proB cells. To complement this 
experiment, young BM hematopoietic progenitors were transferred into aged 
recipient mice, leading to impaired V(D)J recombination in developing proB cells. 
Together, these results suggest altered V(D)J recombinase activity in proB cells 
is dependent on changes to the BM microenvironment that accumulate during 
aging. 
The systemic environment and the decline of B cell development. In 
addition to changes in hematopoietic progenitors and the BM microenvironment, 
one study provides evidence that the peripheral B cell pool that accumulates with 
age negatively regulates B lymphopoiesis. Keren et al. used three approaches to 
deplete peripheral B cells in an attempt to boost B cell development (Keren et al., 
2011).  By generating conditional BAFF receptor deficient mice, or using various 
strategies to deplete peripheral B cells with anti-CD19, anti-B220, anti-CD22 and 
anti-CD20 the authors were able to enhance B cell development. In aged mice, 
depletion of B cells also resulted in increased B lymphopoiesis and an enhanced 
antibody response. Although increased, B cell depleted aged mice did not 
completely recover B lymphopoiesis and antibody responses to levels seen in 
young mice. This suggests that while the peripheral B cell pool may contribute to 
decreased B lineage development, intrinsic and BM extrinsic factors likely also 
contribute. 
The study by Keren et al. brings to light the idea that systemic factors, 
whether generated locally or across the body, can regulate processes occuring in 
the BM. Also, further studies will be needed to see if peripheral B cells negatively 
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regulate B cell development through soluble factors, or if they traffic to the BM to 
exert their effect. Consistent with this study, Montaudouin et al. found that the 
amount of IgG in circulation can regulate the number of IgM producing B cells in 
the periphery through an interaction with the inhibitory Fc receptor, FcγRIIB 
(Montaudouin et al., 2013). It will be interesting to see if B lineage progenitors 
also have a similar ability to quorum sense and regulate new B cell output based 
on demand. Alternatively, aged B cells (ABC) which accumulate with age were 
also found to inhibit B cell development through TNFα production (Ratliff et al., 
2013). Future studies will also be needed to determine if the depletion strategies 
used by Keren et al. altered a quorum sensing system and/or depleted 
inflammatory B cells to boost new B cell generation. 
Decline of B lymphopoiesis in humans 
Evidence of early B lymphopoiesis can be found in the yolk sac of the 
human embryo, and appears in the fetal liver at day 8. At week 12, the BM 
becomes the primary site of B cell production through 80 years of life (Nunez et 
al., 1996). Several studies suggest that B lineage development declines with age 
in humans. Although there are some conflicting data between studies, the 
majority find reductions in B lineage progenitors and ability to differentiate to the 
B lineage. 
Decreased Frequency of B lineage cells with aging. Difficulty in 
collection of BM from healthy donors often limits the number of extensive studies 
performed on this population in humans. In spite of this restriction, several 
investigators were able to characterize the frequency of B lineage progenitors in 
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BM as a function of age. Rego et al. examined the frequency of CD10+CD19+ B 
lineage (proB cells) present in sternums from individuals of various ages (Rego 
et al., 1998). Of the age groups analyzed, this study found the highest frequency 
of CD10+CD19+ cells in the first four years of life. The frequency then decreased 
with increased age being the lowest in individuals categorized as being >15 
years of age. 
Another study analyzed early B lineage cells from human rib sections 
ranging in age from fetal development to 80 years of age (Nunez et al., 1996). 
Several B lineage progenitor cell types were analyzed, including:  CD19+sIgM-, 
CD10+sIgM-, and CD24+sIgM-. Looking at CD19+sIgM- pro/preB cell frequencies 
in human BM samples, the authors found an age-related decrease. The BM 
mononuclear cells of a 19 week fetus and 3 year old contained 55% and 44% 
CD19+sIgM- preB cells, whereas this population was reduced to 15% in the BM of 
a 56 year old individual. Similarly identifying B lineage precursors as CD10+sIgM- 
or CD24+sIgM-, there was a reduced frequency in the 56 year old BM sample. 
A study by McKenna et al., also supports the above studies (McKenna et 
al., 2001), finding a decreased frequency of B lineage precursors in BM samples 
from aged individuals. However, a study by Rossi et al is inconsistent with the 
other studies cited. These authors did not find significant age-related differences 
in B lineage precursor frequencies in BM taken from hip surgeries (Rossi et al., 
2003). Overall, there are some inconsistencies between studies focused on 
human B lymphopoiesis and aging. Obtaining enough healthy BM samples of 
various ages is a limitation that affects the statistical power of these studies. 
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Additionally, differences in BM collection methods and BM samples from different 
types of bone likely contribute to inconsistencies between studies. Access to 
tissues (including BM) from young and old healthy donors is often a limitation to 
aging studies in humans. Establishment of a bank for such tissues was recently 
discussed this past January 2016 at the “Effects of aging on hematopoiesis” 
symposium at the National Institutes of Health (sponsored by the NIDDK and 
NIA). 
Reduced B lineage potential in aged HSCs. The reduction in B lineage 
progenitors may be the result of a reduced capacity for HSCs to differentiate to 
the B lineage. In fact, Pang et al. found this to be true (Pang et al., 2011). HSCs 
isolated from human donors 20-35 years or >65 years were compared for their 
potential to differentiate into the B lineage vs. myeloid lineage in vitro. Compared 
to young HSCs, HSCs from individuals >65 years exhibited reduced B lineage 
potential while maintaining myeloid potential. In addition, xenotransplantation of 
human HSCs into immunodeficient mice resulted in a greater production of 
myeloid cells compared to B lineage cells from aged human HSCs. These data, 
in conjunction with aged HSCs showing increased expression of myeloid lineage 
genes, provide mechanistic evidence for declining B lymphopoiesis in individuals 
>65 years of age (Pang et al., 2011). 
Changes to the BM microenvironment. In addition to reduced B lineage 
potential by HSCs, changes to the BM microenvironment may also contribute to 
the loss of B cell development. Alterations to mesenchymal stem cells (MSC) or 
their progeny; osteoblasts and adipocytes may affect hematopoiesis. Osteoblasts 
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are known to support B cell development, while adipocytes have a negative 
impact on this process (Bilwani and Knight, 2012, Naveiras et al., 2009, Zhu et 
al., 2007). Therefore decreases in osteoblasts and/or increases in BM adipocytes 
could contribute to decreased B lineage development. 
MSCs and aging. Several studies characterized the frequency of MSCs 
found in human BM during aging. One study saw a decrease in frequency of 
MSCs in BM occurring at 30 years of age compared to newborns (Caplan, 2007). 
In contrast with this study, studies by Justesen et al., and Stenderup et al. did not 
find decreases in MSC frequency between young and old (Justesen et al., 2002, 
Stenderup et al., 2001). However, young was defined as approximately 20-40 
years and old was defined as approximately 65-70 years in these later studies. 
Additionally, variations in methods to identify MSCs may have also contributed to 
these inconsistencies. 
Whether or not MSC frequency changes with age in human BM, evidence 
suggests these cells are different in aged individuals. One study found MSCs 
taken from individuals >50 years old were more prone to undergo apoptosis 
compared to MSCs from young donors. Aged MSCs also showed increased 
senescence-associated β-galactosidase, required more time to divide, and had 
reduced capacity to differentiate into osteoblasts (Zhou et al., 2008). 
Arrest of B lymphopoiesis in rabbits 
Consistent with human and mice, B cell development in rabbits is found in 
the fetal liver, where preB cells can be found as early as 25 days into fetal 
development  (Hayward et al., 1978, McElroy et al., 1981). After birth, the BM is 
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the primary site of hematopoiesis. In the first two weeks of life, preB cells peak, 
comprising 9-19% of nucleated BM cells. The frequency of preB and proB cells 
then drops dramatically by 2 months of age and these cells are undetectable by 4 
months of age (Jasper et al., 2003). 
Characterization of declining B cell development. Rabbit B cell 
development arrests at 2 months of age (Jasper et al., 2003, Kennedy et al., 
2016), making the rabbit an accelerated model for declining B lymphopoiesis, 
which usually occurs in the mid to late stages of life in humans and mice 
(McKenna et al., 2001, Scholz et al., 2013). The early loss of B cell development 
is well characterized in rabbits, as evidenced by allotype suppression 
experiments, flow cytometry analysis of B lineage progenitor frequencies, and B 
cell recombination excision circle (BREC) analyses. 
Allotype suppression experiments. The idea that B lymphopoiesis is 
short lived in rabbits came in the 1960s, when Dray performed allotype 
suppression experiments. Antibodies specific for a particular paternal IgH 
allotype were injected into neonate rabbits that were heterozygous for that 
paternal IgH allotype. This treatment effectively depleted the target allotype 
antibody in these rabbits (Dray, 1962). Looking as late as 2 years later, the 
suppressed allotype did not reappear. It is not likely that this specific allotype is 
being actively suppressed through the life of the rabbits, therefore these data 
suggest that B cell development is arrested early in life (Eskinazi et al., 1979). In 
fact, the paternal allotype never recovered even though a low frequency of 
paternal allotype containing progenitors could be found (Simons et al., 1979). 
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Therefore, it was concluded that there must be a block in B cell development. 
Because mouse B lymphopoiesis does not decline until late in life, you would 
expect allotype suppression experiments would not produce a lasting effect. This 
is the case, as one study performing allotype suppression experiments in young 
mice found the suppressed allotype reappeared 6 weeks after suppression (Lalor 
et al., 1989). 
B lineage progenitor frequencies. Several studies have tracked various 
B lineage progenitor frequencies as a function of time by flow cytometry. Jasper 
et al., found that proB cells reach peak levels in the first few weeks following birth 
(Jasper et al., 2003). Several other studies found that preB cells also reach their 
highest frequencies shortly after birth (Gathings et al., 1981, Gathings et al., 
1982, Hayward et al., 1978, McElroy et al., 1981). Within the first month of life 
proB and preB cells each comprise approximately 7% of hematopoietic cells in 
the BM. By 2 months these populations were reduced to 1% of the BM, and 
undetectable in the BM of 4 month old rabbits. These date indicate that active B 
lineage development arrests by 2-4 months of age. Interestingly, Jasper et al. 
(2003) noticed that as B lineage progenitors were lost, increased frequencies of 
mature B cells could be found in the BM. This finding is consistent with that of 
Nunez et al., who saw a similar phenomenon in human BM (Nunez et al., 1996). 
B cell recombination excision circle analysis. The early decline of 
rabbit B lymphopoiesis was further confirmed on the molecular level through 
BREC analysis of rabbit BM. BRECs form in B lineage progenitors during VDJ 
gene recombination and can be used as a measure of ongoing B cell 
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development. Crane et al. utilized this method looking for BRECs formed from 
VD and DJ rearrangements (Crane et al., 1996). As expected, BRECs were 
found at high levels in newborn rabbits and reduced in adult rabbits. Consistent 
with the percentages of B lineage progenitors found in rabbit BM, the highest 
levels of BRECs could be detected in BM shortly after birth. Additionally, BREC 
detection was reduced at 2 months of age, and was barely detectable at 4 
months of age (Jasper et al., 2003). In control experiments, young (1-2 week) 
and adult (4 month) mouse BM was analyzed for BRECs. Young and adult 
mouse BM contained robust levels of BRECs, consistent with ongoing B 
lymphopoiesis at this time in mice.  Overall, these molecular and cellular studies 
of B cell development lead us to conclude that rabbit B lymphopoiesis is lost by 
2-4 months of age. 
Mechanisms that negatively regulate B cell development. As reviewed 
earlier, the decline in mouse B lymphopoiesis can be attributed to both intrinsic 
defects in hematopoietic progenitors and extrinsic changes to the 
microenvironment. To address whether intrinsic or extrinsic mechanisms 
contribute to the arrest in rabbit B lymphopoiesis, Kalis et al. asked if rLPs from 
the BM of >2 month old rabbits are capable of differentiating into B lineage cells 
in vitro (Kalis et al., 2007). The authors cultured isolated MHCII-IL-7R+ rLPs with 
OP9 BM stromal cells (Holmes and Zuniga-Pflucker, 2009), then assessed the 
number of B lineage cells resulting from these cultures. Interestingly, rLPs 
isolated from the BM of >2 month old rabbits were capable of differentiating into 
B lineage cells. To complement this finding, the authors also adoptively 
33 
transferred BM progenitors from >2 month old rabbits into young (<2 month old) 
irradiated rabbits. Consistent with in vitro culture of rLPs, BM progenitors derived 
from >2 month old rabbits were able to differentiate into B lineage cells after 
transferred into young irradiated recipients. The ability of BM cells from >2 month 
old rabbits to differentiate into B lineage cells suggests that the loss of B cell 
development in rabbits is not due to intrinsic defects in hematopoietic 
progenitors, and instead suggests changes to the BM microenvironment are 
responsible for this arrest. 
B lymphopoiesis is an orchestrated process, where even subtle changes 
to the microenvironment can alter the output of naïve B cells. Changes in the BM 
microenvironment fall into two major categories; the loss of supportive factors or 
an increase in negative regulators. Several studies have assessed how each of 
these categories contributes to the decline of B lymphopoiesis in rabbits. 
Together, the studies reviewed next provide the basis for which B cell 
development is lost. 
Loss of supportive microenvironment. IL-7 is one of the most critical 
supportive factors provided by the BM microenvironment. IL-7-/- mice have 
impaired B cell development (Tsapogas et al., 2011, Wei et al., 2000), and 
Stephan et al (1998) found that BM stromal cells from aged mice are defective in 
their ability to supply hematopoietic progenitors with IL-7 (Stephan et al., 1998). 
Further, high fat diet was found to impair B lineage development in mice, at least 
in part through decreased expression of IL-7 in the microenvironment (Adler et 
al., 2014). In rabbits, IL-7 was also found to be critical for B lymphopoiesis (Kalis 
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et al., 2007). Therefore it is plausible that a reduction of IL-7 expression in BM 
from >2 month old rabbits could result in impaired B cell development. To test 
this, Kalis et al. (2007) analyzed IL-7 expression in the BM of <2 month and >2 
month old rabbits by northern blot. Surprisingly, IL-7 was found to increase in the 
older rabbits, suggesting decreased IL-7 is not responsible for the impairment. In 
a separate study, an additional isoform of IL-7 identified as IL-7II, also increased 
in the BM of older rabbits (Siewe et al., 2010). It was thought that this isoform 
could possibly have a negative impact on B lymphopoiesis. However further 
study of IL-7II, found that it bound IL-7R and acted similarly to canonical IL-7. 
From these studies, we can conclude that changes in the supportive cytokine IL-
7 do not contribute to the decline of B lymphopoiesis in rabbits. 
Siewe et al. set out to characterize BM stromal cells to identify supportive 
factors that are altered with age (Siewe et al., 2011). The authors performed a 
representational difference analysis (RDA), comparing MSCs isolated from a 
newborn rabbit and a 2 year old rabbit. Several factors were identified as 
downregulated in the 2 year old rabbit, with periostin (extracellular matrix protein) 
being the lowest expressed. The authors hypothesized that the decrease in 
periostin could contribute to the decline in B cell development. In vitro, the 
authors found periostin to be required for rabbit B lineage development, as 
siRNA knockdown of periostin in OP9 stromal cells inhibited their ability to 
support development. Further gene expression analysis showed that in OP9 with 
siRNA knock down, IL-7 and CXCL12 were also decreased. Periostin-/- mice are 
readily available, and the authors found that B lymphopoiesis was not impaired in 
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these mice, suggesting that in vivo loss of periostin may be masked by other 
redundant supportive factors. 
Expression of fibronectin, collagen type I, thrombospondin, the tumor 
suppressor FAT, and frizzled 4 were also found to be decreased in BM stromal 
cells from the 2 year old rabbit. To date, the decrease in these or other factors 
have not been linked to the loss of B cell development in rabbits. Additional 
studies assessed whether changes in support on the cellular level, as well as 
increases in negative regulators contribute to decreased B cell development. 
Age-related changes to BM stromal cells. To identify changes in BM 
stromal cells at 2 months of age, Bilwani and Knight focused on MSCs which 
give rise to osteoblasts and adipocytes (Bilwani and Knight, 2012). The authors 
first examined if MSC number changes between young rabbits and older rabbits 
(>2 months of age). Through analysis of the number of CFU-Fibroblasts (CFU-F) 
(Mareschi et al., 2012), Bilwani and Knight found that MSC number was reduced 
10-fold shortly after birth. In addition to decreased number, MSCs from rabbits >2 
month old were more likely to differentiate into adipocytes rather than 
osteoblasts. This study suggests that fewer osteoblasts in the BM could 
contribute to decreased B lymphopoiesis, as osteoblasts support this process.  
Adipocytes fill the bone marrow with age. The finding that rabbit MSCs 
had increased potential toward the adipocyte lineage raises some questions; do 
adipocytes increase in rabbit BM with age, and do adipocytes contribute to the 
arrest of B cell development? Interestingly, adult rabbit BM has been reported to 
contain significant amounts of fat (Bigelow and Tavassoli, 1984). In fact, the 
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accumulation of adipose tissue in the BM of rabbits mimics that of aged humans, 
where 50% of the femur and 70% of the tibia fills with adipose tissue (Li et al., 
2013). It should also be noted that while adipose tissue increases with age in  
humans, mice, and rabbits (Chinn et al., 2012, Justesen et al., 2001, Lecka-
Czernik et al., 2010, Rosen et al., 2009, Tuljapurkar et al., 2011), the timing 
correlates with declining B lymphopoiesis.  
In the past, the prevailing view of BM fat was that it is inert and simply 
filling unused space. Recent studies have now established adipocytes as major 
producers of local and systemic factors that influence many processes. Because 
adipocytes accumulate as B lymphopoiesis declines, Bilwani and Knight tested if 
adipocytes influence B lineage development (Bilwani and Knight, 2012). Through 
culture of rabbit BM progenitors with OP9 stromal cells in the presence or 
absence of adipocyte-conditioned medium (ACM), it was found that cultures 
containing ACM had fewer CD79a+ B lineage cells develop. This result suggests 
that adipocytes produce molecules that actively inhibit B lymphopoiesis. 
Therefore, the loss of B cell development in aged rabbits is likely due to having 
decreased support from fewer osteoblasts and an increase in negative regulators 
produced by adipocytes. While adipocytes inhibit B lymphopoiesis, the 
mechanism by which this occurs is unknown. 
SECTION 3: THE IMPACT OF BONE MARROW FAT AND INFLAMMATION 
ON LYMPHOPOIESIS 
Early studies of BM fat were performed in rabbits by Tavassoli and 
colleagues during the 1970s. In recent years there has been renewed interest in 
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understanding BM fat in humans, mice, and rabbits. Adipose tissue can be 
described in multiple ways, such as by color (brown vs. beige vs. white), 
inflammatory state (pro-inflammatory vs. anti-inflammatory), and in terms of its 
ability to fuel hematopoiesis (regulated vs. constitutive). Here I will review critical 
studies which have shaped our understanding of the relationship between 
adipose tissue, hematopoiesis, aging, and obesity. 
In addition to aging, adipocytes commonly accumulate in the BM of 
patients following chemotherapy and irradiation. Therefore, it is important to 
understand how adipocytes impact neighboring red marrow. Several studies 
suggest that BM fat has a negative effect on hematopoiesis (Bilwani and Knight, 
2012, Naveiras et al., 2009). Naveiras et al. compared BM from mouse thoracic 
vertebrae (adipocyte free) and tail vertebrae (adipocyte rich) to understand if 
adipocytes influence hematopoietic activity. Upon analysis of hematopoietic stem 
and progenitor cell populations (HSPC), the frequency and number of progenitors 
was significantly lower in adipocyte rich tail vertebrae compared to thoracic 
vertebrae. A similar analysis of thoracic and tail vertebrae in fatless mice (A-
ZIP/F1) showed no difference in adipocyte accumulation and similar numbers of 
progenitors in these locations, suggesting that the presence of adipocytes 
negatively affects hematopoietic progenitor numbers. Fat accumulates in the BM 
after irradiation and is thought to negatively impact engraftment of newly 
transplanted BM. To test this notion, the authors performed BM transplants in WT 
or fatless mice with the expectation that fatless mice would have better recovery 
of hematopoietic cells compared to WT. As expected, fatless mice had 
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significantly less BM fat than WT mice after irradiation and exhibited better 
recovery of leukocytes after BM transplantation. These results suggest that the 
presence of adipocytes negatively impacts hematopoietic activity. Coupled with a 
study by Bilwani and Knight that found B lymphopoiesis to be particularly 
sensitive to adipocyte factors in human and rabbit cultures (Bilwani and Knight, 
2012), these studies suggest strategies to limit adipocytes in BM would enhance 
hematopoietic activity. 
White, brown, and beige adipocytes 
Adipocytes are typically referred to as white, brown, or beige. White 
adipose tissue is best known for its role in energy storage, expanding in states of 
nutrient excess and contracting with a negative energy balance. Recent 
advances in adipose tissue biology have also identified white adipose tissue as 
an endocrine organ, able to integrate metabolic signals and produce adipokines 
that influence other organs (Ouchi et al., 2011). Consistent with its ability to 
respond to nutrient state, adipose tissue is thought to become a source of pro-
inflammatory cytokines in scenarios of high fat diet (Chatterjee et al., 2009, Ouchi 
et al., 2011). The inflammatory state of adipose tissue will be discussed further 
below. 
Brown adipocytes. Brown adipocytes produce heat through the process 
of thermogenesis. While brown adipocytes also accumulate lipids, they can be 
distinguished from white adipocytes through their abundant numbers of 
mitochondria and high levels of uncoupling protein1 (UPC1), which are critical 
components for heat production (Cannon and Nedergaard, 2004). 
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Thermogenesis from brown adipocytes is important to maintain body temperature 
and is typically induced by cold stress (Peirce et al., 2014). This process requires 
large amounts of energy, therefore making brown adipose tissue is an important 
regulator of energy balance. In fact, Rothwell and Stock (1979) discovered diet 
induced thermogenesis in rats, where heat production was activated by brown 
adipose tissue in response to overeating (Rothwell and Stock, 1979). The 
authors further suggested that brown adipose tissue may counteract obesity.  
Lowell et al. tested if brown adipose tissue counteracts obesity by 
generating two transgenic mouse lines that are deficient in brown adipocytes 
(Lowell et al., 1993). Both mouse lines developed obesity, identifying a role for 
brown adipose tissue in the prevention of obesity. Consistent with this result, one 
of the transgenic mouse strains was able to recover brown adipose tissue over 
time, which was coupled with the resolution of obesity in these mice. Similar 
results were seen in a study by Feldman et al. while studying UCP1 deficient 
mice (Feldmann et al., 2009). As expected the enormous amount of energy 
utilized by brown adipocytes during thermogenesis is key to the anti-obesity 
effect, as Cannon and Nedergaard found that mice kept in cooler temperatures 
needed to eat more calories to maintain the same body weight as mice kept at 
warmer temperatures. Mice kept at room temperature need to eat two thirds 
more than mice kept at 30o to stay at a consistent body weight (Cannon and 
Nedergaard, 2009, Peirce et al., 2014). 
Beige and white adipocytes. Beige adipocytes are similar to brown 
adipocytes in that they are capable of producing heat through thermogenesis 
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(Vitali et al., 2012). Beige adipocytes are induced in white adipose tissue 
suggesting that they share a precursor with white adipocytes, but they behave 
like brown adipocytes which come from a distinct precursor cell (Seale et al., 
2008). In other terms, brown adipose tissue consists of UCP1+ brown adipocytes 
capable of producing heat. White adipose tissue contains UCP1- white 
adipocytes that store excess energy and produce various adipokines, while also 
containing UCP1+ beige adipocytes which are induced to undergo thermogenesis 
by various activators (Petrovic et al., 2010, Wu et al., 2013). Because beige 
adipocytes  expend large amounts of energy, they may also contribute to the 
prevention of obesity (Harms and Seale, 2013). Therefore it is logical that 
changes in adipose tissue leading to less brown/beige fat and increased white 
fat, may contribute to the pro-inflammatory state seen during aging and obesity.  
Age-related change in BM adipose tissue phenotype. Krings et al. 
characterized BM fat in young/adult (5 months) and old mice (24-26 months) for 
brown and white adipocyte characteristics (Krings et al., 2012). While BM 
adipocytes were increased in aged mice, there were also specific changes in the 
type of adipocytes present with increased age. BM adipose tissue was analyzed 
for the expression of six genes characteristic of brown adipose tissue including 
UCP1, as well as leptin and adiponectin which are characteristic of white adipose 
tissue. Young/adult BM adipose tissue expressed genes characteristic of both 
brown and white adipose tissue, suggesting BM fat has a brown and white, or 
beige phenotype. This phenotype, however, changed with age. Compared to 
young/adult mice, old BM adipose tissue lost features of brown adipose tissue, 
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and more closely resembled white adipose tissue. The resemblance of aged BM 
fat to white adipose tissue is also supported by an observation by Bainton et al. 
who observed that yellow marrow stromal cells in adult rabbits had 
characteristics of 3T3.L1 white adipocytes (Bainton et al., 1986). The changes in 
BM adipose tissue phenotype with age, suggests there are also functional 
consequences. Krings et al. found the age-related changes in BM adipose tissue 
to be consistent with the phenotype of BM adipose tissue in yellow agouti 
diabetic mice. Together these results led the authors to suggest the changes in 
BM adipose tissue during aging and diabetes likely contribute to the negative 
effect on hematopoiesis seen in these conditions. 
Regulated versus constitutive marrow fat 
Several studies suggest that fat has a negative effect on 
hematopoiesis/lymphopoiesis (Bilwani and Knight, 2012, Naveiras et al., 2009). 
In light of the studies described above (in this section), it is now clear that 
adipose tissue and the types of adipocytes that comprise adipose tissue are very 
complex. Therefore, it is likely that certain types of adipocytes support 
hematopoiesis in young healthy mammals, but age and obesity related changes 
to BM adipose tissue results in a negative impact on hematopoiesis. 
In support of this idea, several studies have categorized marrow fat as 
regulated or constitutive. This categorization refers to marrow fat and its 
relationship to hematopoiesis. In the 1970s, Tavassoli observed two types of 
adipocytes in rabbit BM differentiated by their fatty acid composition through 
staining with performic acid Schiff reagent (PFAS) (Tavassoli, 1976). PFAS+ 
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adipocytes are found in red marrow and are thought to fuel hematopoiesis, as 
treatment of rabbits with hemolysis agents stimulated hematopoiesis and 
depleted PFAS+ adipocytes. Therefore PFAS+ adipocytes in red marrow are now 
referred to as regulated marrow fat rMAT (Scheller and Rosen, 2014). In contrast 
to rMAT, PFAS- adipocytes are found in yellow marrow and are not deleted by 
hematopoiesis. In fact, PFAS- marrow fat appears to be unresponsive to changes 
in diet, as 10 days of starvation did not reduce the volume of fat in the distal tibia 
of rabbits (Tavassoli, 1974). Therefore, this type of marrow fat was termed 
constitutive marrow fat (cMAT). Similar to that seen in mice (Naveiras et al., 
2009), increased marrow fat was also found to correlate with reduced 
hematopoiesis in rabbits (Bigelow and Tavassoli, 1984).  
While more studies are needed to link the way various studies have 
described adipocytes (color, inflammatory state, in terms of supporting 
hematopoiesis), it is likely that the age/obesity related loss of brown 
characteristics and dysregulation of white adipose tissue resulting in increased 
danger signals and pro-inflammatory cytokines lead to a negative impact on 
lymphopoiesis.  
Adipocytes, inflammation and the decline of T lymphopoiesis 
Inflammatory mediators and lipotoxic danger signals from adipose tissue 
have been implicated in thymic atrophy and the decline of T cell development 
during aging and obesity. Similar to the BM, adipose tissue accumulates in the 
thymus during atrophy with age. Youm et al. hypothesized that increased 
adipose tissue in the thymus provides pro-inflammatory danger signals that 
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contribute to thymic decline. By comparing young and old (24 month) WT or 
inflammasome deficient (NLRP3-/- or ASC-/-) mice, the authors found that blocking 
inflammasome activation delayed thymic atrophy (Youm et al., 2012). This study 
suggested that inflammatory danger signals that accumulate with age negatively 
regulate T lymphopoiesis. Adipose tissue derived products and diet were further 
linked to thymic decline as high fat diet accelerated and calorie restriction 
delayed thymic atrophy (Yang et al., 2009a, Yang et al., 2009b). It is unknown 
whether B lymphopoiesis is negatively regulated through inflammasome 
activation. While B cell development is negatively regulated by adipocyte 
products, the responsible molecules remain to be identified. 
Adipose tissue derived molecules 
Adipose tissue is made up of adipocytes, as well as infiltrating immune 
cells. As a whole, the pro-inflammatory or anti-inflammatory state of adipose 
tissue is representative of the molecules produced by adipocytes and immune 
cells. Healthy adipose tissue is characterized by unstressed adipocytes and anti-
inflammatory immune cells (such as M2 suppressive macrophages) (Chawla et 
al., 2011, Mraz and Haluzik, 2014). Adipose tissue seen in aging and obesity is 
pro-inflammatory in nature, resulting in the production of danger associated 
molecular patterns (from stressed adipocytes) and inflammatory cytokines (from 
adipocytes and immune cells) (Chawla et al., 2011, Lago et al., 2007, Wen et al., 
2011, Youm et al., 2012, Youm et al., 2013). Pro-inflammatory adipose tissue is 
also characterized by an increase in dying adipocytes, pro-inflammatory M1 
macrophages, and interferon-γ producing TH1 cells (Chawla et al., 2011, Winer 
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et al., 2009). While adipose tissue is the source of many molecules, some of the 
most studied are highlighted below. 
Adipocytes secrete many factors that influence processes throughout the 
body, either acting as an endocrine organ or locally. Recent research has 
identified adipose tissue as an immune organ. Adipocytes secrete many classes 
of molecules including: Proteins and lipids. 
Proteins. Adipocytes secrete many immune-modulatory proteins, such as, 
adiponectin, TGFβ, and leptin. Adiponectin and TGFβ are known to inhibit B 
lymphopoiesis indirectly by acting on stromal cells in mouse co-culture 
experiments(Tang et al., 1997). Conversely, adipocytes also have the potential to 
support B lymphopoiesis through the production of leptin(Claycombe et al., 
2008). 
Lipids. Adipocyte-derived lipids consist of a variety of bioactive molecules 
classified based on their relative insolubility in water and include steroids, fatty 
acids, and fatty acids derivatives. For example, adipocytes can produce the 
steroid estrogen(Bulun and Simpson, 1994, Grodin et al., 1973, Nelson and 
Bulun, 2001, Yamada and Harada, 1990), which was found to inhibit B 
lymphopoiesis by acting directly on the CLP and acting indirectly on stromal 
cells(Kouro et al., 2001, Smithson et al., 1995, Yokota et al., 2008). 
Prostaglandins, a fatty acid derivative, are also known to inhibit B lymphopoiesis 
by directly acting on B lymphocyte progenitors(Yokota et al., 2003). Additionally, 
adipocytes produce fatty acids. It is unclear whether fatty acids positively or 
negatively regulate B lymphopoiesis, but fatty acids are known to activate TLRs 
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on macrophages and adipocytes promoting the production of inflammatory 
cytokines and reactive oxygen species (ROS)(Han et al., 2012, Huang et al., 
2012, Shi et al., 2006, Wong et al., 2009). 
Anti-inflammatory molecules 
Adiponectin. Adiponectin is an anti-inflammatory protein produced 
primarily by adipocytes. This protein is at its highest concentration in healthy 
individuals and is decreased in obese patients (Ryo et al., 2004). Oxidative 
stress and pro-inflammatory cytokines produced in dysregulated adipose tissue 
block the production of adiponectin by adipocytes (Berg and Scherer, 2005, 
Hosogai et al., 2007, Ouchi et al., 2003). Reduced adiponectin is associated with 
increased risk of type II diabetes (Li et al., 2009, Ouchi et al., 2003), while calorie 
restriction was found to increase adiponectin production in BM adipose tissue, 
making it the systemic source of this anti-inflammatory molecule (Cawthorn et al., 
2014). In terms of B lymphopoiesis, adiponectin was found to have a negative 
effect (Yokota et al., 2003). Although, adipocyte factors other than adiponectin 
were also found to inhibit B lymphopoiesis (Bilwani and Knight, 2012). 
Pro-inflammatory molecules 
IL-6. IL-6 is a pro-inflammatory cytokine produced by adipocytes and other 
cells in adipose tissue (Fried et al., 1998, Van Snick, 1990). Increased IL-6 levels 
are observed in obese individuals and individuals with type II diabetes. 
Production of this cytokine appears to increase with increased adipose tissue 
and can be controlled by diet, as IL-6 levels were reduced in patients after losing 
weight (Esposito et al., 2003, Fried et al., 1998, Ouchi et al., 2011, Ziccardi et al., 
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2002). Similar to obesity, production of IL-6 from adipose tissue also increases 
during aging (Starr et al., 2009, Tchkonia et al., 2010). This cytokine has many 
immunomodulatory effects and, if available in niches containing HSPCs, has the 
potential to inhibit B cell development (Maeda et al., 2005, Maeda et al., 2009). 
IL-6 can also work with other factors to mediate various outcomes. For example, 
IL-6 treatment in combination with TNFα was found to promote BM macrophage 
differentiation into osteoclast-like cells (Yokota et al., 2014). 
TNFα. TNFα production increases during obesity as adipocytes increase 
in size and ultimately contributes to insulin resistance (Feingold et al., 1992, 
Hotamisligil et al., 1994, Ouchi et al., 2011, Spiegelman et al., 1993). Myeloid 
lineage cells are the main source of TNFα in adipose tissue. Similar to IL-6, 
adipose tissue production of TNFα increases with obesity and type II diabetes 
(Hotamisligil et al., 1993), and can be decreased by weight loss (Kern et al., 
1995, Ziccardi et al., 2002). If present in the BM, TNFα induces an inflammatory 
state that promotes granulopoiesis (Ueda et al., 2004). 
S100A8, S100A9, and S100A8/A9. Adipose tissue is the source of 
S100A8 and S100A9. These proteins can form S100A8/A8 or S100A9/A9 
homodimers in addition to S100A8/A9 heterodimers. S100A8 and S100A9 
proteins have multiple functions intracellularly and extracellularly, which include 
anti-microbial activity, intracellular calcium binding, and alarmin/pro-inflammatory 
effects (Vogl et al., 2012). Activated and dying myeloid cells are the primary 
source of extracellular S100A8 and S100A9 leading to a potent inflammatory 
response (Ehrchen et al., 2009, Nacken et al., 2003). It was initially thought that 
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S100A8/A9 was produced by adipocytes in adipose tissue, but recent evidence 
suggests that S100A8 is primarily produced by adipocytes and S100A9 is 
produced by macrophages within the adipose tissue (Sekimoto et al., 2012). The 
expression of these molecules is upregulated in many tissues during aging and 
obesity (Nagareddy et al., 2014, Schiopu and Cotoi, 2013, Sekimoto et al., 2012, 
Swindell et al., 2013), however the impact these proteins have on B 
lymphopoiesis is unknown. 
Complement factors . Adipose tissue is a source of many complement 
proteins, including C3a, C5a, factor B, and factor D (adipsin) (Pattrick et al., 
2009, Vlaicu et al., 2016). Complement proteins have important functions in the 
maintenance of adipose tissue, but can also contribute to adipose tissue 
inflammation. For example, a cleavage product of C3a, called C3adesArg is 
critical to promote triglyceride synthesis in normal adipocytes and promote 
differentiation of pre-adipocytes into mature adipocytes (MacLaren et al., 2008, 
Maslowska et al., 2005, Saleh et al., 2011, Yasruel et al., 1991). The generation 
of C3adesArg from C3a is mediated by the enzyme carboxypeptidase N. 
C3adesArg is unable to bind the C3 receptor but instead binds the receptor C5-
like receptor 2 (C5L2), which can also be bound by C5a (Vlaicu et al., 2016). This 
process contributes to the normal maintenance of healthy adipose tissue. 
Alternatively, dysregulation of normal homeostasis in adipose tissue leads to 
complement mediated inflammation, where both C3R and C5R have been 
implicated in adipose tissue inflammation during obesity (Lim et al., 2013, 
Mamane et al., 2009, Phieler et al., 2013). Consistent with IL-6 and TNFα serum 
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levels (as reviewed above), C3a serum concentration is increased in obese 
individuals and can be lowered through weight reduction (Nestvold et al., 2015, 
Nilsson et al., 2014, Oberbach et al., 2011, Sleddering et al., 2014). 
Danger associated molecular patterns (DAMPS). In inflammatory 
adipose tissue, adipose tissue macrophages form crown-like structures that 
surround dying adipocytes. These adipocytes become the source of additional 
danger signals such as lipids and reactive oxygen species that trigger an 
inflammatory profile in the macrophages. Adipose tissue macrophages are 
commonly seen phagocytosing lipids and becoming lipid laden cells (Chawla et 
al., 2011, Strissel et al., 2007). Free cholesterol, lipid crystals, ceramides, and 
fatty acids derived from adipocytes and taken up by adipose tissue macrophages 
induce inflammation through inflammasome activation (Coppack, 2001, Lago et 
al., 2007, Vandanmagsar et al., 2011, Wen et al., 2011, Youm et al., 2012). 
These danger signals are sensed by the nod-like receptor, NLRP3, triggering 
inflammasome activation. Nod-like receptor activation results in association of 
the receptor, adaptor protein ASC, and inactive caspase 1; leading to the 
activation of caspase 1. Active caspase 1 then cleaves pro-IL-1β into active IL-
1β, which is a potent mediator of inflammation (Garlanda et al., 2013, Latz et al., 
2013). 
Adipocyte mediated inhibition of B lymphopoiesis: direct block or change 
in lineage potential? 
Adipocyte soluble factors were shown to inhibit B lymphopoiesis in human 
and rabbit BM cultures (Bilwani and Knight, 2012), but the mechanism for this is 
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unknown. While B lineage cells were decreased in cultures treated with ACM, 
this could be due to a block at a specific stage of B lineage development (eg. 
proB cell) or due to a redirection of hematopoiesis away from the B lineage and 
toward another (eg. myeloid, NK, T lineage). Given the large number of 
molecules produced by adipose tissue and the potential for a synergistic effect 
on hematopoiesis, it is reasonable to hypothesize that B lymphopoiesis is not 
simply blocked. In fact, hematopoietic progenitors are able to sense changes in 
their niche, which may lead to changes in differentiation potential. For example, 
pathogen-derived TLR ligands can influence HSCs to differentiate into myeloid 
lineage cells and can induce CLPs to differentiate into dendritic cells (DCs) 
(Nagai et al., 2006, Welner et al., 2008a, Welner et al., 2008b) (Figure 1.6). 
Since adipocytes produce fatty acids that can also activate TLRs, it is possible 
that B cell development is rerouted rather than blocked by adipocyte-derived fatty 
acids.  
Can cells other than adipocytes in the BM negatively regulate B cell 
development? 
Hematopoietic lineage compartments are known to change in the BM in 
response to aging, obesity, infection, etc., but how does this affect B lineage 
development? The degree to which cells in the BM other than adipocytes (such 
as other hematopoietic cells) contribute to declining B lymphopoiesis is not well 
characterized. During aging, aged B cells (ABC) were shown to accumulate in 
aged BM negatively regulating new B lineage development (Ratliff et al., 2013), 
suggesting an altered BM hematopoietic compartment could incluence B cell 
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development. However, additional studies will be needed to understand whether 
other hematopoietic lineage cells can contribute to declining B cell development 
in fatty BM. For example, Enioutina et al. found that myeloid derived suppressor 
cells (MDSCs) accumulate in the BM of aged mice (Enioutina et al., 2011). 
MDSCs are a heterogenous popluation of CD11b+Gr1+ immature myeloid cells 
well known for their ability to suppress T cell responses in cancers (Gabrilovich 
and Nagaraj, 2009). While suppressive to T cell responses, it is unknown 
whether these cells can also affect B cell development. Further study will be 
needed to understand how changes in stromal cells and neighboring 
hematopoietic cells interact with developing B lineage cells.  
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Skewing of hematopoietic lineage potenial. Hematopoietic 
potential can be re-routed away from the B lineage at different stages of 
development. Progenitors sense different molecules in the microenvironment 
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which may result in diversion from the B lineage, to any of the lineages 
diagrammed above. Both TLR ligands and notch ligands have been described to 
act on different stages of development, resulting in altered hematopoietic 
potential. (Adapted from Welner et al., 2008) 
 
SIGNIFICANCE 
Increased susceptibility to infections and poor immune responses to 
vaccination put elderly individuals at an increased risk of mortality. 
Microenvironmental changes in the aged BM and thymus result in decreased 
output of new lymphocytes into the periphery, limiting the immune system’s 
ability to respond and clear new infections. Accumulation of adipose tissue in 
aged BM was previously considered to be inert. But recent understanding of 
adipocytes as immune regulators has allowed the scientific community to realize 
that adipose tissue is actively influencing hematopoiesis. Multiple 
studies(Naveiras et al., 2009, Yang et al., 2009a, Youm et al., 2009, Youm et al., 
2010) have now shown that adipose tissue negatively regulates the development 
of new immune cells in the BM and thymus. But detailed study of the 
mechanisms by which adipocyte-derived factors negatively regulate 
hematopoiesis is imperative, in order to develop therapeutics aimed at 
rejuvenating immune cell development in aged individuals. 
GOAL OF DISSERTATION 
The goal of this dissertation is to understand the mechanism by which 
adipocyte factors inhibit B cell development. We hypothesize that different 
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adipocyte-derived factors inhibit/reroute B lymphopoiesis by: 1.) Acting directly 
on hematopoietic B lineage progenitors and/or 2.) Acting indirectly, altering BM 
stromal cells or neighboring hematopoietic cells. These studies were performed 
with the intention of identifying targets for therapies designed to boost B 
lymphopoiesis in aged and obese individuals with fatty BM. 
An additional goal is to relate the identified mechanisms to the arrest 
of B cell development that occurs at 2 months of age in the BM of rabbits. 
The rabbit appears to be a model of accelerated BM aging, therefore further 
characterization of rabbit BM will be useful in understanding the changes that 
occur later in life of humans and mice. 
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CHAPTER II 
EXPERIMENTAL METHODS 
Mice 
C57BL/6 breeding pairs were purchased from the Jackson Laboratory 
(Bar Harbor, ME). All mice were used in compliance with protocols approved by 
the Loyola University Chicago Institutional Animal Care and Use Committee. 
Rabbits 
New Zealand White rabbits were maintained at Loyola University Chicago. 
All rabbits were used in compliance with protocols approved by the Loyola 
University Chicago Institutional Animal Care and Use Committee.   
Tissue/cell culture reagents  
AlphaMEM and RPMI base medium were purchased from Life 
Technologies (Grand Island, NY), along with all tissue culture supplements. 
Recombinant murine IL-7, SCF, Flt3L, IL-1α, IL-1β, IL-13, G-CSF, KC, MCP-1, 
MIP-1α, MIP-1β, RANTES and human IL-7, SCF, Flt3L were purchased from 
PeproTech (Rocky Hill, NJ). Recombinant murine S100A8 was purchased from  
Abcam (Cambridge, MA) and murine S100A9 was purchased from R&D systems 
(Minneapolis, MN). 
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Flow cytometry 
Antibodies used to stain mouse cells in this study are listed in table 2.1. 
Available antibodies for staining rabbit cells are listed in table 2.2. Dead cells 
were excluded from flow cytometry analyses using BD Horizon fixable viability 
stain (BD Biosciences, San Jose, CA) or Fixable Viability Dye eFluor 450 
(eBioscience, San Diego, CA). FACS sorting was performed using a FACSAria 
cell sorter (BD Biosciences). All stained cells were analyzed by flow cytometry 
using a FACSCanto II or LSRFortessa flow cytometer (BD Biosciences). Flow 
cytometry data were analyzed using FlowJo software (Tree Star, Ashland, OR). 
 
Table 2.1 Mouse antibodies used in this study. 
Antibody reactivity Clone Company 
B220 RA3-6B2 Biolegend 
CD19 6D5 Biolegend 
CD11b M1/70 Biolegend 
Gr1 RB6-8C5 Biolegend 
CD14 Sa14-2 Biolegend 
CD3ε 145-
2C11 
Biolegend 
CD4 GK1.5 Biolegend 
CD8a 53-6.7 Biolegend 
TER-119 TER-119 Biolegend 
CD49b DX5 Biolegend 
CD16/32 –Fc Block 93 Biolegend 
CD28 37.51 Biolegend 
Ly6C HK1.4 Biolegend 
Ly6G 1A8 Biolegend 
Sca1 D7 eBioscience 
CD117 2B8 Biolegend 
CD127 SB/199 Biolegend 
CD135 A2F10 Biolegend 
IL-1α BLa-89 Biolegend 
IL-1β B122 Biolegend 
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Table 2.2 Antibodies available for the detection of rabbit immune cell 
antigens. 
 
Antibody reactivity Clone Specificity 
CD1b LAT3 Rabbit 
CD3 PC3/188A Rabbit 
CD4 Ken4 Rabbit 
CD9 MM2 Rabbit 
CD10 CD-
CALLA 
Human, cross reacts with rabbit 
CD11b 198 Rabbit 
CD11b M1/70 Human, mouse, cross reacts with rabbit 
CD11c 3/22 Rabbit 
CD14 K4 Rabbit 
CD14 TÜK4 Human, cross reacts with rabbit 
CD20 B9E9 Human, cross reacts with rabbit 
CD21 BL13 Human, cross reacts with rabbit 
CD23 9P25 Human, cross reacts with rabbit 
CD24 M1/169 Mouse, cross reacts with rabbit 
CD25 Kei-α1 Rabbit 
CD27 LT27 Human, cross reacts with rabbit 
CD38 IB6 Human, cross reacts with rabbit 
CD43 L11/43 Rabbit 
CD44 W4/86 Rabbit 
CD62L LAM-1 Human, cross reacts with rabbit 
CD79a HM47 Human, cross reacts with rabbit 
CD90 5E10 Human, cross reacts with rabbit 
BAFF Polyclonal Human, cross reacts with rabbit 
BCL6 BL6.02 Human, cross reacts with rabbit 
BR3 Polyclonal Human, cross reacts with rabbit 
Complement C3 Polyclonal Rabbit 
Caspase 3 C92-605 Human, mouse, cross reacts with rabbit 
Ki67 B56 Human, cross reacts with rabbit 
MHC II 2C4 Rabbit 
Anti-Macrophage RAM11 Rabbit 
IgM 367 Rabbit 
IgA 102 Rabbit 
IgG 359 Rabbit 
Ig Light Chain Polyclonal Rabbit 
S100A8/S100A9 MAC387 Rabbit, mouse, human, cow, dog, pig, 
monkey 
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Microscopy 
Microscopy experiments were visualized on a Leica DM IRB microscope 
(Leica Microsystems, Buffalo Grove, IL). Image collection was performed using a 
Magnafire 2.1C camera system and software. 
Preparation of bone marrow cells  
Mouse. Mouse femurs and tibias were cleaned with 70% ethanol, and 
then rinsed with alphaMEM medium. The bones were flushed with medium (15ml 
per 2 femurs and 2 tibias) using a 27 gauge needle, followed by red blood cell 
(RBC) lysis using ammonium-chloride-potassium lysis buffer. Cells were then 
washed with medium and used in downstream assays. 
Rabbit. Femurs and tibia were washed with 70% ethanol and rinsed with 
medium. Bones were broken open and the marrow was flushed with 20-40ml of 
medium using a 16 gauge needle. RBCs were lysed using 0.85% ammonium 
chloride, washed in medium, and used in downstream cultures or analyses. 
B lymphopoiesis assay (BM cultures)  
All B lymphopoiesis culture assays were performed in alphaMEM with 
supplements at the following final concentrations: 10% FCS, 0.5% 
penicillin/streptomycin, 30 mg/ml gentamicin, and 0.5 mg/ml fungizone. 
Mouse. On day 0, 1,000 OP9 BM stromal cells were plated per well in 96 
well plates. Day 1, mouse BM cells were depleted of B220+ B lineage cells by 
magnetic bead separation using an autoMACS Pro separator (Miltenyi Biotec, 
Auburn, CA). Then, 40,000 B220- BM cells were plated in 96 well plates 
(containing OP9 cells) in the presence of murine IL-7 (10ng/ml), SCF (10ng/ml), 
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and Flt3L (10ng/ml). Cultures were performed with or without the indicated 
treatments. ACM treatment was typically performed at a 1:6 dilution and MDSC-
CM was typically used at a 1:3 dilution. Four days later fresh cytokines were 
added to BM cultures, followed by termination of cultures between day 7 and day 
10. At the end of culture, cells were collected, counted, and prepared for flow 
cytometry analysis. 
Arginase and iNos studies. For experiments assessing the contribution 
of arginase and iNos, 0.3mM Nω-hydroxy-nor-arginine (Nor-NOHA) and/or 0.3mM 
NG-monomethyl-L-arginine (L-NMMA) were used to block arginase and iNos, 
respectively. Additionally, the control compound NG-monomethyl-D-arginine (D-
NMMA) was used to assess off-target effects of L-NMMA. 
IL-1 studies. For experiments assessing IL-1, 1µg/ml anti-IL-1α and 
1µg/ml anti-IL-1β antibodies (or isotype control antibodies) were added at the 
initiation of BM cultures. Similar results were obtained using these antibodies in 
combination with 1µg/ml human IL-1R antagonist. 
Hematopoietic progenitor studies. For experiments with purified 
progenitor cells, 500-1,000 HSCs, MPPs, or CLPs were seeded onto OP9 cells in 
the presence of murine IL-7 (10ng/ml), SCF (10ng/ml), Flt3L (10ng/ml), and the 
indicated treatment. Cultures were given fresh cytokines (as described 
previously), followed by flow cytometry analysis 5-10 days after the cultures were 
initiated. Lineage negative cells (Lin-) were defined as B220-CD3ε-CD8a-CD11b-
TER-119-Gr1-CD49b-. 
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Inflammasome inhibitor studies. The NLRP3 inflammasome inhibitor 
glybenclamide was purchased from Invivogen (San Diego, CA). Glybenclamide 
was added at the start of cultures at the concentrations indicated in the figure. 
24 well plate format. For assays performed in 24 well plates, 5,000 OP9 
cells were plated. 24 hours later 120,000-500,000 B220- BM cells were used as a 
source of progenitor cells. 
Transwell cultures. Transwell cultures were performed in the 24 well 
plate format, where ACM-derived MDSCs were cultured in contact (below 
transwell insert) with BM progenitors or separated by transwell (cultured above 
transwell insert). 
Rabbit. 1,000 OP9 cells per well were plated in 96 well plates on day 0. 
On day 1, 20,000 total BM cells/well (isolated from >2 month old rabbits) were 
used as a source of BM progenitors. These cultures were performed in the 
presence of rabbit IL-7 (10ng/ml), SCF (10ng/ml), and Flt3L (10ng/ml). Fresh 
cytokines were added to cultures 4 days after culture start, followed by 
termination of the cultures between day 7 and day 10. 
T cell proliferation assays 
96 well plates were coated with anti-CD3 and anti-CD28 antibodies in 
0.1M borate buffer pH 8.0. The next day, mouse splenocytes were stained with 
5µM CellTrace violet or Carboxyfluorescein succinimidyl ester (CFSE) 
(ThermoFisher Scientific, Waltham, MA), followed by resuspension in modified 
RPMI 1640 containing 10% FCS. Labeled solenocytes were plated in anti-CD3 
and anti-CD28 coated wells at the concentrations of 250,000 cells/well or 
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300,000 cells/well with or without effector cells (ACM-generated CD11bhiGr1+ 
cells or CD19+ control cells) ranging from 12,500-100,000 cells/well. Four days 
later, cultures were stained for flow cytometry analysis with anti-CD4 and anti-
CD8 antibodies and the dilution of CFSE was assessed. 
For experiments assessing arginase and iNos activity, 0.3mM Nor-NOHA 
(arginase inhibitor) and 0.3mM L-NMMA (iNos inhibitor) were added to cultures. 
Adipocyte differentiation and conditioned medium generation 
Mouse Adipocytes. 3T3.L1 pre-adipocytes were used to generate 
adipocytes (provided by Dr. Neil Clipstone – Loyola University Chicago). 80,000 
pre-adipocytes were plated per well in a 6 well plate. Cells were cultured until 
reaching confluency (designated as Day 0). On day 2, MDI adipocyte 
differentiation medium was added. MDI medium consists of Dublecco’s Modified 
Eagle Medium (DMEM) containing 10% FCS, dexamethasone (1µM), insulin 
(10µg/ml), and 3-isobutyl-1-methylxanthine (0.5mM). After 48 hours of culture in 
MDI (Day 4), the medium was aspirated and replaced with DMEM 10% FCS 
containing insulin (10µg/ml). On day 6, the medium was again aspirated and 
replaced with DMEM 10% FCS only. At this point, the cells were cultured four 
more days, replacing with fresh DMEM 10% FCS every two days until the 
adipocytes were fully differentiated. 
To generate conditioned medium, the adipocytes were washed with serum 
free DMEM (to remove trace amounts of differentiation supplements), and then 
cultured for 3 days in 1ml of serum free DMEM. Adipocyte conditioned medium 
(ACM) was then collected and any cell debris was removed. 
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Rabbit Adipocytes. To generate rabbit adipocytes, total BM was isolated 
from rabbits of any age and RBCs were lysed. For BM from rabbits <2 months of 
age, 380,000 BM cells were plated per well in 12 well plates. When using BM 
from >2 month old rabbits for adipocyte generation 3,800,000 cells were plated 
per well in 12 well plates. BM cells were cultured for two days in alphaMEM 
containing 20% FCS and supplemented with penicillin (100 units/L)/streptomycin 
(100µg/L), and fungizone (250µg/L). On day 2, non-adherent cells were removed 
and fresh medium was added. On day 3, the medium was replaced with 
adipocyte differentiation medium (ADI) consisting of alphaMEM with 15% FCS, L-
glutamine (2mM), penicillin (200 units/L)/streptomycin (200µg/L), dexamethasone 
(0.4µM), indomethacin (40µM), and 3-isobutyl-1-methylxanthine (0.4µM). Every 
three to four days, the medium was replaced with fresh ADI, aspirating and 
replacing only half the medium in the well. On day 20, cultures were screened for 
wells containing 85-100% mature adipocytes. Wells containing a high percentage 
of adipocytes were then washed with serum free alphaMEM (to remove 
differentiation supplements), and then ACM was generated by culturing for three 
days in 700µl-1ml of serum free of alphaMEM. Finally, the supernatant was 
collected, cell debris was removed, and ACM was then used in downstream 
assays. 
MDSC generation 
MDSCs were generated in 24 well plates. 5,000 OP9 BM stromal cells 
were plated in each well. The next day, 120,000-500,000 B220- mouse BM cells 
were plated in OP9 containing wells in the presence of murine IL-7, SCF, and 
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Flt3L. Key to generating MDSCs is the addition of mouse ACM at the start of 
cultures (typically at a 1:6 dilution). On day 4, the cultures were given fresh 
cytokines, and on day 7 the cultures were collected for MDSC isolation. Cells 
resulting from ACM-treated cultures were pooled and stained with anti-B220, 
anti-CD19, anti-CD11b, and anti-Gr1 and sorted for B220-CD19-CD11b+Gr1+ 
cells by flow cytometry. Sorted cells were then used for downstream culture or 
analysis. 
MDSC-CM 
MDSC-CM was generated by culturing 100,000 purified MDSCs per well 
in 48 well plates. MDSCs were cultured in serum free alphaMEM for 3 days, and 
then collected for downstream assays. 
BM fat conditioned medium  
BM fat conditioned medium (BM fat-CM) was generated in two steps; 
isolation of BM fat from >2 month old rabbits, followed by conditioned medium 
generation. 
Isolation of BM fat. Greater than 2 month old rabbits were used to isolate 
BM fat because younger rabbits do not have enough BM fat to isolate by this 
method. BM was flushed from rabbit femurs and/or tibia as described previously. 
Next, cells were spun down at 1,200RPM for 5-10min at 4 degrees Celsius. 
Spinning the BM results in two noticeable BM fractions; 1. The BM pellet at the 
bottom of the tube. This fraction contains most BM cell types (eg. RBCs, white 
blood cells, stromal cells), but is largely depleted of mature adipocytes. This 
fraction is also referred to as the stromal vascular fraction (SVF). In this 
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dissertation, we refer to the pellet that forms after spinning down total BM as total 
BM or the SVF. In either terminology, these are depleted of mature adipocytes by 
spinning total BM; 2. In addition to the BM pellet, this method also results in the 
formation of a mature adipocyte fraction at the top of the tube of cells. In this 
dissertation, we refer to this floating fraction as the adipocyte layer or as the BM 
fat layer. The BM fat layer contains mature adipocytes, but we have also isolated 
hematopoietic lineage cells (many CD11b+ cells) that are tightly associated with 
adipocytes in this fraction. Therefore, conditioned medium from BM fat contains 
molecules derived from adipocytes and tightly associated hematopoietic cells. 
Generation of conditioned medium. BM fat-CM was generated upon 
isolation of the adipocyte layer/BM fat layer from >2 month old rabbits. BM fat 
was cultured in serum free alphaMEM for 16-24 hours, supernatant was collected 
(no adipocytes or other cells were taken), followed by the removal of any debris. 
BM fat-CM was then used in downstream assays. 
Isolation of cells from BM fat  
BM fat was isolated from femurs and/or tibias of >2 month old rabbits, then 
cultured overnight in wells of a 12 well plate. By the next day, many cells will 
have fallen out of the BM fat fraction to the bottom of each well. The cells at the 
bottom of each well were collected and combined with cells isolated through 
disruption of the BM fat fraction (pipetting up and down the BM fat). This is the 
gentlest way to isolate cells from BM fat. Alternatively, cells were isolated from 
BM fat after it was digested with 4mg/ml collagenase II in PBS supplemented 
with 0.5% BSA and 10 mM CaCl2, which releases cells from the tissue. Both 
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methods appeared to work well for isolating hematopoietic cells from this fat 
fraction. 
 After isolation of cells from BM fat, CD11b+ and CD11b- cells were 
separated by magnetic bead sorting using an autoMACS Pro separator. These 
cell populations were then used in rabbit BM cultures.  
Bone marrow sections 
BM sections were performed on femurs and/or tibias taken from rabbits of 
various age. The upper bone surface was removed very carefully using a new 
surgical blade (many gentle strokes of the blade on the desired area of bone 
surface until the surface is breached). Upon removal of the bone surface, the 
bone looked like a “half-pipe” (Figure 2.1). Although the surface was removed, 
care was taken so the BM was not disturbed. If BM was disturbed, it was not 
used for sectioning. Multiple slices of BM were taken from opened bones (with 
undisturbed BM) and prepared for cryosectioning sectioning. BM was embedded 
in optimal cutting temperature (OCT) support medium and frozen. Frozen BM 
was then used for sectioning. After sectioning, BM sections were stained with 
Hematoxylin and Eosin, or stained for immunofluorescence analysis. 
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64 
Remove bone 
surface 
without 
disturbing 
inner BM 
 
Bone should 
look like a 
“half pipe” with 
undisturbed 
BM extending 
out of bone 
Rabbit Bone 
Rabbit Bone 
 (after surface removal) 
Rabbit BM  
(to be sectioned) 
• Remove multiple slices of 
BM. 
• Embed in OCT 
• Freeze 
     
  
 
 
 Bone Surface Bone Marrow 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Preparation of rabbit bone marrow for sectioning. Rabbit BM was 
prepared as described in the text and indicated in this figure. 
 
Anion exchange chromatography  
Anion exchange chromatography was performed using a 1ml volume 
HiTrap Q Sepharose High Performance strong anion exchange column (GE 
Healthcare Life Sciences, Pittsburgh, PA). Chromatography experiments were 
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performed with an ÄKTA fast protein liquid chromatography (FPLC) system 
running UNICORN control software (GE Healthcare Life Sciences, Pittsburgh, 
PA). 
Mouse ACM samples were prepared by filtering 8ml of total ACM through 
a 10kDa filter (Amplicon ultra – EMD Millipore, Darmstadt, Germany) until 100µl 
of retenate remained above the filter. Greater than 10kDa ACM was diluted 1:10 
in FPLC buffer A (running buffer), to a final volume of 1ml which was then loaded 
on the column. Proteins bound to the column were eluted using a linear 
increasing salt concentration performed by adding increasing concentrations of 
FPLC Buffer B (elution buffer). 
The protein concentration of each fraction was measured by a UV reader 
within the FPLC system, and was confirmed using a nanodrop 2000 
spectrophotometer (Thermo Scientific, Wilmington, DE). Multiple fractions 
collected from the column were pooled into the following samples and tested for 
inhibitory activity in rabbit B lymphopoiesis assays. 
Sample in  
B 
lymphopoiesi
s assay 
Fractions in each sample 
SAMPLE 1 A1,A2,A3 
SAMPLE 4 B9,B8,B7,B6,B5,B4 
SAMPLE 5 B3,B2,B1,C1,C2 
SAMPLE 6 C3,C4,C5,C6,C7 
SAMPLE 7 C9,C10,C11,C12,D12,D11,D10,D9,D8,D7,D6,D5,D4,D3,D
2,D1,E1 
SAMPLE 8 E2,E3,E4,E5,E6,E7,E8,E9,E10,E11,E12 
 
FPLC Buffer A (running buffer) - 10mM TRIS-HCL pH 8.2  
FPLC Buffer B (elution buffer) - 10mM TRIS-HCL + 1M NaCl pH 8.2 
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System/column storage buffer - 20% Ethanol in water 
Quantitative RT-PCR 
Cells were suspended in TRIzol reagent (Invitrogen, Carlsbad, CA), and 
RNA was isolated. cDNA was made from isolated RNA and used in qPCR 
reactions. PCR experiments were performed using a C1000 thermal cycler with 
CFX96 real-time detection system (Bio-Rad, Hercules, CA). Expression of target 
genes was normalized to β-actin (mouse experiments) or HGPRT (rabbit 
experiments). Tables 2.3 and 2.4 display the primer sets used in qPCR 
experiments.  
 
Gene Forward Primer (5’-3’) (Reverse Primer 5’-3’) 
 Actb 
(β-
actin) 
GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 
Arg1 AGACCACAGTCTGGCAGTTG CCACCCAAATGACACATAGG 
Nos2 CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG 
 
Table 2.3 Mouse qPCR primers. 
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Gene Forward Primer (5’-3’) (Reverse Primer 5’-3’) 
HGPRT AGCCCCAGCGTTGTGATTAGT CATCTCGAGCAAGCCTTTCAG 
IL-1β AGGTCTTGTCAGTCGTTGTG GTAGTCATCCCAGTGTGCAG 
S100A8 TCTACCACAAGTACTCCCTGG TCCAGCTCTTTGAACCAAGTG 
S100A9 ATCATCAACGTCTTCCACCAG TTATGGCTTTCTCATCCCTCG 
 
Table 2.4 Rabbit qPCR primers. 
Cytokine array 
The concentration of 23 cytokines was assessed in ACM, MDSC-CM, and 
control CD11b+Gr1+ conditioned medium (control-CM) samples using a Bio-Plex 
Pro mouse cytokine 23-plex (Bio-Rad, Hercules, CA). The cytokines analyzed 
are as follows: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-
12(p70), IL-13, IL-17A, G-CSF, GM-CSF, IFN-γ, KC, MCP, MIP-1α, MIP-1β, 
RANTES, eotaxin, TNF-α. Three ACMs, three MDSC-CMs, and two control-CMs 
were all generated in independent experiments before being analyzed by 
cytokine array. 
Statistical analysis  
Data were obtained and displayed as indicated in the figure legends. 
Statistical analysis of all experiments was performed using Prism software 
(GraphPad Software; La Jolla, Ca). Statistical tests used in this dissertation are 
indicated in the figure legends, and include unpaired two-tailed Student’s t test or 
analysis of variance (ANOVA) in combination with Dunnet’s or Bonferroni’s test 
for multiple comparisons. * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 
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CHAPTER III 
RESULTS 
SECTION 1: ADIPOCYTES AND THE INHIBITION OF B LYMPHOPOIESIS 
In aging and obesity, declining B lymphopoiesis correlates with an 
accumulation of adipocytes in the BM. Adipocytes were once thought to be inert, 
simply filling empty BM space. However, recent evidence suggests that 
adipocytes can regulate multiple aspects of the immune system, including 
hematopoiesis (Bilwani and Knight, 2012, Naveiras et al., 2009). Therefore, a 
detailed understanding of how adipocytes influence immune cell development will 
prove beneficial in developing therapeutics to restore healthy hematopoiesis in 
scenarios where adipocytes accumulate in the BM, such as aging and obesity. 
Bilwani and Knight found that adipocyte-derived factors inhibit human and 
rabbit B cell development in BM cultures (Bilwani and Knight, 2012), but the 
mechanism by which this occurs is unknown. Due to a greater abundance of 
reagents available to study mice than rabbits, and increased access to BM from 
mice than humans; it would be ideal to tease out the mechanism by which 
adipocyte factors inhibit B cell development in mice. Therefore, we first needed to 
establish whether or not adipocyte factors inhibit B lymphopoiesis in mice. 
To test if adipocyte factors inhibit mouse B cell development, we needed 
to generate mouse adipocyte factors, and develop an approach to study the 
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effect of these factors on B lymphopoiesis. Mouse adipocyte factors were 
generated using the pre-adipocyte cell line, 3T3.L1. Pre-adipocytes were 
differentiated into mature adipocytes with insulin, isobutylmethylxanthine, and 
dexamethasone. Upon differentiation into mature adipocytes, the cells were 
washed to remove trace amounts of differentiation factors, followed by three days 
of culture and the collection of adipocyte conditioned medium (ACM). ACM was 
then used to assess the effect of adipocyte-derived factors on mouse B 
lymphopoiesis. 
B lymphopoiesis was studied using the OP9 stromal cell line, originally 
isolated from mouse BM. OP9 cells are commonly used to study B 
lymphopoiesis, as they have been found to support the differentiation of BM 
progenitors into B lineage cells (Holmes and Zuniga-Pflucker, 2009). In this 
study, we cultured various subsets of hematopoietic progenitors with OP9 cells to 
answer different questions using this system.  
To determine if adipocyte-derived soluble factors inhibit B lymphopoiesis, 
mouse BM cells were depleted of B220+ B lineage cells. We cultured these B220- 
BM cells with OP9 BM stromal cells in the presence of IL-7, SCF, and Flt3L, 
cytokines that support B lineage development. We expected that if adipocyte 
factors inhibit mouse B lymphopoiesis, then treatment of B lymphopoiesis 
cultures with ACM would result in a decreased frequency of B lineage cells (as 
evidenced by fewer B220+ cells) observed at the end of cultures. As expected, 
cultures treated with ACM contained fewer B220+ B lineage cells compared to 
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untreated cultures (Figure 3.1 A & B ), suggesting that adipocyte factors inhibit 
mouse B cell development.  
If the adipocyte-mediated inhibition of B lymphopoiesis is conserved 
among mammals, we also expected that mouse adipocyte factors would inhibit 
rabbit B lymphopoiesis. To study rabbit B lymphopoiesis we modified the above 
described culture system. Total BM cells from >2 month old rabbits was used as 
a source of BM progenitors and cultured with OP9 cells in the presence of IL-7, 
SCF, and Flt3L. BM cells from rabbits >2 months old was used as a source of 
early hematopoietic progenitors because B lymphopoiesis has arrested in rabbit 
BM by this time, and the cultures are not “contaminated” with proB and preB 
cells.  
To understand if mouse adipocyte factors have the potential to inhibit 
rabbit B cell development, we cultured BM cells from >2 month old rabbits with 
OP9 cells in the presence or absence of mouse ACM. We expected that if mouse 
adipocyte factors inhibit rabbit B lymphopoiesis, then ACM-treated cultures will 
result in the development of fewer B lineage cells. Reagents are not available to 
detect the B cell marker B220, therefore we identified the development of new 
rabbit B lineage cells by the appearance of cells expressing the B cell receptor 
(BCR) signaling component CD79a (first expressed at the proB cell stage). 
Interestingly, treatment of rabbit BM cultures with mouse ACM resulted in fewer 
CD79a+ B lineage cells (Figure 3.1 C & D). These data coupled with the findings 
by Bilwani and Knight lead us to conclude that adipocytes negatively regulate B 
lymphopoiesis in a conserved manner between multiple mammals. 
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Figure 3.1 Inhibitory potential of mouse adipocyte-derived factors in mouse 
and rabbit B lymphopoiesis cultures. (A-B) Mouse B220- BM cells were 
cultured with OP9 stromal cells in the presence of mouse IL-7, SCF, and Flt3L. 
Flow cytometric analysis at the end of (A) untreated or (B) msACM-treated 
cultures for the expression of B220 and CD14 on resulting cells. (C-D) BM cells 
from a >2 month old rabbit were cultured with OP9 stromal cells in the presence 
of human IL-7, SCF, and Flt3L. Flow cytometric analysis at the end of (C) 
untreated or (D) msACM-treated cultures for CD79a and CD14 expression on 
resulting cells. (A-D) Data are representative of at least 3 independent 
experiments. 
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Mechanism of adipocyte-mediated inhibition 
Adipocyte factors inhibit B lymphopoiesis; although the mechanism by 
which this occurs is unknown. Because the inhibition of B lymphopoiesis by 
adipocytes appears conserved among mammals, we expect using mice to 
understand the mechanism of inhibition will allow us to gain insights applicable to 
humans, mice, and rabbits. 
There are two ways in which adipocyte molecules could inhibit B cell 
development; directly acting on a B lineage progenitor or indirectly through 
another cell (such as OP9 stromal cells) in BM cultures. While ACM treatment of 
cultures containing mouse B220- BM cells and OP9 stromal cells resulted in the 
development of very few B220+ B lineage cells (Figure 3.2 A, B&E), these 
cultures contained a large population of cells that do not express B220. We 
became interested in identifying which cell type develops after treatment of BM 
cultures with adipocyte factors. To characterize these B220- cells, we stained the 
cells with a panel of lineage specific antibodies (including myeloid [eg. anti-
CD11b], NK [eg. anti-NK1.1], T lineage [eg. anti-CD3] specific antibodies) and 
analyzed the cells by flow cytometry. We expected that if ACM promoted the 
development of another hematopoietic lineage, then we would visualize the 
resulting lineage with our panel of antibodies. Alternatively, if adipocyte factors 
directly block B cell development and hematopoietic progenitors accumulate in 
ACM-treated cultures, then we would not see staining with our lineage panel. In 
the latter scenario, additional staining would be needed to identify hematopoietic 
progenitors. As evidenced by flow cytometric analysis of cells resulting from ACM 
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treatment, the vast majority of B220- cells were identified with the myeloid 
markers CD11b and Gr1 (Figure 3.2 C, D, &F), suggesting that adipocyte factors 
promote the accumulation of myeloid lineage cells. 
In addition to increased quantity of CD11b+Gr1+ myeloid cells after ACM 
treatment (Figure 3.2 C, D, &F), the quality also appeared to differ from the 
CD11b+Gr1+ cells generated in untreated cultures. Flow cytometric analysis 
showed that CD11b+Gr1+ cells from ACM-treated cultures had higher expression 
of CD11b, were larger (FSC), and more granular (SSC) than myeloid cells from 
untreated cultures (Figure 3.3). Although yet to be determined, these phenotypic 
differences suggest CD11bhiGr1+ cells generated in the presence of adipocyte 
factors might also have different functional properties as compared to 
CD11b+Gr1+ cells from untreated cultures. 
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Figure 3.2 Characterization of cells resulting after treatment with adipocyte 
factors. Flow cytometric analysis and absolute cell numbers after mouse B 
lymphopoiesis cultures were treated with ACM or left untreated. Cells were 
stained and analyzed for (A&B) B220 and CD14 expression, followed by (C&D) 
CD11b and Gr1 expression in the B220- gate (C&D). Number of (E) B220+ and 
(F) CD11b+Gr1+ cells present after culture. Data are representative of 3 
independent experiments. For (E&F), Student’s t test was used to determine 
significance. Error bars represent the average of triplicate wells +/- SD.  
 
 
 
 
 
 
 
 
Figure 3.3 Phenotypic analysis of myeloid populations in ACM-treated and 
untreated cultures. Flow cytometric analysis of mouse B lymphopoiesis cultures 
7 days post initiation. Cells were stained for B220, CD14, CD11b, and Gr1 
expression to identify B220-CD11b+Gr1+ cells. CD11b+Gr1+ cells resulting from 
ACM-treated or untreated (NT) cultures were analyzed for mean fluorescence 
intensity (MFI) of (left) CD11b, (middle) forward scatter (FSC), and (right) side 
scatter (SSC). Data are representative of at least 3 independent expedriments. 
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In young healthy BM, cells defined as CD11b+Gr1+ are considered 
myeloid progenitors, which will quickly differentiate into cells such as monocytes, 
macrophages, and neutrophils. Although in pathologies such as cancer, MDSCs 
(also defined as CD11b+Gr1+) accumulate (Gabrilovich and Nagaraj, 2009). To 
test if the CD11bhiGr1+ cells that develop in the presence of ACM are MDSCs, 
we asked if they possess classical characteristics of MDSCs. We assessed if 
ACM-derived CD11bhiGr1+ cells have the functional ability to suppress T cell 
proliferation, as well as co-express Arg1 and Nos2 which encode for the 
enzymes arginase and iNos; important effector molecules for MDSC-mediated 
suppression of T cell responses. 
To understand whether ACM-generated CD11bhiGr1+ cells express Arg1 
and Nos2, we FACS-sorted CD11bhiGr1+ cells resulting from ACM-treated BM 
cultures and performed qPCR. We expected if ACM-generated CD11bhiGr1+ cells 
are MDSCs, they should co-express higher levels of Arg1 and Nos2 compared to 
CD11b+Gr+ myeloid cells isolated from control untreated cultures and CD19+ B 
lineage cells. As expected, compared to CD11b+Gr+ myeloid cells (-ACM) and 
CD19+ cells (CD19+) from untreated BM cultures, the myeloid cells isolated from 
ACM-treated cultures (+ACM) co-expressed large amounts of Arg1 and Nos2 
(Figure 3.4 A). 
To determine if myeloid cells isolated from ACM-treated cultures actively 
suppress T cell proliferation, we analyzed their ability to suppress in T cell 
proliferation assays. In these assays, splenocytes were CFSE-labeled and 
stimulated with plate-bound anti-CD3 and anti-CD28. Stimulation of splenocytes 
76 
activates CD4+ T cells to proliferate, which can be visualized via flow cytometry 
as the dilution of CFSE in this splenocyte population. The reason this can be 
visualized is because CFSE is cell permeable and covalently binds to 
intracellular molecules, and as each division occurs the CFSE labeled 
components of a parent cell become shared by the resulting daughter cells 
(diluting the amount of stain per cell).  
To assess the suppressive activity of ACM-generated CD11bhiGr1+ 
myeloid cells, these cells were FACS-sorted and cultured with stimulated CFSE-
labeled splenocytes. If ACM-generated myeloid cells suppress T cell 
proliferation, then culturing CD4+ T cells with CD11bhiGr1+ myeloid cells will 
prevent CFSE dilution (proliferation) in CD4+ T cells. Compared to cultures 
containing an equal number of control effector cells (Figure 3.4 B dashed line), 
CD4+ cells in cultures containing ACM-generated myeloid cells proliferated less 
(Figure 3.4 B solid line). These data coupled with the co-expression of Arg1 and 
Nos2 lead us to conclude that adipocyte soluble factors promote the 
accumulation of MDSCs. 
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Figure 3.4 Phenotypic and functional characterization of ACM-generated 
CD11bhiGr1+ cells. (A) qPCR analysis of Arg1 and Nos2 expression comparing 
CD11b+Gr1+ cells isolated by FACS from ACM-treated (+ACM), untreated (-
ACM) BM cultures, and CD19+ control cells . (B) Flow cytometric plot of anti-CD3 
and anti-CD28 stimulated CD4+ splenocytes (CFSE-labeled) cultured with ACM-
generated CD11bhiGr1+ cells (solid line) or CD19+ control cells (dashed line). 
Data in (A) are representative of two independent experiments and in (B) are 
representative of three independent experiments. 
 
There are two major subsets of MDSCs; monocytic and granulocytic. 
These subsets can be differentiated based on staining for the molecules Ly6C 
and Ly6G, where monocytic MDSCs are defined as Ly6C+Ly6G- and granulocytic 
MDSCs are defined as Ly6C+Ly6G+ (Gabrilovich and Nagaraj, 2009, Youn et al., 
2008). While both types of MDSCs suppress T cell responses, the mechanisms 
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regulating their induction and suppressive activity can vary. Understanding the 
type of MDSC induced by adipocyte factors will be help us identify critical 
molecules for MDSC induction and suppressive activity.  
By flow cytometric analysis of CD11b+ cells resulting from ACM-treated 
BM cultures, we found that 65% of CD11b+ cells were Ly6C+Ly6G- monocytic, 
while 21% exhibited the Ly6C+Ly6G+ granulocytic MDSC phenotype (Figure 3.5 
A). To complement this result, we also visualized the nuclei of ACM-generated 
MDSCs, as monocytic MDSCs have nuclei resembling immature monocytes and 
granulocytic MDSCs have polymorphic nuclei similar to neutrophils. We FACS-
sorted ACM-generated CD11b+Gr1hi MDSCs, plated the MDSCs in tissue culture 
wells, and then stained with Diff-QuickTM stain to visualize nuclei by light 
microscopy. Based on our flow cytometry data, we expected that the majority of 
the MDSCs would have nuclei that resemble monocytic MDSCs. In fact, 
microscopy analysis of sorted MDSCs confirmed that this population is primarily 
of the monocytic subset (Figure 3.5 B), as very few MDSCs had a 
polymorphonuclear appearance similar to neutrophils. These data lead us to 
conclude that adipocyte factors mainly promote the generation of monocytic 
MDSCs in vitro. Further, the above experiments indicate that the use of 
adipocyte factors is an efficient means to generate a pure population of MDSCs. 
This culture system will be a useful tool to generate MDSCs for further study of 
these cells, as well as for the use of MDSCs as a therapeutic agent. 
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Figure 3.5 Ly6C vs Ly6G expression and morphology of CD11b+Gr1+ cells 
isolated from ACM-treated or control BM cultures. (A) Flow cytometric 
analysis of CD11b+ cells from ACM-treated or untreated cultures for the 
expression of Ly6C and Ly6G. (B) FACS-sorted CD11b+Gr1+ cells were plated in 
wells and stained with Diff Quick (Siemens, USA). 
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SECTION 2: MDSCs AND THE INHIBITION OF B LYMPHOPOIESIS 
MDSCs are well characterized for their ability to suppress T cells, but it is 
not known whether these cells alter hematopoiesis. The generation of MDSCs by 
adipocyte soluble factors could be the result of skewed hematopoiesis, where 
MDSCs are simply bystanders. Alternatively, because MDSCs are suppressive in 
nature we hypothesized that ACM-generated MDSCs might contribute to the 
inhibition of B lymphopoiesis. To test if MDSCs have the functional capacity to 
inhibit B cell development, we added FACS-sorted MDSCs from ACM-treated 
cultures or CD11b+Gr1+ myeloid cells from untreated cultures directly to new B 
lymphopoiesis cultures (no ACM added). If MDSCs contribute to the inhibition of 
B lymphopoiesis, then we expect BM cultures containing MDSCs will result in a 
decreased number of B220+ B lineage cells compared to control cultures. 
Strikingly, wells with ACM-generated MDSCs contained very few B220+ B 
lineage cells; whereas cultures treated with control myeloid cells exhibited a 
similar number of B lineage cells to untreated cultures (Figure 3.6). We conclude 
that MDSCs actively inhibit B lymphopoiesis. 
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Figure 3.6 Effect of MDSCs on B lymphopoiesis cultures.  Absolute number 
of B220+ cells resulting from BM cultures treated with the following FACS isolated 
effector cells: 5,000 CD11bhiGr1+ MDSCs from ACM-treated cultures (pink), 
5,000 CD11b+Gr1+ control cells from untreated cultures (blue), or no effectors 
(black). Data are representative of 3 independent experiments. Student’s t test 
was used to determine significance. Error bars represent the average of triplicate 
wells +/- SD. 
Mechanism of MDSC-mediated inhibition of B lymphopoiesis 
The finding that MDSCs potently inhibit B lymphopoiesis is novel. 
Therefore, we asked by what mechanism these MDSCs mediate their inhibitory 
effect. Further understanding how adipocyte soluble factor generated MDSCs 
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inhibit B cell development will help us identify the active molecules produced by 
adipocytes to trigger this MDSC-mediated inhibition. 
Since MDSC effector mechanisms are well-known for the suppression of T 
lymphocytes, we asked if B cell development is also sensitive to one of these 
mechanisms. The most well-known way MDSCs suppress T cell responses is 
through the effector molecules arginase and iNos. These enzymes both use L-
arginine as a substrate and can suppress through L-arginine depletion. In 
addition, nitric oxide produced by iNos has suppressive activity (Gabrilovich and 
Nagaraj, 2009, Rodriguez and Ochoa, 2008). The idea that these effector 
molecules could alter B lymphopoiesis is plausible, as one study found arginine 
deficient mice have impaired B cell development (de Jonge et al., 2002).  
To test if arginase and/or iNos are responsible for MDSC-mediated 
inhibition of B lymphopoiesis, we cultured BM progenitors, OP9 cells, and 
MDSCs with or without nor-NOHA (arginase inhibitor) and L-NMMA (iNos 
inhibitor). We expected that if arginase and/or iNos mediate the MDSC inhibitory 
activity, then blocking these effectors will restore B lymphopoiesis in cultures 
containing MDSCs. Surprisingly, B lymphopoiesis was not restored when 
blocking arginase and iNos in cultures containing MDSCs. BM cultures with 
MDSCs in the absence of any inhibitors contained significantly fewer B220+ B 
lineage cells compared to control wells (Figure 3.7 A). Consistently, the number 
of B lineage cells in all wells containing MDSCs was significantly lower than 
untreated wells and cultures containing control cells, regardless of the addition of 
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arginase and iNos inhibitors. This result suggests that MDSCs do not inhibit B 
lymphopoiesis through arginase/iNos. 
To ensure the nor-NOHA and L-NMMA inhibitors were active, we tested 
them in the context of T cell proliferation assays. If ACM-generated MDSCs 
behave like classical MDSCs, we expected they would inhibit T cell proliferation 
via arginase and iNos. Therefore using these inhibitors in T cell proliferation 
assays should restore T cell proliferation in wells containing MDSCs. To test this, 
CFSE labeled splenocytes were stimulated with anti-CD3 and anti-CD28, and 
then T cell proliferation (CD4+ and CD8+) was assessed comparing cultures with 
MDSCs in the presence or absence of nor-NOHA and L-NMMA. If ACM-
generated MDSCs inhibit T cell proliferation in an arginase and iNos dependent 
manner, and if the nor-NOHA and L-NMMA inhibitors are active, then T cell 
(CD4+ and CD8+) proliferation will decrease in the presence of MDSCs, but will 
be restored to untreated levels when arginase and iNos are inhibited. Flow 
cytometric analysis of the CD4+ and CD8+ splenocyte populations showed similar 
results. CD4+ and CD8+ splenocytes from cultures containing MDSCs exhibited 
decreased CFSE dilution (proliferation) compared to when no effector cells were 
added. Further, CFSE dilution (proliferation) was significantly increased in 
cultures with MDSCs in which arginase and iNos were blocked (Figure 3.7 B & 
C). We conclude that ACM-generated MDSCs inhibit T cell proliferation in an 
arginase and iNos dependent manner, although this is not the primary 
mechanism by which MDSCs inhibit B cell development. 
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Figure 3.7 MDSC-mediated inhibition of B lymphopoiesis in the absence of 
arginase and iNos. (A) Number of B220+ cells resulting from B lymphopoiesis 
cultures containing no effector cells, ACM-generated MDSCs, or non-inhibitory 
CD11b+Gr1+ control cells. The indicated wells were treated with 0.3mM L-NMMA 
(iNos inhibitor), 0.3mM D-NMMA (control compound), and/or 0.3mM nor-NOHA 
(arginase inhibitor). (B-C) Proliferation of (B) CD4+ or (C) CD8+ splenocytes after 
anti-CD3 and anti-CD28 stimulation in the presence or absence of ACM-
generated MDSCs, and treated with 0.3mM L-NMMA and nor-NOHA where 
indicated. Data in (A-C) are representative of three independent experiments. 
Error bars represent the average of triplicate wells +/- SD. Data in (A) were 
analyzed for statistical significance by ANOVA coupled with the Dunnet multiple 
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comparison test (p<0.0001). Data in (B&C) were analyzed for statistical 
significance by ANOVA coupled with the Bonferroni multiple comparison test 
(p=0.001 and p=0.003 respectively). 
 
Do MDSCs require contact with target cells? MDSCs do not use 
arginase and iNos to inhibit B lymphopoiesis, suggesting MDSCs inhibit via a 
novel mechanism. To gain a better sense of how MDSCs negatively regulate B 
cell development, we asked if inhibition required contact with BM progenitors. BM 
progenitors were cultured with OP9 cells in B lymphopoiesis assays, either with 
MDSCs in contact with BM progenitors or separated by transwells. We expected 
that if MDSCs require contact with target cells to mediate inhibition, then MDSCs 
will not inhibit B lymphopoiesis when cultured in transwells. Interestingly, the 
number of B220+ B lineage cells was significantly reduced compared to no 
MDSC controls regardless of whether MDSCs were cultured in contact or away 
from BM progenitors (Figure 3.8 A). This result suggested that ACM-generated 
MDSCs do not require contact with target cells to mediate inhibition, and likely 
inhibit through the production of a soluble factor. 
To complement the above finding and to test if MDSC-derived soluble 
factors inhibit B lymphopoiesis, we asked if conditioned medium from MDSCs 
(MDSC-CM) contained inhibitory activity. To generate conditioned medium, we 
isolated MDSCs (by FACS) from ACM-treated BM cultures and plated the 
isolated cells in wells of a 48 well plate. Several days later, supernatant from 
MDSC cultures was collected and used as a source of MDSC-derived soluble 
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factors. The inhibitory activity of MDSC factors was tested by treating mouse BM 
cultures with MDSC-CM and analyzing the resulting frequency and absolute 
number of B220+ B lineage cells by flow cytometry. We expected that if MDSCs 
inhibit via a soluble factor(s), then MDSC-CM treated cultures would exhibit 
decreased development of B lineage cells compared to untreated cultures. As 
expected, MDSC-CM inhibited B cell development, where the percentage and 
number of B220+ cells were significantly reduced in cultures containing MDSC-
CM (Figure 3.8 B, D&F). Together these data suggest MDSCs do not require 
contact with target cells to negatively regulate B lymphopoiesis. We conclude 
that MDSCs inhibit through the production of a soluble factor(s). 
Interestingly, we noticed that BM cultures treated with MDSC-CM 
exhibited an increased percentage and number of CD11b+Gr1+ myeloid lineage 
cells (Figure 3.8 C, E&G). These data suggest that MDSCs either produce 
multiple factors that separately inhibit B lymphopoiesis and promote 
myelopoiesis, or one factor that has a dual function to inhibit B cell development 
and promote myeloid cell development and/or survival. Therefore we decided to 
profile MDSC-derived soluble factors to identify molecules that could recapitulate 
this phenomenon. 
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Figure 3.8 Effect of MDSC-derived soluble factors on B lymphopoiesis. (A) 
Number of B220+ cells resulting from B lymphopoiesis cultures containing no 
effector cells (no MDSC), MDSCs, or MDSCs cultured in a transwell. (B-G) B 
lymphopoiesis assays were performed with or without (untreated) MDSC-CM 
treatment. (B-E) Flow cytometric analysis of cells stained with antibodies to 
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(B&D) B220 and CD19, or (C&E) CD11b and Gr1. Number of (F) B220+ cells and 
(G) CD11b+Gr1+cells resulting from untreated cultures or cultures treated with 
MDSC-CM. Data in (A) are representative of 2 independent experiments and 
were analyzed by ANOVA in combination with a Bonferroni multiple comparison 
test (p<0.0001). Data in (B-G) are representative of 3 independent experiments. 
Statistical significance in (F&G) was analyzed by Student’s t test. Error bars 
represent the average of triplicate wells +/- SD. 
 
Soluble factors produced by MDSCs. Since MDSCs inhibit through 
soluble factors, we performed a cytokine array to profile MDSC-derived 
molecules. Conditioned medium was generated from FACS isolated MDSCs 
(inhibit B cell development) and control CD11b+Gr1+ myeloid cells (do not inhibit 
B cell development), then profiled for the concentrations of 23 different factors. 
We expected that potential inhibitory factor(s) would be present at higher 
concentrations in MDSC-CM than control-CM. Cytokine array analysis showed 
that MDSCs produced increased concentrations of IL-1α, IL-1β, IL-13, G-CSF, 
KC, MCP, MIP-1α, MIP-1β, and RANTES (Figure 3.9), many of which are 
classified as inflammatory cytokines or chemokines known to recruit 
inflammatory cells. Alternatively, IL-12(p40) and IL-9 concentrations were higher 
in control-CM; ruling out these molecules as the MDSC-derived inhibitory factors. 
Additional proteins that were assessed but not detected in MDSC-CM include: IL-
2, IL-3, IL-5, and GM-CSF. Further IL-2, IL-4, IL-6, IL-10, IL-12(p70), IL-17, 
TNFα, and IFNγ were present, but at levels <10pg/ml. For subsequent studies 
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we focused only on IL-1α, IL-1β, IL-13, G-CSF, KC, MCP, MIP-1α, MIP-1β, and 
RANTES, as these were present in MDSC-CM at higher levels than control-CM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Profile of MDSC-derived soluble factors by cytokine array. 
Protein concentrations of the indicated factors as detected by cytokine array in 
MDSC-CM or control-CM. Data are from three different MDSC-CM and two 
different control-CM generated in individual experiments. Error bars show the 
average of the two or three different conditioned media +/- SD. ND= not 
detected. 
We identified nine factors that were upregulated in MDSC-CM and asked 
if any of these molecules inhibit B lymphopoiesis. B lymphopoiesis cultures were 
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performed in the presence or absence of each factor (recombinant) individually, 
and then the number of B lineage cells was analyzed at the end of culture. We 
did not think all nine identified factors would inhibit B cell development, but 
perhaps one or two. We expected if any of these molecules have the potential to 
inhibit B lymphopoiesis, then BM cultures containing an inhibitory molecule would 
result in decreased development of B220+ B lineage cells compared to untreated 
cultures. In fact this experiment drastically narrowed our search for MDSC-
derived inhibitory factors because, of all the molecules assessed, only cultures 
containing IL-1α and IL-1β had significantly lower numbers of B220+ B lineage 
cells (Figure 3.10 A); suggesting these molecules inhibit B cell development. 
Only IL-1α and IL-1β could inhibit when added to B lymphopoiesis cultures 
individually, but we also sought to determine if the other seven identified factors 
could inhibit when in combination with the others. To test this, we compared the 
inhibitory potential of adding all nine factors (IL-1α, IL-1β, IL-13, G-CSF, KC, 
MCP, MIP-1α, MIP-1β, and RANTES) to BM cultures in combination or without 
IL-1α/β. We know IL-1α/β can inhibit alone, therefore treatment with all nine 
factors should result in reduced B lineage development. If the other seven factors 
are able to inhibit B lymphopoiesis when combined, we expected adding IL-13, 
G-CSF, KC, MCP, MIP-1α, MIP-1β, and RANTES would also inhibit B 
lymphopoiesis. However, this did not occur. Cultures containing all nine factors 
resulted in the development of significantly fewer B220+ cells compared to 
untreated cultures. But treatment of BM cultures with all factors without IL-1α/β 
contained a similar number of B220+ cells compared to untreated cultures (Figure 
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3.10 B). These data suggest that IL-1α and IL-1β are the only molecules 
identified in MDSC-CM with inhibitory activity to B lymphopoiesis. 
Do MDSCs inhibit B lymphopoiesis via IL-1? MDSCs produce IL-1α/β 
and these cytokines inhibit B lineage development. But is the mechanism by 
which MDSCs inhibit mediated through IL-1α/β? Our approach to answer this 
question was to neutralize IL-1α/β in B lymphopoiesis cultures containing 
MDSCs, and then determine if B lymphopoiesis was restored to untreated levels. 
We added MDSCs to B lymphopoiesis cultures in the presence or absence of 
anti-IL-1α and anti-IL-1β to neutralize these cytokines. We expected that if IL-
1α/β were the major inhibitory factors produced by MDSCs, then blocking these 
molecules would enhance B lymphopoiesis in cultures containing MDSCs. 
Compared to control cultures lacking MDSCs, cultures containing MDSCs 
exhibited a significant reduction in the number of B220+ B lineage cells. However 
when IL-1α/β was neutralized in cultures containing MDSCs, the number of 
B220+ B lineage cells was restored to control levels (Figure 3.10 C). These data 
lead us to conclude that MDSCs inhibit B lymphopoiesis via IL-1α/β. 
 
 
 
 
 
 
 
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Identification of MDSC-derived inhibitory factors. (A&B) Number 
of B220+ cells resulting from B lymphopoiesis cultures treated with the indicated 
recombinant cytokine(s) (1ng/ml). (C) Number of B220+ cells resulting from B 
lymphopoiesis cultures with or without MDSCs and treated with anti-IL-1α 
(1µg/ml) and anti-IL-1β (1µg/ml), or isotype control antibodies where indicated. 
Data in (A-C) are representative of three independent experiments. Statistical 
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significance in (A) was determined using ANOVA coupled with a Dunnet multiple 
comparison test (p<0.0001). Statistical significance in (B & C) were determined 
using ANOVA coupled with a Bonferroni multiple comparison test (p<0.0001 and 
p=0.001 respectively). Error bars represent the average of triplicate wells +/- SD. 
 
Hematopoietic target of IL-1. The identification that MDSCs inhibit B cell 
development via IL-1 has uncovered a novel interaction between MDSCs and 
hematopoiesis. But how does IL-1act to inhibit B cell development?  We know 
that IL-1 treatment of BM cultures results in the development of very few (if any) 
B220+ cells. Because B220 is first expressed at the pre-proB cell stage, we 
hypothesized that the hematopoietic target of IL-1 treatment is a progenitor prior 
to the pre-proB cell stage. Therefore IL-1 must act at the HSC to MPP, MPP to 
CLP, or CLP to pre-proB transition. To identify the hematopoietic target of IL-1 
we FACS-sorted either HSCs (Lin-Sca1+c-kit+Flt3-), MPPs (Lin-Sca1+c-kit+Flt3+), 
or CLPs (Lin-Sca1loc-kitloFlt3+IL-7R+) (Figure 3.11 A) and assessed the ability of 
these progenitors to differentiate into B lineage cells on OP9 stromal cells when 
treated with IL-1β. We expected that if IL-1β targets CLPs to inhibit B cell 
development, for example, then B lymphopoiesis assays seeded with CLPs will 
have fewer B220+ B lineage cells develop in IL-1β treated cultures. Interestingly, 
IL-1β treatment did not affect the ability of CLPs to differentiate into B220+ B 
lineage cells. Flow cytometric analysis of cultures starting with CLPs showed no 
difference in the frequency of B lineage cells comparing untreated and IL-1β 
treated wells (Figure 3.11 B). Similarly, there was no significant difference in the 
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number of B220+ cells resulting from these cultures (Figure 3.11 C). Alternatively, 
analysis of cultures seeded with MPPs resulted in a large reduction in B220+ B 
lineage cell frequency (Figure 3.11 D) coupled with a significant decrease in the 
number of B220+ B lineage cells in IL-1β treated cultures (Figure 3.11 E). Flow 
cytometric analysis of cultures beginning with purified HSCs showed a similar 
result to cultures seeded with MPPs upon IL-1β treatment (Figure 3.11 F & G). 
Because IL-1β inhibited B lymphopoiesis in both cultures seeded with purified 
HSCs and MPPs, this could suggest that IL-1β targets both the HSC and the 
MPP. Alternatively, the inhibitory effect observed in cultures of HSCs could be 
mediated once HSCs differentiate into MPPs. We conclude that IL-1β treatment 
targets early hematopoietic progenitors, likely the MPP, to inhibit B cell 
development. IL-1α treatment showed similar results, suggesting these MDSC-
derived molecules inhibit through the same mechanism. This was also expected 
as IL-1α and IL-1β both act through the same receptor on target cells. 
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Figure 3.11 Identification of hematopoietic progenitors targeted by IL-1. (A) 
B lineage developmental stages and key markers for identification. (B, D&F) Flow 
cytometric analysis of cells resulting from B lymphopoiesis cultures starting with 
purified (B) CLPs, (D) MPPs, or (F) HSCs. Cultures were performed in the 
presence or absence (untreated) of IL-1β and stained with anti-B220 and anti-
CD19. (C, E, &G) Number of B220+ cells or CD11b+Gr1+ cells resulting from B 
lymphopoiesis cultures seeded with (C) CLPs, (E) MPPs, or (G) HSCs and 
treated with or without (untreated) IL-1β. Data in (B-G) are representative of three 
independent experiments. Statistical significance in (C, E, &G) was determined 
by Student’s t test. Error bars represent the average of triplicate wells +/- SD. 
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IL-1 treatment acts at the MPP stage to inhibit B lymphopoiesis. But is B 
cell development blocked at the MPP stage, or is hematopoiesis re-routed? The 
answer to this question came from flow cytometric analysis of myeloid lineage 
cells resulting from cultures seeded with HSCs, MPPs, or CLPs (Figure 3.11 C, 
E&G). If B lymphopoiesis is blocked at the MPP stage, we expected to find an 
accumulation of MPPs in IL-1 treated cultures seeded with HSCs and MPPs. 
Alternatively, if IL-1 treatment re-routes hematopoiesis to another lineage, then 
we expected to find the accumulation of cells of another hematopoietic lineage 
(eg. myeloid lineage) in IL-1 treated cultures. Interestingly, IL-1 treatment of 
cultures seeded with HSCs or MPPs resulted in a large significant increase in the 
development of CD11b+Gr1+ myeloid cell number. While IL-1 treatment of CLPs 
also resulted in an increase in myeloid cells, this increase was small compared to 
the number observed in HSC and MPP cultures. Overall, these data suggest that 
IL-1 treatment acts at the MPP stage to promote myelopoiesis at the expense of 
B lymphopoiesis. Further, we conclude that IL-1 does not block B cell 
development, but instead skews hematopoiesis to the myeloid lineage. 
In summary, our data suggest that adipocytes inhibit B lymphopoiesis in 
vitro by promoting the accumulation of MDSCs. These MDSCs produce IL-1, 
which then skews hematopoiesis to the myeloid lineage. While we know that 
MDSCs produce IL-1, we do not know what adipocyte factor(s) promote MDSCs. 
We also do not know if adipocytes produce only one factor or many factors that 
contribute to the loss of B lymphopoiesis, as adipocytes are known to produce 
many immunomodulatory factors, such as adiponectin and leptin. Further 
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characterization of ACM is needed to understand if adipocytes produce multiple 
inhibitory factors and to identify the most critical factors that induce MDSCs. 
 
SECTION 3: CHARACTERIZATION OF ADIPOCYTE-DERIVED MOLECULES 
IN THE NEGATIVE REGULATION OF B LYMPHOPOIESIS 
The mechanism of MDSC-mediated inhibition of B lymphopoiesis, 
elucidated above, is initiated by adipocyte-derived soluble factors. This made us 
interested in understanding how adipocyte factors promote MDSC accumulation 
and ultimately lead to the loss of B lymphopoiesis. We asked; 1. Do multiple 
adipocyte factors contribute to the inhibition of B lymphopoiesis; 2. What 
adipocyte-derived molecules are most critical for generating MDSCs; and 3. Can 
we target adipocyte factors to prevent MDSC accumulation? 
Do multiple adipocyte factors contribute to the inhibition of B 
lymphopoiesis? 
Adipocytes are capable of producing many factors that modulate the 
immune system and other processes throughout the body. Adiponectin is one 
adipocyte-derived product known to influence hematopoiesis (Yokota et al., 
2003), but we hypothesized that adipocytes produce additional molecules that 
can affect immune cell development. To understand how adipocyte-derived 
soluble products negatively regulate B lymphopoiesis as a whole, we decided to 
characterize different fractions (based on molecular weight) of ACM. We 
expected this would give us a better understanding of how adipocyte products 
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lead to the inhibition of B lymphopoiesis and how they lead to the accumulation 
of IL-1 producing MDSCs. 
To assess the type of inhibitory molecule(s) produced by adipocytes, we 
fractionated mouse ACM by size and assessed the inhibitory potential of each 
fraction on B lymphopoiesis. ACM was fractionated using a 10kDa filter to 
generate ACM <10kDa molecules and ACM >10kD molecules. We reasoned that 
if ACM contains multiple inhibitory molecules, then we expect that treatment of B 
lymphopoiesis cultures with ACM <10kDa and ACM >10kDa would result in 
reduced B lineage development compared to untreated cultures. As expected 
total ACM-treated BM cultures resulted in a decreased percentage of B220+ B 
lineage cells compared to untreated cultures (Figure 3.12 A). In separate 
experiments, treatment with ACM <10kDa (Figure 3.12 B) and ACM >10kDa 
(Figure 3.12 C) also resulted in a decreased percentage of B220+ B lineage cells 
compared to their respective medium controls. Similar results were obtained 
when studying the >10kDa and <10kDa fractions of rabbit ACM (data not shown), 
suggesting that ACM contains multiple inhibitory factors of different size.  
The above result only indicates that there is more than one inhibitory 
factor produced by adipocytes. Naturally, there could be more than one inhibitory 
factor in the ACM <10kDa, as well as the ACM >10kDa. Our subsequent 
experiments were aimed to further characterize inhibitory molecules in ACM, to 
address whether or not they are protein in nature; as this information will guide 
attempts to identify ACM-derived molecules. 
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Figure 3.12 Effect of <10kDa and >10kDa adipocyte molecules on B 
lymphopoiesis. Flow cytometric analysis of B lymphopoiesis cultures performed 
in the presence or absence (untreated) of (A) total ACM, (B) ACM <10kDa, or (C) 
ACM >10kDa. (A&B) Flow cytometry plots displaying cells stained with anti-B220 
and anti-CD14. (C) Flow cytometry plots displaying cells stained with anti-B220 
and anti-CD19. Note the different staining scheme in panel (C). For all panels, 
total B220+ cells are considered B lineage (49% untreated vs 6% ACM >10kDa in 
panel C). Data are representative of at least two or three independent 
experiments per fraction. 
 
Are the inhibitory molecules in ACM protein in nature? 
Adipocytes can produce both protein and lipid products. To understand 
the contribution of these major classes of molecules to the inhibitory effect, we 
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proteinase K treated the >10kDa and <10kDa fractions of ACM. We expected 
that if proteins are responsible for the inhibitory effect in either of these fractions, 
then proteinase K treatment would remove the inhibitory activity of ACM >10kDa 
or <10kDa. B lymphopoiesis assays performed with mouse ACM and rabbit ACM 
both suggest that adipocytes produce inhibitory factors both protein and non-
protein (likely lipid) in nature (data not shown), as proteinase K treatment 
removed the inhibitory activity of >10kDa ACM but not smaller molecule fractions. 
This information is critical for developing strategies to purify the inhibitory activity 
in ACM. Now that we know the active molecules in ACM <10kDa and ACM 
>10kDa have different biochemical make up, we tried to exploit this information to 
purify inhibitory molecules. 
Purification of adipocyte derived-inhibitory factors 
Since ACM >10kDa is protein in nature, we asked if we could purify the 
inhibitory molecule(s) via anion exchange chromatography. We used mouse 
ACM to purify ACM >10kDa molecules because mouse ACM can be generated 
in greater abundance and in less time than rabbit and human ACM. By fast 
protein liquid chromatography (FPLC), using a strong anion exchange column 
and increasing salt concentration to elute, we separated ACM >10kDa based on 
charge (Figure 3.13 A). There was a large protein peak in the column flow 
through, suggesting not all ACM proteins bound to the column, and two defined 
peaks were observed after elution was started. We collected and concentrated 
the effluent into five fractions (4-8) as seen in Figure 3.13 A. 
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To assess whether any of the peaks contained inhibitory activity, we 
added various column fractions/samples to rabbit B lymphopoiesis assays and 
analyzed the percentage of CD79a+ B lineage cells resulting after treatment. If 
this strategy was effective in purifying inhibitory molecules, we expect to find 
some column samples that contain inhibitory activity and some that do not. 
Although the flow through contained a large protein concentration peak, this 
fraction did not contain significant inhibitory activity (Figure 3.13 A&B). In 
contrast, treatment with samples 6 and 7 resulted in decreased B lineage 
development similar to unfractionated ACM treatment (positive control for 
inhibition). Therefore the inhibitory activity was in part purified through this 
method and could be found in samples 6 and 7. 
To see how effective this purification strategy was, we assessed the purity 
of the inhibitory fractions. We performed SDS PAGE to separate proteins within 
each column sample and visualized the proteins in each fraction after silver 
staining. If this strategy effectively purified ACM inhibitory proteins, we expected 
samples 6 and 7 would only contain several stained protein bands. As expected, 
unfractionated ACM >10kDa contained many protein bands of various sizes 
(Figure 3.13 C ACM lane). Although the inhibitory fractions 6 and 7 contained 
fewer protein bands, there were still many, suggesting that additional purification 
methods will be needed to purify single protein bands (Figure 3.13 C Sample 6, 
Sample 7a, 7b, 7c lanes). In sample 6 there was a prominent protein band 
between the 75kDa and 50kDa size markers, which was less concentrated in the 
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other samples. Additional experiments will be needed to determine the identity of 
the corresponding protein and its inhibitory potential. 
 As seen in Figure 3.13 C, we further divided sample 7 into 3 smaller 
fractions (Sample 7a, 7b, and 7c) and found two of the three fractions contained 
an inhibitory factor(s) (as indicated with +). Inhibitory activity was determined 
similar to that seen in Figure 3.13 B, where each fraction was dialyzed against 
cell culture medium then added to rabbit B lymphopoiesis assays at a 1:2 
dilution. Further division of sample 7 did not substantially change the number of 
protein bands observed after silver staining (Figure 3.13 C sample 7a, 7b, and 7c 
lanes), therefore future studies will be needed to obtain more pure samples to 
identify single inhibitory factors. 
Our attempts to characterize and purify ACM molecules with inhibitory 
activity have focused on the overall inhibition of B lymphopoiesis. Because we 
found that adipocyte factors induce inhibitory MDSCs, we focused our search to 
identify ACM molecules that promote the accumulation of MDSCs. 
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Figure 3.13 Purification of inhibitory molecules in ACM >10kDa. Anion 
exchange chromatography was performed on msACM >10kDa with increasing 
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salt concentration used to elute material from the column. (A) Protein 
concentration profile corresponding to fractions collected from the column. Green 
arrow marks when linear increasing salt elution (0-1M NaCl) was started. 
Collected fractions/samples tested for inhibitory activity in (B) are indicated on 
the profile in (A). (B) Percent of maximum B lymphopoiesis resulting from rabbit 
BM cultures treated with the indicated samples taken after anion exchange 
chromatography of msACM >10kDa. Percent of maximum was calculated by 
setting the percentage of CD79a+ cells from “no treatment” cultures to 100%. (C) 
Silver stained SDS PAGE gel loaded with the indicated samples. Samples 6, 7a, 
7b, and 7c were loaded in anion exchange running buffer. Samples 7a Med, 7b 
Med, and 7c Med were dialyzed in alpha mem culture medium, and then loaded 
(contain additional medium derived proteins). Inhibitory activity on B 
lymphopoiesis is summarized as + (inhibits B lymphopoiesis) or – (does not 
inhibit). Precision plus protein standard (BioRad) was used as a size reference 
(250kDa, 150kDa, 100kDa, 75kDa (most prominent band mid gel), 50kDa, 
37kDa, 25kDa, and 10kDa). Data were obtained only in one experiment but will 
provide the basis for future purification strategies.  
 
Which adipocyte-derived soluble factors induce MDSCs? 
The above results suggest that adipocytes produce multiple molecules 
that negatively regulate B lymphopoiesis. Because ACM promotes the 
accumulation of MDSCs that in turn inhibit B lymphopoiesis, we sought to identify 
and neutralize the adipocyte-derived molecules responsible for inducing 
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inhibitory MDSCs. We hypothesized that preventing the accumulation of MDSC, 
would result in enhanced B lymphopoiesis. 
To characterize which ACM molecules promote the accumulation of 
MDSCs, we used a similar approach as before. We generated ACM <10kDa and 
>10kDa fractions, and then compared total ACM, ACM <10kDa, and ACM 
>10kDa for the ability to promote CD11b+Gr1+ MDSCs in vitro. Mouse BM 
progenitors were cultured with OP9 stromal cells and treated with each ACM 
fraction individually, followed by flow cytometric analysis to determine the number 
of CD11b+Gr1+ cells resulting after treatment. For example, if ACM >10kDa 
molecules are sufficient to promote MDSC accumulation, then we expected that 
treatment with total ACM and ACM >10kDa would result in an increased number 
of MDSCs compared to untreated cultures. As expected for total ACM-treated 
cultures, there was a significant increase in the number of CD11b+Gr1+ cells 
compared to untreated cultures (Figure 3.14). ACM >10kDa treatment also 
resulted in significantly more CD11b+Gr1+ cells compared to control cultures 
(Figure 3.14), while ACM <10kDa treatment contained a similar number of 
CD11b+Gr1+ cells compared to untreated controls (Figure 3.14). These results 
suggest that an adipocyte factor(s) >10kDa is responsible for generating MDSCs. 
For the remainder of studies, we focused on adipocyte factors >10kDa.  
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Figure 3.14 Characterization of adipocyte factors for the capacity to induce 
CD11b+Gr1+ myeloid cells. Number of CD11b+Gr1+ cells resulting from B220- 
BM cells cultured with OP9 stromal cells in the presence or absence of total ACM 
(left), ACM <10kDa (middle), or ACM >10kDa (right). Data are representative of 
three independent experiments. Statistical significance was determined using 
Students t test. Error bars represent the average of triplicate wells +/- SD. 
 
To identify potential MDSC-promoting adipocyte molecules, we performed 
a cytokine array focused on 23 cytokines/chemokines. In this experiment ACM 
(inhibits B lymphopoiesis/induces MDSCs) was compared to MDSC-CM (inhibits 
B lymphopoiesis) and CD11b+Gr1+ control-CM (does not inhibit B 
lymphopoiesis). We expected that MDSC promoting factors would be increased 
in ACM as compared to control-CM, because CD11b+Gr1+ control cells do not 
induce MDSCs in BM cultures. Interestingly, ACM contained IL-6, IL-12(p40), IL-
12(p70), IL-13, G-CSF, KC, MCP, TNFα, Eotaxin, MIP-1α, and RANTES (Figure 
3.15). Many of these factors are inflammatory in nature, suggesting that 
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adipocyte factors produce an inflammatory environment. Additionally, multiple 
factors in ACM identified by us (eg. IL-6, IL-13, G-CSF, TNFα, MCP1, 
complement C3 [data not shown]) and reported by others to be produced by 
adipocytes (eg. S100A8) (Hiuge-Shimizu et al., 2011, Sekimoto et al., 2012) are 
known to induce MDSCs (Bunt et al., 2007, Cheng et al., 2008, Drevets et al., 
2004, Gabrilovich and Nagaraj, 2009, Gallina et al., 2006, Hsieh et al., 2013, 
Huang et al., 2007, Movahedi et al., 2008, Sawanobori et al., 2008, Sinha et al., 
2008, Terabe et al., 2003, Zhao et al., 2012). Upon identifying that ACM contains 
multiple factors known to induce MDSCs, we suggest a combination of these 
molecules (rather than one) are likely responsible for the generation of MDSCs 
by ACM. This finding is important to consider when developing strategies to 
target adipocyte factors. 
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Figure 3.15 Profile of adipocyte-derived soluble factors by cytokine array. 
Protein concentrations of the indicated factors as detected by cytokine array in 
ACM, MDSC-CM, or control-CM. Data are from three different ACM, three 
different MDSC-CM and two different control-CM generated in individual 
experiments. Error bars show the average of the two or three different 
conditioned media +/- SD. 
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Can adipocyte factors be targeted to prevent MDSC accumulation? 
To develop therapeutics aimed at blocking adipocyte-mediated generation 
of MDSCs, we must devise a strategy to target the adipocyte, the MDSC, or 
neutralize adipocyte factors. Since ACM is a source of multiple factors able to 
induce MDSCs, it would be difficult to identify and block all potential MDSC 
promoting factors. An approach to identify and block a common pathway used by 
adipocyte-factors to induce MDSCs might be more successful. Cytokine array 
analysis of ACM showed that while ACM induces IL-1 producing MDSCs, IL-1 
was not detected in the ACM (Figure 3.15), suggesting that a factor (or 
combination of factors) in ACM other than IL-1, induces this inflammatory 
molecule. Because IL-1 production is induced through inflammasome activation 
(Garlanda et al., 2013, Latz et al., 2013) and adipocytes produce NLRP3 
inflammasome activators (eg. S100A8, DAMPs) (Coppack, 2001, Nagareddy et 
al., 2014, Wen et al., 2011, Youm et al., 2012, Youm et al., 2013), we 
hypothesized that blocking the NLRP3 inflammasome would prevent adipocyte 
induced MDSC activation/accumulation. To test this we performed BM cultures 
treated with ACM >10kDa in the presence or absence of glybenclamide, which 
reportedly blocks NLRP3 inflammasome activation and downstream IL-1 
production in myeloid cells (Lamkanfi et al., 2009, Henriksbo et al., 2014, 
Laliberte et al., 1999, Dostert et al., 2009, Chen et al., 2012, Tavares et al., 
2013). We expected that if ACM induces MDSCs through NLRP3 inflammasome 
activation, then blocking this pathway would prevent MDSC accumulation. As 
predicted, glybenclamide treatment significantly reduced CD11b+Gr1+ MDSC 
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generation compared to cultures containing only ACM >10kDa (Figure 3.16 A 
and C). Additionally, because MDSCs negatively regulate B lineage 
development, we expected that blocking MDSC accumulation would enhance B 
lymphopoiesis in cultures containing ACM >10kDa. Strikingly, as seen in Figure 
3.16 B and D, blocking MDSC accumulation did increase B cell development as 
evidenced by an increase in B220+ cells. These data suggest that blocking the 
NLRP3 inflammasome is potentially an effective strategy to prevent MDSC 
accumulation and boost B lymphopoiesis in fatty BM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
Figure 3.16 Effect of glybenclamide treatment on MDSC accumulation. BM 
cultures were performed in the presence of ACM >10kDa with or without 
glybenclamide (NLRP3 inflammasome inhibitor). (A&B) Representative flow 
cytometric profiles displaying (A) CD11b and Gr1, or (B) B220 and CD19 
expression at the end of culture. Percent of (C) CD11b+Gr1+ or (D) B220+ cells 
resulting after culture with the indicated treatments. Data are representative of 
three to four individual experiments per condition. Significance was determined 
by ANOVA in combination with a Bonferroni multiple comparison test (p=0.0005 
and p=0.0001 for (C) and (D) respectively). Error bars represent the average of 
individual experiments +/- SD. 
 
SECTION 4: CHARACTERIZATION OF RABBIT HEMATOPOIESIS 
Through mouse BM cultures, we have uncovered a mechanism where 
adipocytes induce inflammatory myeloid cells which inhibit B cell development 
through IL-1. This inhibition does not lead to a direct block of B cell development; 
rather IL-1 promotes myelopoiesis at the expense of B lymphopoiesis. Because 
large amounts of BM fat have been observed in adult rabbit BM, we asked if this 
mechanism could be occurring in vivo in rabbits at two to four months of age, 
when B lymphopoiesis is lost. If true, we expected to find an accumulation of 
adipocytes, increased BM myeloid cell compartment, and increased expression 
of IL-1 in the BM of rabbits >2 months of age. 
In addition to testing whether or not the mechanism of adipocyte-mediated 
inhibition of B lymphopoiesis could be occurring in rabbit BM, we also sought to 
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determine if rabbit BM could be studied as an accelerated model of BM aging. 
Our laboratory has established that rabbit B lymphopoiesis arrests early in life, 
compared to humans and mice. In this study, we characterized rabbit BM to see 
if additional changes occurring at two months of age resemble the BM of two 
year old mice; the time when B lymphopoiesis declines (Kirman et al., 1998, 
Miller and Allman, 2003, Riley et al., 1991, Sherwood et al., 1998, Stephan et al., 
1996). If the BM of >2 month old rabbits resembles that of aged mice, we would 
expect to find increased BM fat and an increase in BM myeloid cells at the time B 
lymphopoiesis declines; as mentioned in the previous paragraph, these 
characteristics would also be consistent with the elucidated mechanism of 
adipocyte-mediated inhibition of B lymphopoiesis. 
 Several studies allude to the abundance of fat in the BM of adult rabbits 
(Bigelow and Tavassoli, 1984, Bilwani and Knight, 2012); however, B 
lymphopoiesis arrests in rabbits prior to adulthood. It is unknown if adipocytes 
accumulate in the BM at the exact timing B lineage development is lost. Jasper et 
al. found that rabbit B lymphopoiesis peaks in the first few weeks of life and 
arrests by two to four months of age (Jasper et al., 2003). To visualize the 
appearance of BM fat at the time B cell development arrests in rabbits, we 
sectioned BM from rabbits of various ages followed by H&E staining. If increased 
BM fat correlates with the timing B lymphopoiesis is lost in rabbits, then we 
expected to find an increase in fat spaces observed in BM sections taken from 
>2-4 month old rabbits compared to <2 month old rabbits. As expected, 
representative BM from a 3 month old rabbit (a time after B cell development is 
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arrested) exhibited an increased number and size of fat spaces compared to 
representative BM from a 3 week old rabbit (active B cell development) (Figure 
3.17). Interestingly, rabbits older than two to three months (ranging to 13 months 
old) also had increased BM fat that appeared similar to that of a two to three 
month old rabbit (data not shown). These data suggest that adipocytes 
accumulate in rabbit BM at the time B lineage development is arrested. These 
data are consistent with increased BM fat found in aged mice (Krings et al., 
2012). 
 
 
 
 
 
 
 
 
Figure 3.17 Characterization of bone marrow fat in rabbits. Representative 
BM sections generated from femurs of a 3 week old rabbit (left) and a 3 month 
old rabbit (right). Sections were H&E stained and visualized for the proportion of 
fat (white spaces) vs red marrow (pink and purple staining). Multiple sections and 
multiple fields of each section were visualized from each rabbit to obtain 
representative images. BM sections analyzed from rabbits >3 months of age had 
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a profile similar to the 3 month (right) section shown above. The displayed 
images were taken at 10x magnification. 
 
If the mechanism of adipocyte-induced inhibition of B cell development 
(elucidated in this dissertation) occurs in the BM of >2 month old rabbits, we 
expect this BM would exhibit a myeloid skew. This would also be consistent with 
the myeloid skew observed in two year old mice (Enioutina et al., 2011), when B 
lymphopoiesis is declining. To test this, we performed flow cytometric analysis on 
BM isolated from rabbits of various ages. If hematopoiesis is skewed toward 
myelopoiesis in BM of >2 month old rabbits, we expected to find a greater 
frequency of CD11b+ myeloid cells in the BM of >2 month old rabbits as 
compared to younger rabbits. Interestingly, the percentage of CD11b+ myeloid 
cells was increased in the BM of rabbits >2 months old as seen by flow cytometry 
(Figure 3.18 A-C). These data suggest that rabbit BM exhibits a myeloid skew at 
2 months of age similar to that seen in two year old mice. 
Further flow cytometric analysis of the CD11b+ cells from >2 month old 
and <2 month old rabbits showed that myeloid cells from >2 month old rabbits 
have higher CD11b expression (Figure 3.18 D). This phenotype is similar to 
CD11bhiGr1+ ACM-generated MDSCs (Figure 3.3), suggesting these cells may 
be similar. If CD11b+ cells from aged BM are similar to ACM-generated MDSCs, 
we expect they would be influenced by adipocyte-derived molecules. To 
characterize the localization of CD11b+ cells relative to BM adipocytes, we 
generated frozen OCT embedded BM sections from <2 month old and >2 month 
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old rabbits, stained for CD11b+ cells and analyzed them by fluorescence 
microscopy. If BM CD11b+ cells are influenced by BM adipocytes, we expected 
to find CD11b+ cells near BM adipocytes. Consistent with our flow cytometry 
data, BM of >2 month old rabbits contained many more cells staining for CD11b 
expression, compared to BM of <2 month old rabbits (Figure 3.18 E). Further, 
immunofluorescence analysis of BM sections from >2 month old rabbits sections 
showed a large proportion of BM CD11b+ cells (Figure 3.18E- green) near large 
fat spaces (Figure 3.18E- black). These data suggest that CD11bhi rabbit BM 
cells are likely influenced by adipocyte products. 
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Figure 3.18 Characterization of rabbit bone marrow before and after two 
months of age. (A&B) Flow cytometry profiles of nucleated cells from (A) BM of 
<2 month old or (B) >2 month old rabbits. BM cells were analyzed for FSC vs 
SSC (left), then for CD11b and CD14 (right) staining. (C) Percentage of BM 
CD11b+ cells in <2 month old (circles) and >2 month old rabbits (squares) (total 
n=11). (D) Representative flow cytometry profile of CD11b expression in the BM 
3 week rabbit 3 month rabbit E. 
CD11b 
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CD11b+ cell gate comparing a <2 month old rabbit (young) and a >2 month old 
rabbit (old). (E) Fluorescence microscopy analysis of BM sections stained with 
Hoechst (blue), anti-CD11b (green), and anti-kappa light chain (red) – very few 
cells stained with anti-kappa. (A&B) Data are representative of a panel of 11 
rabbits. Data in (E) are representative of a panel of 7 rabbits. Significance in (C) 
was determined by Student’s t test. Error bars represent the average percentage 
over multiple rabbits per group +/- SD. 
 
We found that ACM-induced MDSCs inhibit B lymphopoiesis through IL-1 
production. To further compare BM of >2 month old rabbits to the mechanism of 
adipocyte-mediated inhibition of B cell development, we performed qPCR 
analysis on rabbit BM cells to assess IL-1 expression. BM was isolated from 
rabbits <2 months of age and >2 months of age, followed by qPCR analysis for 
IL-1β expression. If IL-1β contributes to the loss of B lymphopoiesis in rabbit BM, 
we expected to find increased expression of IL-1β in BM cells isolated from >2 
month old rabbits. In fact, qPCR analysis of total rabbit BM showed that IL-1β 
expression increased with age (Figure 3.19 A). 
If IL-1β is produced by an MDSC-like cell in BM of >2 month old rabbits, 
we expected to find IL-1β expression localized to BM myeloid cells. As anti-
CD11b is the best reagent available to identify myeloid cells in rabbits, we used 
this reagent to isolate CD11b+ and CD11b- cells from BM of >2 month old rabbits 
by FACS, then performed qPCR analysis for the expression of IL-1β. If IL-1β is 
expressed by BM myeloid cells, then we expected CD11b+ cells to express 
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higher amounts of IL-1β compared to CD11b- cells. As expected, we found IL-1β 
was expressed at much higher levels (~30x) in CD11b+ cells (Figure 3.19 B). 
Together, these data suggest that BM of >2 month old rabbits exhibits a larger 
myeloid compartment compared to younger rabbits, and that these myeloid cells 
resemble ACM-generated MDSCs based on CD11b and IL-1β expression. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 Quantitative PCR anaysis of IL-1β expression in rabbit bone 
marrow. (A) Total BM cells from rabbits <2 months and >2months of age. (B) 
FACS-sorted CD11b- and CD11b+ populations from BM of >2 month old rabbits. 
Each sample was normalized to HGPRT housekeeping gene to determine 
relative expression. Data in (A) are calculated from a panel of 7 rabbits. Data in 
(B) display the average of 3 independent experiments. Statistical significance in 
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(A) was determined by Student’s t test. Error bars represent the average 
expression of multiple rabbits per group +/- SD. 
SECTION 5: CONTRIBUTION OF THE BONE MARROW 
MICROENVIRONMENT TO ALTERED HEMATOPOIESIS IN RABBITS 
The arrest of B lymphopoiesis and the myeloid skew seen at 2 months of 
age in rabbits could be due to intrinsic changes to hematopoietic progenitors or 
due to changes in the BM microenvironment. Due to the large increase in BM fat 
and our findings linking adipocytes to the generation of inhibitory myeloid cells, 
we hypothesized that the BM microenvironment of >2 month old rabbits 
recapitulates the myeloid skew seen in BM of >2 month old rabbits. To test this, 
we isolated the adipocyte layer that forms when preparing BM from >2 month old 
rabbits and generated conditioned medium from these fat explants (BM fat-CM) 
(Figure 3.20 A). We know that the adipocyte layer also contains CD11b+ myeloid 
cells that are tightly associated with adipocytes (data not shown); therefore the 
factors in BM fat-CM are the combination of adipocyte factors and myeloid-
derived factors. We expected if this combination of factors is responsible for 
decreased B lymphopoiesis and increased myelopoiesis, then rabbit BM cultures 
treated with BM fat-CM will have decreased CD79a+ cells and increased CD11b+ 
cells. As seen in untreated cultures, BM progenitors from >2 month old rabbits 
are able to differentiate to the B lineage (Figure 3.20 B), suggesting the 
progenitors do not have intrinsic defects. Alternatively, cultures treated with BM 
fat-CM had significantly fewer CD79+ B lineage cells and an increase in CD11b+ 
myeloid cells (Figure 3.20 C-E). These data suggest that the BM 
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microenvironment, made up of adipocytes and myeloid cells, is a major 
contributor to decreased B cell development and increased myeloid development 
as seen in BM of >2 month old rabbits. 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Effect of BM fat-CM on rabbit B lymphopoiesis cultures. (A) 
Schematic diagram: The adipocyte layer from >2 month old rabbits was isolated 
and then cultured 16-24 hours to generate BM fat-CM. BM fat-CM was added to 
rabbit B lymphopoiesis cultures and the development of B lineage cells was 
assessed. (B&C) Flow cytometry profiles of cells resulting from B lymphopoiesis 
cultures with or without (no treatment) BM fat-CM, and analyzed for CD79a and 
CD11b expression. (D&E) Number of (D) CD79a+ or (E) CD11b+ cells resulting 
from no treatment or BM fat-CM treated cultures. Data are representative of four 
independent experiments. Statistical significance in (D&E) was determined using 
Student’s t test. Error bars represent the average of triplicate wells +/- SD. 
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Do rabbit bone marrow myeloid cells inhibit B cell development? 
Through mouse BM cultures treated with ACM, we learned that adipocyte 
factors activate myeloid cells to inhibit B lymphopoiesis. The previous experiment 
suggests the combination of adipocyte and myeloid-derived factors also 
negatively impact B lymphopoiesis in rabbits. We asked if inhibitory myeloid cells 
could be isolated directly from BM of >2 month old rabbits. We tested this by 
using magnetic beads to isolate CD11b+ myeloid cells from both the BM 
adipocyte layer, as well as the adipocyte free BM pellet. The adipocyte-free BM 
pellet is called the SFV (stromal vascular fraction) and contains all BM cells that 
are not in the adipocyte layer (corresponds to red BM pellet displayed in Figure 
3.20 A). These are the BM cells prepared in previous experiments, referred to as 
“total BM”, and are the only cells isolated from <2 month old rabbits; as an 
adipocyte layer does not form when preparing younger rabbit BM. 
While isolation of CD11b+ cells from the SVF pellet can be performed 
easily, isolation of hematopoietic cells from the adipocyte layer requires more 
effort. This was typically done in one of two ways. The first approach is to culture 
BM fat overnight to allow hematopoietic cells to fall out of the floating adipocyte 
layer. These hematopoietic cells can then be isolated along with additional cells 
that are released from the adipocyte layer after repetitive pipetting. The second 
approach is to digest the adipocyte layer with collagenase, which will release 
cells that can then be isolated. Both approaches showed similar results in our 
hands. 
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Reagents to detect Gr1 in mice, are unavailable for rabbits. Therefore we 
used CD11b to isolate general BM myeloid cells, reasoning that an inhibitory 
population would be contained in a smaller percentage of these cells. We 
isolated CD11b+ cells from the BM adipocyte layer and the BM SVF pellet, then 
added them to B lymphopoiesis cultures, and assessed the number of B lineage 
cells that developed. If BM of >2 month rabbits contains an inhibitory myeloid 
population, we expected treatment of BM cultures with CD11b+ cells isolated 
from both the BM adipocyte layer and SVF pellet would result in fewer CD79a+ B 
lineage cells compared to control cultures. In fact, cultures containing CD11b+ 
cells isolated from the BM fat layer and SVF pellet had a decreased number of B 
lineage cells develop compared to untreated cultures, and cultures containing an 
equal number of CD11b- cells isolated from BM fat (Figure 3.21). These results 
suggest that a suppressive population within the CD11b+ BM myeloid 
compartment is capable of inhibiting rabbit B lymphopoiesis in vitro. We 
hypothesize the inhibitory activity in this myeloid population is activated by 
adipocyte products in the BM of >2 month old rabbits. Generation of additional 
reagents to study rabbit myeloid cells will be critical to characterizing specific 
myeloid lineage suppressor cells in BM. 
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Figure 3.21 Effect of BM myeloid cells from >2 month rabbits on B 
lymphopoiesis in vitro. Rabbit B lymphopoiesis cultures were performed 
starting with 10,000 BM progenitors with no effectors (no treatment) or the 
indicated number of CD11b- cells from BM fat, CD11b+ cells from BM fat, or 
CD11b+ cells from the SVF fraction of BM. Error bars represent the average of 
triplicate wells +/- SD. Data were analyzed for statistical significance by ANOVA 
coupled with the Dunnet multiple comparison test (p<0.0001). Data are 
representative of 3 independent experiments. 
 
Characterization of inflammatory myeloid cells in bone the marrow of >2 
month old rabbits 
Inflammatory cells that accumulate with age, such as aged B cells, have 
been shown to negatively regulate B lymphopoiesis (Ratliff et al., 2013). 
Activation of an inflammatory profile in myeloid cells by adipocytes in adipose 
tissue has also been reported (Nagareddy et al., 2014, Vandanmagsar et al., 
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2011, Wen et al., 2011, Youm et al., 2012). Because BM of >2 month old rabbits 
has increases in adipocytes and myeloid cells, we looked for the presence of 
additional inflammatory factors in rabbit BM with age. 
Expression of the inflammatory proteins S100A8 and S100A9 is 
upregulated in many tissues, including adipose tissue during aging and obesity 
(Schiopu and Cotoi, 2013, Sekimoto et al., 2012, Swindell et al., 2013). 
Additionally, these factors induce inflammasome activation (Nagareddy et al., 
2014, Simard et al., 2013) and promote MDSCs, which can in turn produce more 
inflammatory S100A8 and/or S100A9 (Sinha et al., 2008). We profiled rabbit BM 
by flow cytometry using an antibody that recognizes S100A8 and S100A9, to 
determine if these proteins are increased in the BM of >2 month old rabbits. 
Interestingly, by flow cytometry, we found a population of S100A8/S100A9 
expressing myeloid cells that was increased in the BM of older rabbits (Figure 
3.22 A&B), suggesting that inflammatory myeloid cells accumulate in rabbit BM 
at the time B lymphopoiesis is lost. 
The anti-S100A8/S100A9 antibody used to profile rabbit BM by flow 
cytometry (described above) does not discriminate between S100A8 and 
S100A9, therefore we do not know if the expression of just one or both S100A8 
and S100A9 is increased with age. To determine if the expression of S100A8 
and/or S100A9 is increased in the BM of >2 month old rabbits we performed 
qPCR analysis on rabbit BM cells (BM SVF pellet – without the adipocyte layer). 
We expected that both S100A8 and S100A9 expression would be increased in 
the BM of >2 month old rabbits. To our surprise, analysis of S100A8 expression 
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was similar between young and older rabbits (Figure 3.22 C), whereas S100A9 
expression was increased in the BM of rabbits >2 months of age (Figure 3.22 D). 
We conclude that S100A9 expressing myeloid cells are increased in the BM of 
>2 month old rabbits. 
 
 
 
 
 
 
 
Figure 3.22 Characterization of S100A9+ myeloid cells in rabbit bone 
marrow. (A) Flow cytometry profile of rabbit BM nucleated cells stained with anti-
CD11b (surface) and anti-S100A8/A9 (intracellular). (B) Percent of 
CD11b+S100A8/A9+ cells in nucleated BM cells from <2 month (circles) and >2 
month (squares) old rabbits. (C&D) qPCR analysis of total BM nucleated cells 
from <2 month and >2 month old rabbits analyzed for the expression of (C) 
S100A8 and (D) S100A9. Expression was normalized to HGPRT housekeeping 
gene. For data in (B) n=12 rabbits total. Error bars represent the average of each 
population of rabbits +/- SD. (C-D) Data are the average of three independent 
experiments. Error bars represent the average of three experiments +/- SD. (B-D) 
Statistical significance was determined by Student’s t test. 
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S100A9 and the inhibition of B lymphopoiesis 
S100A9 is known for its potent inflammatory properties, but it is unknown 
if this molecule negatively regulates B lymphopoiesis. Because expression of this 
molecule is increased in BM of >2 month old rabbits (when B lymphopoiesis is 
arrested), we hypothesized that S100A9 negatively regulates B lymphopoiesis. 
To test this, we treated mouse B lymphopoiesis cultures with recombinant 
S100A9, and then assessed the number of B220+ B lineage cells resulting from 
these cultures. We expected that if S100A9 inhibits B cell development, then 
cultures containing S100A9 will have fewer B220+ cells develop compared to 
controls. Flow cytometric analysis of cultures treated with S100A9 exhibited a 
decreased percentage and number of B220+ B lineage cells compared to 
untreated cultures (Figure 3.23 A-C). In addition to decreased B lineage 
development, S100A9 treatment resulted in significantly more CD11b+Gr1+ 
myeloid cells (Figure 3.23 D-F), reminiscent of cultures treated with IL-1. We 
conclude that S100A9 inhibits B lymphopoiesis and promotes myeloid cell 
development/survival. 
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Figure 3.23 Effect of S100A9 on B lymphopoiesis in vitro. Mouse B 
lymphopoiesis cultures of B220- BM progenitors with OP9 cells were performed 
in the presence or absence (no treatment) of recombinant S100A9. Flow 
cytometry profiles displaying (A&B) B220 and CD19, (D&E) CD11b and Gr1. 
(C&F) Number of (C) B220+ cells or (F) CD11b+Gr1+ cells resulting from cultures 
treated with the indicated amount (bar graphs) or 5µg/ml (flow cytometry plots) of 
S100A9. Data are representative of 3 independent experiments. Statistical 
significance in (C&F) was analyzed by ANOVA coupled with the Dunnet multiple 
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comparison test (p<0.0001 and p<0.0001 respectively). Error bars represent the 
average of triplicate wells +/- SD. 
Hematopoietic target of S100A9 
We showed for the first time that S100A9 negatively regulates B 
lymphopoiesis. Because S100A9 is an inflammatory molecule, like IL-1, we 
asked if S100A9 inhibits in a similar manner. We set out to identify the 
hematopoietic target of S100A9 treatment. If the mechanism of inhibition mirrors 
that of IL-1 mediated inhibition, we expect S100A9 alters the differentiation 
potential of MPPs. To test this, we cultured FACS-sorted HSCs, MPPs, or CLPs 
(Figure 3.24 A) with OP9 cells in the presence or absence of S100A9 treatment. 
To our surprise, the number of B220+ B lineage cells resulting after S100A9 
treatment did not differ from untreated cultures seeded with HSCs, MPPs, or 
CLPs (Figure 3.24 B). We conclude that neither HSCs, MPPs, nor CLPs are the 
the direct target of S100A9 treatment. 
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Figure 3.24 Impact of S100A9 treatment on hematopoietic progenitors. (A) B 
lineage developmental stages and key markers for identification. (B) Number of 
B220+ cells resulting from B lymphopoiesis cultures seeded with HSCs, MPPs, or 
CLPs and treated with or without (untreated) S100A9. Data are representative of 
three independent experiments. Statistical significance was determined by 
Student’s t test. Error bars represent the average of triplicate wells +/- SD. 
 
The finding that S100A9 treatment does not act on HSCs, MPPs, or CLPs 
raised several questions. If early hematopoietic progenitors (with B lineage 
potential) are not the target of S100A9 mediated inhibition, what cell type is? 
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Also, if S100A9 does not inhibit B lymphopoiesis in cultures of purified HSCs, 
how did inhibition occur in previous B lymphopoiesis assays? We were able to 
answer these questions after comparing the methodology used in the experiment 
shown in Figure 3.23, and in S100A9 treatment of individually purified 
hematopoietic progenitors (Figure 3.24). 
In B lymphopoiesis cultures that were inhibited by S100A9 (Figure 3.23), 
the starting population of cells was B220- BM, which contains a mix of non-B 
lineage BM progenitors including HSCs, MPPs, etc. In addition to early 
progenitors, B220- BM also contains a population of CD11b+Gr1+ myeloid 
progenitors (without suppressive activity) that either do not survive in B 
lymphopoiesis promoting conditions or differentiate into normal mature myeloid 
lineage cells. This information coupled with a study that found S100A9 treatment 
induces pro-inflammatory cytokine production from mature myeloid cells in 
human peripheral blood (Simard et al., 2013), led us to ask whether immature 
myeloid cells could also respond in a similar manner. To test this, we isolated 
CD11b+Gr1+ myeloid cells from healthy mouse BM using magnetic beads (Figure 
3.25 A), treated these cells with S100A9 and used qPCR to analyze the 
expression of inflammatory mediators known to inhibit B lymphopoiesis (IL-1β, 
NLRP3, IL-6, and TNFα) at various time points after treatment. If S100A9 inhibits 
B lymphopoiesis by inducing the production of inhibitory molecules from 
otherwise normal CD11b+Gr1+ BM myeloid progenitors, we expected S100A9 
treatment would induce increased expression of IL-1β, NLRP3, IL-6, and TNFα in 
these cells. Interestingly, S100A9 treatment induced an early burst in expression 
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of IL-1β, NLRP3, IL-6, and TNFα. Increases were observed as early as 2 hours 
after treatment, peaking at the 4 hour time point for most of these molecules. 
Several novel conclusions can be drawn from this experiment. First, BM 
CD11b+Gr1+ myeloid progenitors have the appropriate machinery to respond to 
S100A9 treatment, similar to that seen in mature human peripheral blood myeloid 
lineage cells. Second, S100A9 treatment induces otherwise normal myeloid 
progenitors to express inflammatory mediators known to negatively regulate B 
lymphopoiesis. Finally, this result (induction of IL-1) suggests that S100A9-
mediated inhibition also feeds into the mechanism previously described for IL-1. 
This explains why S100A9 treatment (similar to IL-1 treatment) induces 
myelopoiesis and the loss of B lymphopoiesis. 
Overall, our analysis of rabbit BM led/leads us to: 1. Suggest the 
mechanism of adipocyte-mediated inhibition of B lymphopoiesis (elucidated in 
mouse BM cultures) contributes to the arrest of B cell development in rabbits; 2. 
Identify similarities between BM of >2 month old rabbits and two year old mouse 
BM (to be discussed further); and 3. Identify S100A9 as a negative regulator of B 
lineage development. 
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Figure 3.25 Effect of S100A9 treatment on bone marrow myeloid cells. (A) 
Flow cytometry profile of mouse BM CD11b+Gr1+ myeloid cells after anti-CD11b 
magnetic bead isolation, and prior to treatment with S100A9 (5µg/ml). (B-E) 
qPCR analysis of CD11b+Gr1+ BM cells either no treatment, or treated with 
S100A9 for the indicated amount of time. Following treatment the resulting cells 
were analyzed for the expression of (B) IL-1β, (C) NLRP3, (D) TNFα, and (E) IL-
6. Data are representative of three independent experiments.  
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CHAPTER IV 
DISCUSSION 
The findings in this study provide mechanistic insight into the negative 
regulation of B lymphopoiesis by adipocytes. We have found that adipocytes 
produce soluble factors that promote the accumulation of MDSCs (Figure 4.1). 
As described for the first time, these MDSCs have the ability to potently inhibit B 
lymphopoiesis. B cell development does not appear to be directly blocked by 
MDSCs, instead MDSC-derived IL-1 acts at the MPP stage in development 
driving myelopoiesis at the expense of B lymphopoiesis. 
 Our characterization of rabbit BM suggests the above mechanism could 
contribute to the loss of B lymphopoiesis that occurs at two to four months of 
age. These findings also lead us to propose the rabbit as an accelerated model 
to study changes in the BM that result in the decline of B lymphopoiesis occurring 
in mid to late life in humans and mice. We propose that our observations can be 
applied to situations that result in adipocyte accumulation in the BM, such as 
aging and obesity (Adler et al., 2014, Chinn et al., 2012, Justesen et al., 2001, 
Lecka-Czernik et al., 2010, Luo et al., 2015, Rosen et al., 2009, Tuljapurkar et 
al., 2011), and will provide the basis for therapeutics aimed at boosting B 
lymphopoiesis in these scenarios. 
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Figure 4.1 Model of Adipocyte-mediated inhibition of B lymphopoiesis. 
Hematopoiesis in healthy BM is characterized by a balance of lymphoid and 
myeloid cell production. This balance is lost with an increased number of 
adipocytes in the BM. Adipocytes secrete inflammasome activators leading to the 
accumulation of MDSCs. Adipocyte factor induced-MDSCs produce IL-1, which 
acts at the MPP stage to promote myelopoiesis resulting in the loss of B 
lymphopoiesis. Adapted from Kennedy and Knight, 2015. 
 
The bone marrow microenvironment and the arrest of rabbit B 
lymphopoiesis 
The decline of B lymphopoiesis in aging mice has been attributed to both 
intrinsic changes in hematopoietic progenitors and extrinsic changes to the BM 
microenvironment (reviewed in chapter I). Our study suggests that the arrest of B 
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lymphopoiesis in rabbits is primarily mediated through extrinsic changes to the 
BM microenvironment. Through analysis of BM sections from rabbits of various 
age, we found that adipocytes accumulate by 3 months of age (Figure 3.17). 
While it was known that adult rabbits contain significant amounts of BM 
adipocytes (Bigelow and Tavassoli, 1984), B lymphopoiesis is lost before 
adulthood. Our observation is the first to suggest that the accumulation of BM 
adipocytes occurs in the same time frame that B lymphopoiesis arrests in rabbits 
(by two to four months of age) (Jasper et al., 2003); suggesting adipocyte factors 
could negatively regulate B lymphopoiesis. 
Isolation of BM fat from >2 month old rabbits and the observation that BM 
fat-CM inhibits B lymphopoiesis in rabbit B lymphopoiesis assays (Figure 3.20) 
further implicates that the microenvironment negatively regulates B 
lymphopoiesis in >2 month old rabbits. In fact, adipocyte layers are not found in 
the BM of <2 month old rabbits (Figure 3.20 A), suggesting the inhibitory 
component of the microenvironment is only found in older rabbits. Additionally, 
hematopoietic progenitors from >2 month old rabbits robustly differentiate into B 
lineage cells in BM cultures, suggesting they are normal. Complementary to our 
findings, Kalis et al. performed an adoptive transfer study in rabbits to understand 
if intrinsic or extrinsic mechanisms regulate the loss of B lymphopoiesis. BM from 
>2 month old GFP+ rabbits was transferred into young irradiated recipients, and 
then the generation of B lineage cells from GFP+ BM was assessed. Consistent 
with our results, GFP+ hematopoietic cells from the BM of older rabbits were able 
to differentiate into B lineage cells after transfer into young recipients (Kalis et al., 
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2007), suggesting that BM progenitors from >2 month old rabbits retain the 
potential to differentiate to the B lineage. These data lead us to conclude that B 
cell development is inhibited by the BM microenvironment of >2 month old 
rabbits. 
We described a mechanism in which adipocytes produce negative 
regulators to inhibit B lymphopoiesis. But the accumulation of BM adipocytes can 
lead to decreased B cell development via other means as well. In addition to 
producing negative regulators, the accumulation of adipocytes in the BM of 
humans, mice, and rabbits during aging and obesity could impair B 
lymphopoiesis by disrupting the normal supportive capacity of the 
microenvironment. For example, MSCs from rabbit BM were found to have a 
decreased propensity to differentiate into osteoblasts (actively support B cell 
development) and increased ability to differentiate into adipocytes (actively inhibit 
B cell development) starting at two months of age (Bilwani and Knight, 2012). 
While we showed the increase in adipocytes adds negative regulators to the BM 
environment, the loss of osteoblasts alone would result in decreased support for 
B cell development. Further evidence for this notion comes from a study of mice 
fed a high fat diet. These mice exhibited increased BM adipocytes and reduced B 
cell development (Adler et al., 2014). Molecules produced by adipocytes were 
not addressed in this study, but the authors suggested that an increased number 
adipocytes in the BM physically disrupted the normal supportive niche. While the 
loss of supportive cells in the BM microenvironment contributes to the loss of B 
cell development, this dissertation focused on adipocyte-derived negative 
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regulators that actively inhibit B cell development, as adipocytes have only 
recently been appreciated for their ability to modulate the immune system. 
Adipocytes and the accumulation of inhibitory myeloid-derived suppressor 
cells  
Through mouse BM cultures, we found that adipocytes produce a 
combination of molecules that induce MDSC generation. MDSCs are a 
population of immature myeloid cells identified by the markers CD11b and Gr1, 
and commonly found to accumulate in cancers (Gabrilovich and Nagaraj, 2009). 
Most studies of MDSCs highlight their well-known ability to suppress T cell 
responses (Gabrilovich and Nagaraj, 2009, Talmadge and Gabrilovich, 2013). 
Important for this suppression, MDSCs co-express the effector molecules 
arginase and iNos. Expression of these enzymes can be used to differentiate 
MDSCs from mature inflammatory M1 macrophages and anti-inflammatory M2 
macrophages, as M1 macrophages only express iNos and M2 macrophages only 
express arginase (Gabrilovich and Nagaraj, 2009).  
MDSCs come in two varieties; monocytic MDSCs (CD11b+Ly6C+y6G-) 
and granulocytic (CD11b+Ly6Cloy6G+) MDSCs (Gabrilovich and Nagaraj, 2009, 
Youn et al., 2008). By flow cytometric and microscopy analysis we found that 
adipocyte factors primarily promote the accumulation of monocytic MDSCs 
(Figure 3.5). 
The majority of MDSC studies focus on MDSCs in the context of T cell 
responses. While a few studies of MDSCs interacting with other cell types exist 
(Green et al., 2013, Green et al., 2015, O'Connor et al., 2015, Zhu et al., 2012), a 
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thorough understanding of these interactions is lacking. Therefore our finding that 
MDSCs inhibit B lymphopoiesis is novel (Figure 3.6). Even more interesting is the 
mechanism by which they inhibit B cell development. ACM-generated MDSCs 
co-express large levels of arginase and iNos (Figure 3.4) and, similarly to classic 
MDSCs, utilize these enzymes to suppress CD4+ and CD8+ T cell proliferation 
(Figure 3.7 B&C). Arginase and iNos use L-arginine as a substrate, and as T 
cells need L-arginine to proliferate, depletion of this amino acid is one way in 
which MDSCs suppress through these enzymes (Gabrilovich and Nagaraj, 
2009). Further, over expression of arginase in transgenic mice resulted in 
arginine deficiency and impaired B cell development (de Jonge et al., 2002). 
Together these data suggest that MDSCs could inhibit B cell development 
through arginase and iNos. However we found that ACM-generated MDSCs do 
not inhibit B lineage development via these enzymes (Figure 3.7A). 
MDSCs and the production of IL-1. MDSCs inhibited B lymphopoiesis 
not by arginase or iNos, but by producing IL-1 (Figure 3.10). This finding 
suggests that adipocytes induce inhibitory MDSCs with an inflammatory profile, 
which was confirmed through cytokine array analysis of MDSC-CM (Figure 3.9). 
IL-1 is a potent inflammatory molecule that was previously described to inhibit B 
lymphopoiesis (Dorshkind, 1988a, Hirayama et al., 1994), although the 
hematopoietic target was unknown until now. In BM cultures we found that IL-1 
treatment promoted myelopoiesis, whereas B lymphopoiesis was lost in cultures 
starting with HSCs and MPPs. In contrast, B cell development in cultures seeded 
with CLPs appeared to be unaffected by IL-1 treatment. Because IL-1 treated 
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HSC and MPP cultures exhibited this effect, IL-1 treatment likely acts on the 
MPP to promote myeloid development. IL-1 has been shown to expand HSCs 
(Ueda et al., 2009), but it is unknown if differentiation potential is affected before 
the MPP stage. In addition to modulating expansion/differentiation of HSCs and 
MPPs, IL-1 has been reported to act on additional cells in the BM 
microenvironment. IL-1 promotes myelopoiesis in myeloid progenitors 
(Nagareddy et al., 2014), as well as alters the secretion profile of BM stromal 
cells. IL-1 induces BM stromal cells to produce GM-CSF, G-CSF, and M-CSF 
which further inhibit B lymphopoiesis and amplify myelopoiesis (Billips et al., 
1990, Dorshkind, 1988a, Dorshkind, 1988b, Ueda et al., 2009). We conclude that 
IL-1 is a master regulator of inflammation with multiple targets in the BM, and as 
supported by a simple in vivo injection of IL-1 into mice (Ueda et al., 2004), this 
molecule specializes the BM for myeloid development. 
Rabbit bone marrow: An accelerated model of bone marrow aging. 
Consistent with the above studies and our finding that adipocyte factors promote 
IL-1 production, rabbit BM also exhibits increased expression of IL-1 in >2 month 
old rabbits (Figure 3.19). This timing correlates with an accumulation of BM 
adipocytes (Figure 3.17), the arrest of B lymphopoiesis (Jasper et al., 2003), and 
an increased BM myeloid compartment that appears to be the source of IL-1 
expression (Figure 3.19).  
The characterization of rabbit BM starting at two months of age appears to 
share multiple characteristics with BM from aged (2 years old) mice. Consistent 
with our observations of BM from >2 month old rabbits, 2 year old mice have 
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increased BM fat (Krings et al., 2012), declining B lymphopoiesis (Kirman et al., 
1998, Miller and Allman, 2003, Riley et al., 1991, Sherwood et al., 1998, Stephan 
et al., 1996), and an expanded myeloid compartment (Enioutina et al., 2011). We 
conclude that the rabbit is an accelerated model to study how changes in the BM 
microenvironment affect hematopoiesis, as occurs in aged mice and presumably 
elderly humans. In fact, the accumulation of BM fat in rabbits appears to mimic 
that of elderly humans, where 40-50% of the proximal femur and 70% of the tibia 
fill with adipose tissue (Li et al., 2013); further suggesting that rabbits are a good 
model to understand these changes that occur later in life for humans and mice. 
The mechanisms contributing to the arrest of B lymphopoiesis in rabbits 
appear to be in contrast to intrinsic defects in hematopoietic progenitors, which 
have been found, in part, to contribute to the decline of B lymphopoiesis in mice 
(Rossi et al., 2005, Stephan et al., 1997, Sudo et al., 2000). Because the arrest 
of rabbit B cell development is primarily due to changes in the BM 
microenvironment (Figure 3.20 and Kalis et al., 2007), we suggest that the rabbit 
is a great model to study the extrinsic regulation of B lymphopoiesis in the 
absence of hematopoietic progenitor defects, which could confound results. 
Our characterization of rabbit BM at the time when B lymphopoiesis is lost 
(increased adipocytes, increased myeloid compartment, increased IL-1β 
expression), implies that the mechanism of adipocyte-mediated inhibition of B 
lymphopoiesis (elucidated in mouse BM cultures) could be occurring in rabbits by 
two months of age. Similar to our studies of ACM and inhibitory MDSCs, we 
found that rabbit BM fat-CM (contains factors from both adipocytes and myeloid 
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cells) inhibits B cell development and promotes myelopoiesis in rabbit BM 
cultures (Figure 3.20). Further, we identified an inhibitory myeloid population in 
rabbit BM (Figure 3.21), that we suggest contains rabbit MDSCs. Additional 
studies and reagents will be needed to confirm these observations in vivo and to 
further characterize rabbit BM subpopulations. 
Bone marrow suppressor cells and declining B cell development  
BM stromal cells are commonly referred to as major component of the BM 
microenvironment. Therefore changes to BM stromal cells are usually attributed 
to changes in hematopoiesis (eg. decreased osteoblasts and increased 
adipocytes). While BM stromal cells are important to the regulation of B 
lymphopoiesis, our work highlights the contribution of additional cell types in the 
BM microenvironment. 
Our work has implicated MDSCs in the inhibition of B lymphopoiesis. We 
expect in scenarios where MDSCs are present in the BM, B lymphopoiesis will 
be negatively regulated. Interestingly, Enioutina et al. found that MDSCs are 
increased in the BM of 22 month old mice (Enioutina et al., 2011), the time when 
B lymphopoiesis is impaired (Kirman et al., 1998, Miller and Allman, 2003, Riley 
et al., 1991, Sherwood et al., 1998, Stephan et al., 1996), and increased fat is 
observed in the BM (Krings et al., 2012). MDSCs from the BM of aged mice were 
found to have increased suppressive activity in T cell proliferation assays and 
respond to inflammatory stimuli more robustly, compared to CD11b+Gr1+ myeloid 
cells isolated from young BM (Enioutina et al., 2011). We suggest it is possible 
that inflammatory molecules derived from BM fat (which is increased and has 
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different properties in aged BM) (Krings et al., 2012) during aging could influence 
these MDSCs to produce pro-inflammatory molecules that inhibit B cell 
development. 
It is unknown whether MDSCs isolated from the BM of aged mice inhibit B 
lymphopoiesis, but the identification of an inhibitory myeloid population in the BM 
of >2 month old rabbits (Figure 3.21) suggests it is possible. The idea that 
MDSCs inhibit B lymphopoiesis is novel, and it is very interesting to think of how 
this finding fits into the field as a whole. In fact our work is complemented very 
well by a series of studies by Soderberg and colleagues, who identified two types 
of suppressor cells in rabbit BM in the 1980’s.  
One of the suppressor cells identified in rabbit BM was described as 
having adherent properties and macrophage-like morphology (Soderberg, 
1984a). These cells appear similar to the mouse monocytic MDSCs identified 
after ACM treatment (Figure 3.5), and could be the suppressive population we 
found to be contained within the rabbit CD11b+ BM fraction (Figure 3.21); as 
CD11b is a common marker for macrophages. 
Soderberg defined rabbit BM macrophage-like cells as suppressors based 
on the ability to suppress BM responses to immune complex stimulation 
(Soderberg, 1984a). While the target of this suppression is unknown, immune 
complex stimulation has been reported to act on B lineage cells (Morgan and 
Weigle, 1983). Additional studies and reagents will be needed to further 
characterize the myeloid lineage suppressor cells identified by both Soderberg 
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and our study, to determine the exact mechanism(s) of suppression (target cells 
and effector molecules). 
The other suppressor cell identified in rabbit BM was described as non-
adherent, FcRγ+, and complement receptor negative (Soderberg, 1984a, 
Soderberg, 1984b). These cells exhibited the ability to suppress baseline 
proliferation of BM cells and could suppress T cell responses (Soderberg, 1985). 
The mechanism in which they suppress T cells is through blockade of IL-2 (Maes 
et al., 1988). Alternatively, the mechanism by which these cells suppress BM cell 
proliferation is unknown. The authors suggest these are likely suppressor 
lymphocytes of the B, T, or NK lineage, ruling them out as potential MDSCs. 
Future studies are needed to determine the exact lineage of non-adherent 
FcRγ+ BM suppressor cells. If they are of the B lineage, these could be IL-10-
producing Bregs (Tedder, 2015) or possibly inflammatory TNF-producing aged B 
cells (ABCs) (Ratliff et al., 2013). In aged mice, ABCs were found to inhibit B cell 
development through the production of TNF (Ratliff et al., 2013), a potent 
inflammatory molecule known to synergize with IL-1 to induce granulopoiesis 
(Ueda et al., 2004). In addition to adipocyte factors, it is possible that TNF 
producing ABCs also promote IL-1 producing MDSCs in aged BM, as TNF is 
known to promote MDSC accumulation (Zhao et al., 2012). Overall, our study in 
combination with the referenced studies, highlight the importance of 
hematopoietic lineage suppressor populations in the regulation of the BM state. 
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Inflammation and the regulation of lymphopoiesis   
The BM as a source of inflammatory factors. The presence of systemic 
inflammatory factors, such as IL-6, TNFα, and IL-1, is a hallmark of aging and 
obesity (Baylis et al., 2013, Jung and Choi, 2014, Vasto et al., 2007). For 
example, a study examining obese mice identified visceral adipose tissue as a 
source of IL-1 and proposed that IL-1 can travel systemically to promote 
myelopoiesis in the BM (Nagareddy et al., 2014). In addition to the increase in 
systemic inflammatory factors, our study leads us to propose that the BM 
microenvironment could become a local source of IL-6, TNFα, and IL-1, which 
inhibit B lymphopoiesis (Figure 3.10, Dorshkind, 1988a, Hirayama et al., 1994, 
Maeda et al., 2005, Maeda et al., 2009, Ratliff et al., 2013, Ueda et al., 2004). 
This idea is supported by studies that suggest inflammatory cells accumulate in 
the BM during aging and obesity. In fact, adipocytes accumulate in the BM during 
aging and obesity (Adler et al., 2014, Krings et al., 2012), and can act as a 
source of IL-6 (Figure 3.15 and Fried et al., 1998, Van Snick, 1990). TNF 
producing ABCs also increase in the BM during aging (Ratliff et al., 2013), as do 
MDSCs (Enioutina et al., 2011), which we suggest could be a source of IL-1 in 
fatty BM. Overall, we propose that the presence of these cells make the BM 
microenvironment a local source of inflammatory factors that alter hematopoiesis, 
as well as a source of factors that potentially contribute to the increased systemic 
inflammation seen in aging and obesity. 
The effect of inflammasome activation on lymphopoiesis. A major 
pathway shown to contribute to the inflammation observed in aging and obesity is 
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through inflammasome activation (Vandanmagsar et al., 2011, Youm et al., 
2013). The NLRP3 inflammasome, for example, is critical for integrating danger 
signals that accumulate during aging and obesity, and for triggering active IL-1 
production by myeloid lineage cells. Since adipocyte-derived molecules induce 
IL-1 producing myeloid cells (Figure 3.9), it is logical that inflammasome 
activation is involved in the adipocyte-mediated induction of MDSCs and the loss 
of B lymphopoiesis. In fact, blocking the NLRP3 inflammasome with 
glybenclamide prevented MDSC accumulation, and effectively boosted B 
lymphopoiesis (Figure 3.16). These data suggest that targeting the 
inflammasome pathway, instead of individual molecules produced by adipocytes, 
could be an effective means to enhance the production of naïve B cells. 
One limitation of the above finding is that this experiment was only 
performed in vitro. Additional studies will be needed to determine the 
effectiveness of blocking the NLRP3 inflammasome in vivo. However, a study of 
T lymphopoiesis and aging found that blocking the NLRP3 inflammasome in vivo 
prevented thymic atrophy and the decline of T lymphopoiesis (Youm et al., 2012). 
Similar to our findings, the authors suggested that adipocyte-derived 
inflammasome activators initiated the decline of T lymphopoiesis, and could be 
prevented through blockade to the NLRP3 inflammasome. These data, in 
combination with our study, implicate NLRP3 inflammasome activation in the 
negative regulation of both B and T lymphopoiesis.  
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S100A9 and the amplification of inflammation  
Characterization of BM from >2 month old rabbits allowed us to identify a 
previously unrecognized negative regulator of B lymphopoiesis. We found that 
S100A9+ myeloid cells increase in the BM of >2 month old rabbits (Figure 3.22), 
which is consistent with studies that found increased expression of S100A8 and 
S100A9 during aging and obesity (Sekimoto et al., 2012, Swindell et al., 2013). 
While the expression of these inflammatory proteins increase in many tissues 
with age (Sekimoto et al., 2012), it was unknown whether S100A8 and S100A9 
also increase in the BM. Interestingly, we found that S100A9 increases in the BM 
of >2 month old rabbits, correlating with increased BM fat and the loss of B cell 
development.  
We identified that S100A9 expression increases in the BM of >2 month old 
rabbits by analyzing the SVF BM pellet containing BM cells separated from the 
adipocyte layer. As S100A8 and S100A9 are known to be expressed by adipose 
tissue, one possibility why we did not find increased expression of S100A8 could 
be because we did not assay mature adipocytes. Consistent with this idea, a 
recent study found while S100A8 and S100A9 are expressed in adipose tissue, 
S100A8 expression was primarily from adipocytes and S100A9 expression came 
from the SVF pellet (containing myeloid cells) (Sekimoto et al., 2012). In fact, we 
suggest S100A8 does contribute to the adipocyte-induced inhibition of B 
lymphopoiesis, as S100A8 is expressed by 3T3.L1 adipocytes (Hiuge-Shimizu et 
al., 2011, Sekimoto et al., 2012), which we used as a source of ACM. Further, 
S100A8 has been implicated in NLRP3 inflammasome activation (Simard et al., 
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2013) and MDSC induction (Sinha et al., 2008). Future studies will be needed to 
confirm the contribution of S100A8 to adipocyte-mediated inhibition of B 
lymphopoiesis.  
The ability of S100A9 to inhibit B lymphopoiesis (Figure 3.23) further 
supports the idea that inflammatory factors negatively regulate B cell 
development. It was very interesting to us that S100A9 did not act on HSCs or 
MPPs like IL-1 (Figure 3.24), but instead induced the expression of IL-6, TNF, 
and IL-1β in BM myeloid progenitors (Figure 3.25). One interpretation of these 
data is that S100A9 acts to amplify inflammation, a known role of S100A9 in 
inflammatory processes (Cesaro et al., 2012). In fact one study found that while 
S100A9 monomers are relatively unstable, stimulation of cells with the 
inflammatory factors IL-1β and TNFα resulted in the formation of S100A9 
homodimers that were incredibly stable and resistant to proteolytic digestion 
(Riva et al., 2013). In combination with our findings, these data suggest S100A9 
inhibits B lymphopoiesis indirectly acting through BM myeloid cells to amplify the 
production of inflammatory factors that in turn inhibit B cell development. 
Therapeutic strategies to boost B lymphopoiesis during aging and obesity 
Our study has uncovered multiple targets for intervention to enhance B 
lymphopoiesis in scenarios with fatty BM. The mechanism we identified can be 
targeted at the level of the adipocyte, the MDSC, or at the downstream effector 
molecules. Below are potential strategies that can be used individually, or in 
combination, to target each step in the mechanism of adipocyte-mediated 
inhibition of B cell development. 
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Targeting the adipocyte 
Calorie restriction. Adipocytes induce the mechanism of inhibition 
described in this dissertation, and we suggest targeting adipocytes has the 
potential to prevent all downstream events leading to inhibition. One mechanism 
to target the adipocyte is through diet and exercise. 
Calorie restriction was shown to be beneficial in the prevention of thymic 
atrophy and the decline of T cell development. Calorie restriction delayed thymic 
decline, while obesity accelerated this decline (Yang et al., 2009a, Yang et al., 
2009b). Additionally, one study found that high fat diet resulted in increased 
adipocytes in the BM and reduced B cell development (Adler et al., 2014), 
implying that calorie restriction might be beneficial to boost B lymphopoiesis. 
Alternatively, calorie restriction appears to regulate the thymus and BM 
marrow differently. Several studies in humans and mice found that calorie 
restriction actually increased BM fat (Bredella et al., 2009, Cawthorn et al., 2014, 
Devlin et al., 2010). Further, Cawthorn et al. found that during calorie restriction 
BM adipose tissue expands and becomes the primary systemic source of 
adiponectin (Cawthorn et al., 2014), a factor known to inhibit B cell development  
(Yokota et al., 2003).  Although adiponectin is an anti-inflammatory molecule 
which might offset the negative regulation of B lymphopoiesis through 
inflammatory factors, it is unknown if calorie restriction will restore B 
lymphopoiesis in the presence of adiponectin. 
Exercise. While calorie restriction increases BM fat, exercise was found to 
reduce BM adipose tissue volume. In fact, Styner et al. found this to be true in 
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healthy as well as obese mice (Styner et al., 2014). The BM adipose tissue 
reducing effects of exercise are probably due to mechanical stimulus. For 
example in rabbits, Bilwani and Knight found that older rabbit MSCs were more 
prone to differentiate into adipocytes (inhibit B cell development) instead of 
osteoblasts (support B cell development) (Bilwani and Knight, 2012). Exercise 
could reverse this effect as a study in mice found that in vivo mechanical 
stimulation of MSCs promoted MSC differentiation into osteoblasts instead of 
adipocytes (Rubin et al., 2007). Consistent with this observation mechanical 
stimulation of MSCs was found to decrease PPAR-γ signaling, which is critical for 
adipocyte differentiation (Case et al., 2013). Mechanical stimulus also negatively 
regulates adipocyte differentiation by increasing β-catenin levels (Case et al., 
2010, Sen et al., 2008). Because β-catenin levels are induced downstream of 
WNT receptors and MSCs from older rabbits have decreased expression of 
frizzled 4 (WNT receptor), exercise could be beneficial to prevent/reduce 
adipocyte accumulation in rabbit BM. 
Diet and exercise. Diet and exercise in combination could be very 
beneficial to enhance B cell development. The studies above suggest that anti-
inflammatory conditioning of BM adipose tissue through calorie restriction will 
reduce the inflammatory state of the BM, in effect removing inhibitory molecules. 
In addition, exercise appears to be beneficial in regulating the volume of marrow 
adipose tissue and promoting osteoblast generation. This would provide more 
space for hematopoiesis and potentially keep adiponectin levels at a manageable 
level for B lymphopoiesis to occur. 
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Targeting myeloid-derived suppressor cells 
Since MDSCs have been identified as a therapeutic target in many 
cancers, there are a plethora of strategies available to target these cells. Current 
strategies act to deplete MDSCs, block MDSC development, inactivate MDSC 
effector mechanisms, and induce differentiation of MDSCs into mature myeloid 
cells that lack suppressive activity (Wesolowski et al., 2013). 
Deplete MDSCs. Gemcitabine is one cytotoxic agent used to deplete 
MDSCs in lung and mammary cancers (Suzuki et al., 2005). This drug has also 
been used in combination with an anti-IL-6R neutralizing antibody to block the 
accumulation of MDSCs (Sumida et al., 2012). Other drugs that are toxic to 
MDSCs include 5-fluorouracil and Docetaxel (Kodumudi et al., 2010, Talmadge 
and Gabrilovich, 2013, Vincent et al., 2010, Wesolowski et al., 2013). One study 
using 5-fluorouracil to deplete MDSCs in mice with thymoma found that 5-
fluorouracil did not affect most other immune cell lineages. However 5-
fluorouracil treatment did result in an increased number of B cells (Vincent et al., 
2010), which the authors suggest is to compensate for the loss of MDSCs. 
Overall, these drugs are an effective means to deplete MDSCs, although it will be 
important to verify their safety at doses used to target cells in the BM. 
Block MDSC development. Several strategies to block MDSC 
development target signaling pathways responsible for MDSC formation. For 
example MDSCs require STAT3 activation for development and survival, 
therefore inhibiting this pathway will result in fewer MDSCs (Sansone and 
Bromberg, 2012, Wesolowski et al., 2013). In fact, a small molecule has been 
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developed to target STAT3 phosphorylation (Lin et al., 2010) and could be used 
to target MDSCs. 
Inactivate MDSC effector mechanisms. We found that MDSCs inhibit B 
lymphopoiesis and suppress T cell responses via different mechanisms. While 
there are many strategies to block MDSC-mediated suppression of T cell 
responses, such as blocking arginase and iNos, the treatments developed to 
target these mechanisms cannot be used to block the inhibition of B 
lymphopoiesis. Targeting MDSC effector mechanisms in the context of B 
lymphopoiesis will be discussed in the next section. 
Promote MDSC differentiation into non-suppressive myeloid cells. 
MDSCs are a population of immature myeloid cells, and it is now understood that 
inducing differentiation into mature myeloid cells is an effective strategy to target 
MDSCs in the context of cancer. One such agent capable of doing this is the 
vitamin A metabolite all-trans-retinoic acid (ATRA). ATRA treatment of mice was 
found to induce MDSC maturation into macrophages, granulocytes, and dendritic 
cells (Kusmartsev et al., 2003). Overall, ATRA treatment reduced the number of 
MDSCs in several tumor models (through inducing maturation), increased anti-
tumor immune responses, and improved the effect of 2 different anti-tumor 
vaccines. Another study found ATRA treatment of MDSCs isolated from cancer 
patients induced differentiation in these cells (Kusmartsev et al., 2008), 
implicating this as an effective strategy to use in humans. In addition to ATRA, 
other agents that can be used to induce differentiation include vitamin A, vitamin 
D, and CpG (TLR9 agonist) (Wesolowski et al., 2013). These are effective 
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treatments to reduce MDSC numbers in cancers, however the molecule used to 
enhance B lymphopoiesis must be chosen carefully. For example, while CpG can 
induce the maturation of MDSCs to less suppressive myeloid cells, CpG 
recognition by TLR9 was also found to induce CLPs to differentiate into dendritic 
cells (Welner et al., 2008). Therefore adaptation of this and other strategies for 
the modulation of hematopoiesis will require additional studies to identify any 
undesirable outcomes. 
Targeting adipocyte and/or MDSC effector molecules 
IL-1. Adipocyte-induced MDSCs inhibit B lymphopoiesis through the 
production of IL-1. One strategy to boost B lymphopoiesis is to target IL-1. This is 
possible with the drug anakinra, which is an IL-1R antagonist commonly used to 
treat rheumatoid arthritis (Kavanaugh, 2006). Anakinra may prove useful in 
preventing the effects of IL-1, but perhaps is not the best strategy because this is 
the most downstream target identified for adipocyte-mediated inhibition of B 
lymphopoiesis. One of the most promising therapeutic strategies we identified will 
be targeting adipocyte products. 
Preventing inflammasome activation. Our results suggest that 
preventing NLRP3 inflammasome activation to promote B lymphopoiesis could 
be very effective. Glybenclamide treatment (NLRP3 inflammasome inhibitor) of 
BM cultures containing adipocyte factors prevented MDSC accumulation and 
enhanced B lymphopoiesis. Blocking the inflammasome acts at the level of 
adipocyte products preventing downstream events to improve B cell development 
(removing MDSCs and IL-1 from the equation). Preventing NLRP3 activation in 
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aged mice was shown to block the atrophy of the thymus, improving T 
lymphopoiesis (Youm et al., 2012). If targeting the inflammasome is also found to 
be beneficial for B lymphopoiesis in vivo, modulating NLRP3 inflammasome 
activation could be a powerful treatment to improve general lymphopoiesis. In 
fact, aged NLRP3-/- mice have a significant increase in MPPs compared to aged 
WT mice (Youm et al., 2012), which might provide a larger progenitor pool for 
lymphocyte development. Additional studies will be needed to address this 
question. 
Statins, inflammasome activation, and B lymphopoiesis 
Prior to the current study, our laboratory attempted to prevent/restore 
rabbit B lymphopoiesis using lovastatin. Statins are widely prescribed for their 
LDL-cholesterol lowering effects, which are mediated through inhibiting the 
enzyme hydroxymethylglutaryl-CoA reductase. The logic for using lovastatin to 
enhance B lymphopoiesis in rabbits came from studies that showed statins also 
inhibit adipocyte differentiation (Nakata et al., 2006, Nicholson et al., 2007), and 
therefore was used as a strategy to target the accumulation of adipocytes in 
rabbit BM. While preliminary results using lovastatin treatment were promising, 
the overall ability to enhance B lymphopoiesis was limited. This dissertation 
provides new insight into why the effect on B lymphopoiesis was limited and a 
potential strategy to improve B cell development using lovastatin. 
In addition to the functions of statins described above, statins were found 
to activate the NLRP3 inflammasome in macrophages leading to IL-1β 
production (Henriksbo et al., 2014, Mandey et al., 2006). This mechanism 
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appears to contribute to an increased incidence of type II diabetes seen in 
patients using statins (Culver et al., 2012, Henriksbo et al., 2014, Ridker et al., 
2012). In fact, inflammasome activated myeloid cells are found in patients with 
type II diabetes (Lee et al., 2013). Similar to using NLRP3-/- mice, Henricksbo et 
al. found that statin induced insulin resistance and induction of IL-1β secretion by 
macrophages could be blocked by preventing NLRP3 inflammasome activation 
with glybenclamide treatment (inflammasome inhibitor) (Henriksbo et al., 2014). 
These authors suggested that glybenclamide treatment (and other NLRP3 
inflammasome inhibitors) in combination with statins will prevent insulin 
resistance due to statin use. In light of our findings, a combination therapy using 
statins to prevent adipocyte accumulation and NLRP3 inflammasome inhibitors to 
prevent statin-induced IL-1β production could be a promising strategy to enhance 
B lymphopoiesis. 
The rabbit as a model system and remaining questions 
We envision that the insights gained from this dissertation will be relevant 
to many situations resulting in fatty BM, such as aging and obesity. As discussed 
previously, characterization of rabbit hematopoiesis in our study and by others 
suggests the rabbit is an accelerated model of aging hematopoiesis. The 
phenotypes observed correlate with an increase in BM adipose tissue occurring 
by two to four months of age, which is consistent with the accumulation seen in 
elderly humans (Li et al., 2013). While the rabbit model is valuable to gain an 
understanding of the processes that occur in aged BM, can the rabbit also be 
used to model other BM situations? 
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The rabbit as a model of bone marrow failure 
Could rabbits be used as a model for other BM pathologies, such as BM 
failure? Additional studies will be needed to assess the plausibility of this notion, 
but available evidence suggests there are some similarities between the BM of 
>2 month old rabbits and the BM of patients undergoing BM failure. Aplastic 
anemia and myelodysplastic syndrome (MDS) are both forms of BM failure 
leading to cytopenias in one or more hematopoietic lineages; including defective 
production of B lineage cells (Ogata et al., 2006, Ribeiro et al., 2006, Sandes et 
al., 2012). While ultimately different, the similarities between these diseases 
often make aplastic anemia and MDS hard to distinguish in some patients. In 
aplastic anemia, the BM fills with fat (Takaku et al., 2010). Originally it was 
thought that fat fills the empty BM space, but it has now been posed that 
adipocytes could cause or contribute to the disease (Islam, 1988, Young, 2013). 
Certainly this is similar to the process that occurs naturally by two to four months 
in rabbits. Rabbits shut down the production of new B lymphocytes at this time, 
but it is unknown if the underlying mechanism could be considered a form of 
preprogramed BM failure. 
MDS also results in altered hematopoiesis that can progress into 
leukemia, and sometimes exhibits infiltration of BM fat similar to that seen in 
aplastic anemia (Rovo et al., 2013). Defective hematopoiesis in MDS is often 
characterized by a large number of hematopoietic progenitors undergoing 
apoptosis (Gersuk et al., 1998, Raza et al., 1995). The BM in these patients is 
influenced by inflammatory factors such as IL-1β, TNFα, and Fas-ligand (Gersuk 
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et al., 1998, Shetty et al., 1996), which can contribute to apoptosis seen in the 
BM (Hirai, 2003). This is consistent with increased IL-1β expression in BM from 
>2 month old rabbits and the increases of inflammatory factors seen during 
aging.  
How changes in BM MSCs influence the development of MDS is not fully 
understood. Several studies suggest MSCs from patients with MDS have 
chromosomal abnormalities (Blau et al., 2007, Flores-Figueroa et al., 2005). 
Additionally, Borojevic et al. found that plating cord blood hematopoietic 
progenitors on BM stromal cells from MDS patients resulted in altered 
hematopoiesis, and suggest the BM stroma in MDS might promote the disease 
(Borojevic et al., 2004). Further, Raajimakers et al. found that genetic deletion of 
Dicer1 or Sbds (mutated in Schwachman-Bodian-Diamond syndrome) in mouse 
osteoprogenitors resulted in a BM phenotype resembling MDS. Additional studies 
will be needed to assess whether the changes that occur to MSCs in MDS are 
similar to the changes occurring in MSCs by two months of age in rabbit BM. 
While there are similarities between BM failure and the changes occurring 
in rabbit BM, it may be too early to tell if the rabbit is a good model to study BM 
failure. Aplastic anemia and MDS both contain a known autoimmune component 
that contributes to BM failure (Barrett and Sloand, 2009), which is not known to 
occur in rabbit BM. In terms of hematopoietic progenitors, there is a wealth of 
information suggesting that genetic defects in hematopoietic progenitors 
contribute to MDS (Hirai, 2003). Our data in rabbits (Figure 3.20 and Kalis et al., 
2007), suggest the loss of B lymphopoiesis is mediated by changes in the 
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microenvironment as opposed to hematopoietic progenitor defects. Additional 
differences between available information on rabbit hematopoiesis and BM 
failure include; 1. MDS can progress into leukemia, but we rarely find leukemia 
develop in our rabbit colony; 2. Rabbits continue to live for years after the arrest 
of B lymphopoiesis that occurs at two months of age, while BM failure usually 
results in death if untreated; and 3. Although B cell development is lost in rabbits, 
decreases in peripheral white blood cell numbers are not known to occur. 
Overall, while the rabbit might serve as a good model to assess how changes in 
the BM microenvironment impact hematopoiesis, rabbit BM does not exhibit 
other common features of BM failure. Most notably, even in the absence of B 
lymphopoiesis the rabbit immune system remains intact.  
Maintaining adaptive immunity in the absence of B lymphopoiesis 
B lymphopoiesis shuts down early in the life of rabbits, generating a very 
perplexing question. How do rabbits remain immune competent? In fact, the 
arrest of B lymphopoiesis does not prevent rabbits from responding to new 
antigens. Adult rabbits are commonly used to generate polyclonal antibodies to 
various antigens. Additionally, rabbit monoclonal antibody technology, a powerful 
tool developed by Knight and colleagues uses adult rabbits to generate highly 
specific monoclonal antibodies (Spieker-Polet et al., 1995). This suggests the 
rabbit must have a mechanism to maintain the ability to respond to a diverse 
array of antigens in the absence of B lymphopoiesis. One possible explanation is 
that rabbit GALT maintains antibody diversity throughout the life of rabbits. As 
described in Figure 1.4, B cells made in the BM traffic to rabbit GALT and 
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undergo further maturation. It is possible that unknown mechanisms in GALT 
support the maintenance of B lineage cells. Alternatively, perhaps rabbit B 
lineage cells can self-renew. One study found that rabbit B cells express the 
molecule CD5 (Raman and Knight, 1992), a molecule used to identify B1a cells 
in mice. Although it is unknown if rabbit B cells can self-renew, mouse B1a cells 
are maintained throughout life by self-renewal (Forster and Rajewsky, 1987, 
Hayakawa et al., 1985, Hayakawa et al., 1986, Herzenberg et al., 1986, 
Herzenberg and Kantor, 1993). Future studies will be needed to understand how 
B cells are maintained, as this may alleviate the demand for B lymphopoiesis in 
the BM and contribute to the arrest of new B lymphocyte production. 
Understanding changes in MSCs before and after two months of age 
Bilwani and Knight found that there are fewer MSCs present in the BM of 
>2 month old rabbits (the time when B lymphopoiesis arrests), and that the MSCs 
are more prone to differentiate into adipocytes compared to MSCs from younger 
rabbits (Bilwani and Knight, 2012). Because adipocytes initiate the mechanism of 
inhibition described in this dissertation, preventing the accumulation of 
adipocytes in the BM could result in enhanced B lymphopoiesis. It will be 
important for future studies to identify what triggers changes in MSCs at two 
months of age in rabbits.  
Similar to hematopoietic progenitors, intrinsic changes to MSCs or 
extrinsic changes in the systemic environment might contribute to increased 
potential to become adipocytes over osteoblasts. While this altered potential is 
not fully understood, one study found that serum from adult rabbits induced 
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adipocyte differentiation in several human, mouse, and rat 
osteoblast/osteosarcoma cell lines (Diascro et al., 1998). These data suggest a 
systemic factor in rabbits could influence this differentiation decision. Further 
analysis of adult rabbit serum identified the fatty acids palmitic, oleic, and linoleic 
acids were responsible for inducing adipocyte differentiation (Diascro et al., 
1998). What causes these fatty acids to be present in adult rabbit serum, and the 
genetic and epigenetic effects they have on MSCs is yet to be determined. 
An alternative mechanism that may modulate MSC adipogenic vs 
ostobalastic potential could come from altered WNT signaling in older rabbits. 
RDA analysis comparing BM MSCs from a young and a 2 year old rabbit found 
frizzled 4 (WNT ligand receptor) expression was decreased in MSCs isolated 
from the 2 year old rabbit (Siewe et al., 2011). This is important because 
decreased WNT signaling results in low β-catenin levels, and having low 
amounts of active β-catenin in MSCs promotes adipocyte differentiation (Sen et 
al., 2008). More studies will be needed to truly understand the mechanisms 
initiating the accumulation of adipocytes in BM. This may be due to changes in 
diet and exercise leading to changes in serum fatty acids, and/or currently 
undefined genetic/epigenetic mechanisms. 
Additional studies are also needed to better understand the features of 
regulated BM adipose tissue (supports hematopoiesis) vs constitutive BM 
adipose tissue (does not support hematopoiesis), and how these types of fat 
contribute to the state of the BM microenvironment. 
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Conclusion 
This study has improved our understanding of how adipocytes influence 
the BM microenvironment and affect hematopoiesis. We propose a model 
occurring in fatty BM that is initiated by adipocytes and results in altered 
hematopoiesis (Figure 4.2). Adipocytes produce inflammasome activating 
molecules that promote the accumulation of MDSCs/inflammatory myeloid cells 
which, in turn produce IL-1. IL-1 acts on hematopoietic progenitors and stromal 
cells to produce an inflammatory state that drives MPPs to differentiate to the 
myeloid lineage, instead of the B lineage. The inflammatory state negatively 
regulating B lymphopoiesis and promoting myelopoiesis can be amplified by 
S100A9 production from myeloid cells (Figure 4.3). S100A9 acts on BM myeloid 
cells to induce IL-1, IL-6, and TNFα expression, known inhibitors of B 
lymphopoiesis (Dorshkind, 1988a, Hirayama et al., 1994, Maeda et al., 2005, 
Maeda et al., 2009, Ratliff et al., 2013, Ueda et al., 2004). 
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Figure 4.2 Negative regulation of B lymphopoiesis in adipocyte-rich bone 
marrow. Healthy BM is characterized by the presence of osteoblasts and stromal 
cells that support B lymphopoiesis. In fatty BM, adipocytes accumulate while 
supportive stromal cells are decreased in number. Adipocytes actively influence 
hematopoiesis by producing inflammasome activating molecules, as well as 
inflammatory cytokines. Adipocyte-rich BM exhibits an increased myeloid 
compartment, which contains a population of cells that inhibit B lineage 
development. Overall, inflammatory factors derived from adipocytes and 
inflammatory MDSCs create an environment that promotes myelpoiesis and 
negatively affects B cell development. Adapted from Kennedy et al. 2016. 
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Figure 4.3 Effect of S100A9 on hematopoiesis. Inhibition of B lymphopoiesis is 
initiated by inflammasome activating adipocyte factors (can be blocked with 
glybenclamide) and mediated through IL-1 producing MDSCs (as described in 
Figure 4.1). In addition to this mechanism, the presence of S100A9 further 
amplifies inflammation in the BM. S100A9 derived from myeloid cells in fatty BM 
does not act at the MPP stage like IL-1. Instead, S100A9 induces IL-1β 
expression in BM myeloid progenitors cells which can feed into the inhibition of B 
lymphopoiesis already described for IL-1. Further, S100A9 also induces the 
production of IL-6, and TNFα in BM myeloid cells which can directly inhibit B 
lymphopoiesis. Adapted from Kennedy and Knight, 2015. 
 
B cells and antibodies are critical for generating productive immune 
responses. Situations resulting in decreased output of new B cells into the 
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periphery put the host at risk for infection. Our study highlights the importance of 
the BM microenvironment (consisting of stromal and hematopoietic cells) in the 
regulation of B lymphopoiesis, and how changes to this environment negatively 
regulate B lineage development. We provide mechanistic insight into how 
adipocytes and MDSCs inhibit B lymphopoiesis, and identified several 
therapeutic targets for intervention. Accumulation of BM fat occurs in multiple 
pathologies (eg. obesity, BM failure, aging), we expect the knowledge gained in 
this dissertation will be used to develop treatments aimed at increasing B 
lymphopoiesis in a broad context of pathologies resulting in altered white blood 
cell development due to increased BM fat. 
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